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Abstract 
A clinical need for small-diameter vascular grafts exists, particularly in cases 
where coronary artery bypass surgery is the best treatment option, but the patient lacks a 
viable autologous graft due to repeat procedures or diseased vasculature. The 
comprehensive goal of this work was the in vitro fabrication and assessment of a 
completely biological, small-diameter vascular graft. Our approach uses tissue cells 
entrapped in a tubular fibrin gel with blood outgrowth endothelial cells (BOECs) seeded 
on the lumenal surface, in an attempt to recreate important properties of the medial and 
intimal layers of a native artery. Two major areas were examined to achieve this goal: 1) 
controlled fibrin degradation and its possible role in improving new matrix deposition, 
cellularity, and ultimately, mechanical properties and 2) seeding of BOECs on these 
small-diameter grafts to form a complete vessel and ensure thromboresistance.  
We hypothesized that controlling the rate of fibrin degradation could allow for 
improved matrix remodeling in fibrin-based constructs. To this end, we examined 
collagen and elastin deposition and cellularity in fibrin-based constructs grown in varied 
concentrations of the fibrinolysis inhibitor ε-aminocaproic acid (ACA). Decreasing the 
concentration of ACA led to increased fibrin degradation and better biochemical and 
mechanical properties. The byproducts of fibrin degradation, fibrin degradation products 
(FDPs), were shown to be physiological stimulators of collagen deposition, a fact that can 
be exploited to increase collagen deposition in fibrin-based vascular constructs.  
These fibrin-based constructs were then utilized as a substrate for seeding of 
BOECs, a novel endothelial cell expanded from circulating endothelial progenitor cells in 
peripheral blood. BOECs adhered to the bioartificial tissue and remained adherent under 
physiological shear stress. They also exhibited low expression of pro-inflammatory 
markers and reduced platelet binding compared to unseeded tissue. Exposure to shear 
stress decreased pro-inflammatory marker expression on TNF-α stimulated BOECs, 
increased endothelial nitric oxide synthase expression and nitric oxide production, and 
decreased platelet adhesion during whole blood flow. These outcomes indicate that 
BOECs are shear stress responsive and are functionally similar to mature endothelial cells 
in their response to shear stress and their ability to limit platelet binding to bioartificial 
vascular grafts.  
Together, these lines of research allow for the formation of a functional, small-
diameter vascular graft, while elucidating key aspects of the remodeling process and 
BOEC phenotype.  
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Chapter 1: Introduction 
1.1 Motivation 
In 2006, an estimated 448,000 coronary artery bypass surgeries on 253,000 
patients were performed in the United States (1). Autologous transplant of the saphenous 
vein or internal mammary artery remains the standard for these surgeries. However, due 
to diseased vasculature or repeat bypass surgeries, many patients with coronary artery 
disease do not have an acceptable native vessel available. In an attempt to fill this 
pressing need, synthetic materials have been explored for use as bypass grafts. These 
materials have been used successfully as replacements for large-caliber arteries, but a 
new set of issues arise when attempting to replace small-caliber vessels, such as the 
coronary artery. Lower flow velocities and the more compliant nature of small-diameter 
vessels, combined with poor endothelial cell retention rates on synthetic materials, can 
cause acute thrombogenicity, anastomotic intimal hyperplasia and aneurysm formation 
(2, 3). These issues with synthetic grafts motivate the need for a more biological 
approach. 
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Through the use of cells and a polymeric scaffold, tissue-engineered grafts have 
the potential to more closely mimic the native vessel. Our group utilizes this paradigm, 
through the incorporation of natural biopolymer matrices and vascular cells, to create 
completely biological, living vascular grafts. While great progress has been made, both 
by our group and others, a number of key parameters still need to be elucidated. The 
following chapters will describe specific methods for improving tissue engineered 
vascular grafts, by addressing a number of these shortcomings. Specifically, the 
following chapters will examine 1) controlled fibrin gel remodeling and new matrix 
deposition, 2) fabrication of a complete vascular graft through formation of a functional 
neoendothelium on tissue-engineered vascular grafts, and 3) utilization of blood 
outgrowth endothelial cells as a possible autologous cell source for vascular tissue 
engineering. The current chapter will provide background on native arteries and current 
small-diameter graft technologies, as well as tissue engineered vascular grafts to date, in 
order to lay the framework for understanding key vascular graft requirements and current 
shortcomings. 
1.2 Coronary Artery Disease and Current Vascular Grafts 
Coronary artery disease (CAD) is associated with atherosclerosis, a process that 
causes narrowing of the blood vessels that supply oxygen and nutrients to the heart. This 
narrowing can lead to weakening of the wall of the heart and eventually to myocardial 
infarction. The progression of CAD causes a reduction of blood flow in the coronary 
artery and changes in fluid dynamics as the blood interacts with the diseased area (4). The 
current treatment for CAD, either after myocardial infarction or when a heart attack is 
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imminent, is replacement of the diseased arteries by coronary artery bypass surgery 
(CABG). The most common graft utilized is a patient’s own internal mammary artery or 
saphenous vein, which can be used to circumvent the diseased vasculature. While nearly 
500,000 bypass surgeries are performed each year (1), many other patients are in need of 
surgery, yet do not have healthy vasculature for use due to disease progression or 
previous harvest when repeat procedures are required. In addition to the limited supply, 
native grafts have limited dimensions, creating possible complications with size 
mismatch, and require surgery at a secondary site. Venous grafts are particularly prone to 
thrombotic and hyperplastic occlusion and have lower patency rates (5). This creates a 
pressing need for small diameter (< 6mm) vascular substitutes that do not rely on a 
patient’s own vasculature.  
1.3 Structure and Function of Native Arteries 
Arteries are responsible for nutrient, waste and oxygen transport to the body. In 
order to accomplish this task, the walls of the vessel must be strong and capable of 
interfacing with the blood. The native arterial wall is composed of three distinct layers, 
the intima, media, and adventitia, each of which has a unique role in the overall vessel 
function.  
1.3.1 Tunica Intima 
The innermost layer of the artery is made up of a monolayer of endothelial cells 
adherent to an underlying basement membrane. This layer is referred to as the tunica 
intima, and has been shown to be responsible for much of the functionality of the vessel. 
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Healthy endothelium is anti-thrombogenic and responsible for maintaining blood 
homeostasis. Though the requirements for thromboresistance have not been fully defined, 
some combination of anticoagulant molecules, fibrinolytic activity, and anti-platelet 
factors is necessary for maintenance of hemostasis. Endothelial cells produce molecules 
such as prostacyclin (PGI2), nitric oxide (NO), and ecto-adenosine diphosphatase (ecto-
ADPase) which are important for suppressing platelet activation and adhesion (6). 
Endothelial cells also express molecules that control coagulation, such as von Willebrand 
factor (vWF), thrombomodulin (TM), tissue factor (TF) and tissue factor pathway 
inhibitor (TFPI), and fibrinolytic molecules, such as tissue-plasminogen activator (tPA) 
and urokinase-type plasminogen activator (uPA). A variety of stimuli, including viral 
infections, endotoxin, tumor necrosis factor (TNF), interleukin 1 (IL-1), and hypoxia, can 
lead to increased expression of pro-coagulant factors and decreased expression of anti-
coagulant factors by ECs (7-9). Cytokine and microbial toxin stimulation of ECs also 
leads to the expression of the membrane adhesion molecules, P-Selectin, E-Selectin, 
intercellular adhesion molecule-1 (ICAM-1) and vascular adhesion molecule-1 (VCAM-
1), which function as receptors and ligands for leukocyte interactions, including rolling, 
adhesion and emigration (6). The endothelium can also influence thrombogenicity 
through the regulation of vascular tone. Molecules such as NO, endothelin, and PGI2 
regulate vascular tone, causing vasodilation or constriction, thus altering flow rates in 
blood vessels and influencing thrombosis dynamics (10).  
The endothelium serves as a permeability barrier between the blood and the 
vascular tissue. It regulates nutrient transport across the vessel wall and is involved in 
translation of mechanical signals from the blood into the artery. The tunica intima creates 
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a clear barrier between the blood and vascular cells within the adjoining layer, the tunica 
media. As a selectively permeable barrier, the endothelium inhibits smooth muscle cell 
(SMC) growth by blocking diffusion of circulating growth factors into the medial layer 
(11), while also producing molecules such as NO and transforming growth factor-β 
(TGF-β) that limit SMC proliferation and migration (12). A healthy endothelium thus 
suppresses SMC growth, while injury to the endothelium can be accompanied by intimal 
hyperplasia, the proliferation and migration of SMCs into the intima layer leading to 
narrowing of the artery. Imitating this layer will be vital for creating a functional vascular 
graft. Without the endothelium, the vessel would become a passive conduit without the 
ability to respond to its environment, and the exposure of the basement membrane would 
make the vessel thrombogenic. 
The functional properties of the endothelium are strongly influenced by the 
mechanical environment, with evidence indicating an important role for shear stress in 
influencing endothelial cell structure, growth, and function (13, 14). Shear stress on the 
endothelium appears critical for maintenance of a thromboresistant surface, control of 
vessel diameter and vascular permeability, and even endothelial cell survival (6, 13, 15). 
Shear stress resulting from the flow of blood over the endothelium can lead to junction 
and cytoskeletal reorganization, altered EC gene expression (10) and altered expression 
and secretion of proteins associated with fibrinolysis, platelet and leukocyte adhesion, 
and coagulation. Some of these shear-responsive molecules are shown in Table 1.1, and 
have been elucidated most commonly with one of two types of studies: 1) research into 
atherosclerosis through the examination of shear stress effects at regions of disturbed or 
low shear stress or 2) in vitro studies examining the effects of shear stress when applied 
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to previously statically cultured cells. Both types of studies implicate shear stress as a 
vastly important parameter in pathophysiology and the maintenance of a quiescent, non-
activated endothelium. 
 
Table 1.1:  Shear Stress-Responsive Endothelial Cell Surface Molecules.                                          
 Molecule Location Response to 
inflammatory 
agonist 
Shear Stress 
Coagulation Thrombomodulin cell surface Down (16) Up (17, 18) 
 Tissue Factor  cell surface Up (19) Up, but decreased 
activity due to TFPI (20) 
 TF Pathway 
Inhibitor (TFPI) 
cell surface, 
secreted 
Constitutively 
expressed (20) 
Up (20) 
Blood Cell 
Interactions 
ICAM-1 cell surface Up (21) Up (22-24)  
LSS Up, HSS Down (25) 
No change (26) 
 VCAM-1 cell surface Up (21) Down (27) 
Unchanged (22) 
 PECAM (CD31) cell surface No change (28) Tyrosine 
phosphorylated (29) 
 E-Selectin cell surface Up (21) Down 
Unchanged (22, 24) 
 Nitric Oxide (NO) secreted Down (30) Up (31, 32) 
 Nitric Oxide 
Synthase (NOS) 
intracellular Down (16) Up (33, 34) 
 Prostacylin (PGI2) secreted Up (35) Up (36)  
Complement All are secreted or constitutively expressed: Complement inhibitors, CD46, 
CD55, CD59, C3, C1s, factor B 
Fibrinolysis Secreted: Tissue plasminogen activator (tPA-1) and Plasminogen activator 
inhibitor-1 (PAI-1) 
 *LSS: low shear stress; HSS: high shear stress 
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1.3.2 Tunica Media  
 The middle layer, or tunica media, of arteries is composed of circumferentially 
aligned collagen fibers, SMCs and thick elastic lamellae. This layer, with its 
circumferential arrangement of fibers and cells, accounts for the integrity of the vessel 
under physiological loading. The mechanical properties of native arteries have been 
described by the individual contributions of collagen, elastin, and smooth muscle in the 
medial layer (37, 38). Elastin has a large role in defining the mechanical properties at low 
strains, while collagen is the predominant influence at high strains (39). Elastin, which is 
arranged concentrically in the media layer, provides recoil after each cycle of vessel 
inflation, preventing dilation. The circumferentially aligned SMCs within the arterial wall 
are powerful contractile elements, responsible for vasoconstriction and dilation 
depending on a number of chemical and mechanical cues. Elastin, in conjunction with 
contractile SMCs, regulates arterial compliance. Collagen, with its high tensile strength, 
maintains the structure of the vessel and gives it good surgical handling properties and 
prevents rupture under physiological, and supra-physiological, pressures. 
1.3.3 Tunica Adventitia 
The medial layer and outermost layer, the tunica adventitia, are separated by the 
outer elastic lamina, which forms a distinct boundary between the two layers. The 
adventitia is made up of a loose fibrous matrix, which anchors the vessel to the 
surrounding connective tissue. It is composed primarily of collagen, fibroblasts, and some 
elastin, with nerves and small blood vessels running through this layer to supply the 
vessel wall with nutrients and oxygen. 
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1.4 Synthetic Materials 
The earliest attempts at fabricating vascular grafts involved the use of endothelial 
cell-seeded synthetic materials (40). While synthetic materials have been successfully 
utilized as replacements for large-diameter blood vessels, these materials encounter a host 
of new issues when intended as small-diameter grafts (4). A major issue involves the 
likelihood of clot formation on the thrombogenic lumenal surface. This has made the 
endothelialization of synthetic material an important area of research, particularly since 
synthetic materials have displayed issues with EC attachment, survival and adhesion 
under flow (3). Though surface modification techniques have been promising for 
improving EC attachment and survival (41), long-term survival and proliferation of ECs 
on synthetic materials still needs to be addressed. Furthermore, in vivo remodeling of a 
non-biodegradable, synthetic graft, such as ePTFE or Dacron is limited, making long-
term adaptation of the vessel impossible. The graft will not be able to grow with young 
patients, nor will it have all the physiological responses, such as vasoactivity, of living 
vessels.  
1.5 Vascular Tissue Engineering 
Tissue engineering relies on the use of tissue cells, a scaffold and various culture 
conditions to fabricate new tissues, and ultimately, new organs. The most common tissue 
engineering paradigm includes the use of all three of these components; however some 
therapies focus solely on the scaffold or the cells. As compared to synthetic materials, 
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tissue-engineered therapies have the potential to more closely mimic the native tissue, as 
well as integrate with the patient’s own tissue.  
The design criteria for small-diameter, tissue-engineered vascular grafts are 
motivated by the functions of each of the arterial wall layers. The ideal artificial artery 
would be non-thrombogenic and non-immunogenic, most likely through the 
incorporation of a confluent, quiescent endothelial cell monolayer. It would possess the 
mechanical properties similar to the medial layer of native arteries, including 
physiological compliance, viscoelasticity, elastic recoil, and high burst pressure. As the 
vessel is exposed to continuous distention, it must not be susceptible to permanent creep 
or aneurysm formation. The healing response upon implantation will be another critical 
consideration for a tissue-engineered vascular graft, since the grafts cannot be a 
significant source of inflammation, hyperplasia, or fibrous capsule formation after 
implant. Other issues must be addressed for practical application of a tissue engineered 
vessel include the ease of suturing and handling, integration with native tissue upon 
implantation, durability, scale-up, availability, and cost. All of these issues will need to 
be considered for a tissue-engineered vessel to transition from the lab to clinical use.  
These properties will motivate the choice of biomaterial while the incorporation 
of cells into the matrix could allow for important physiological properties, such active 
remodeling of the extracellular matrix in vitro prior to implantation and in vivo. In 
addition, the artery must withstand a number of dynamic forces, including the transmural 
pressure acting normal to the vessel wall and the tangential shear stress. Thus, a 
successful vascular graft will likely have mechanical properties similar to those of a 
native vessel, so that it can withstand the pressures associated with blood flow and avoid 
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compliance mismatch issues at the anastomoses. The incorporation of an EC layer will 
require assessment of adhesion under flow, to ensure a confluent monolayer can be 
established and maintained under physiological shear stress. 
A variety of tissue-engineering approaches have been explored to meet these 
criteria, including utilization of cell sheet methods, decellularized vascular grafts, 
biodegradable polymer scaffolds, and biopolymer scaffolds (42). The cell sheet method 
relies on “self-assembly” by cells grown on tissue culture plastic (43-45). By inducing 
high ECM synthesis in these cells, sheets of cells and ECM can be created and rolled into 
tubular form to create multi-layered vessels. This translates to a vascular graft that is 
made only from human proteins, as the entire ECM is synthesized by human dermal 
fibroblast (HDFs) or SMCs. This method has allowed for the fabrication of vascular 
grafts with burst pressures equivalent to native vessels, but requires long culture times to 
produce these results (45, 46). 
While the cell-sheet method starts with cells only, a second category of tissue 
engineering relies on an acellular scaffold that, upon implantation, can recruit cells from 
the host tissue. Acellular approaches avoid the necessity of isolating and expanding 
autologous cells, thus significantly shortening the fabrication time and allowing for quick 
implantation. The use of native tissue has advantages for mechanical properties and 
biocompatibility (47). The small intestinal submucosa (SIS) is a cell-free, collagen layer 
that has been rolled for use as a vascular graft with appropriate mechanical properties 
(48-51). Wilson et al. examined detergent and enzymatic extraction to removed cells 
from allograft vessels and showed no inflammation in a canine model, but limited cell 
recruitment (52). Gui et al. showed similar mechanical properties for decellularized 
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umbilical arteries compared to non-decellularized vessels; however, some of the 
decellularized umbilical artery grafts occluded within 24 hours of implantation as aortic 
replacements in nude rats, leading to higher mortality rates in those rats. The 
decellularized umbilical artery grafts also developed various levels of thrombosis at the 
proximal anastomosis sites during an 8-week implantation period. Vascular cell 
migration in vivo is not well understood and the means to recruit the appropriate cells still 
requires extensive research (4). Furthermore, this method will require a quick recruitment 
of ECs to the lumenal surface to prevent thrombus formation and long-term intimal 
hyperplasia. Seeding of decellularized tissue with ECs prior to implantation may prevent 
some of these issues. 
Use of cell-seeded, polymeric scaffolds represents another promising method for 
vascular graft formation (53-58). Methods reliant on biodegradable polymer scaffolds 
require the formation of tubular constructs first followed by cell seeding, as the cells 
would not survive the conditions required for polymer synthesis. Even distributions of 
cells, and thus homogenous remodeling, are potential issues that will need to be 
overcome. Good results have been attained with these methods; however an 
inflammatory response to residual, degrading polymer will need to be ruled out.  
A fourth approach utilizes biopolymers formed with entrapped cells. Biopolymers 
are an ideal substrate for cell attachment and signaling; however, the initial gel is 
inherently weak (59). The entrapment of vascular cells is required for cell-mediated 
restructuring to improve biopolymer organization, remodeling, and mechanical 
properties. The most prevalent examples of this approach involve reconstituted type I 
collagen gels that are populated and compacted by SMCs (60-63). As first shown by 
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L’Heureux et al. (60) and more thoroughly examined by our group (62), constrained 
compaction around a non-adhesive mandrel generates circumferential alignment of the 
collagen fibrils and SMCs. Cell and fiber circumferential alignment are important for 
improving mechanical properties, but also for vasoactivity and structural integrity. The 
use of biopolymers to mimic the aligned structure of the medial layer makes them 
promising matrix materials for artificial artery design.  
1.6 Fibrin-based Vascular Constructs  
Our group has also investigated the use of fibrin as an alternative biopolymer to 
type I collagen for the fabrication of a tissue-engineered vessel (64, 65). Fibrin gels have 
the same advantages as collagen-based constructs, namely direct cell entrapment during 
construct synthesis and the ability to produce circumferential alignment of cells and 
fibrils with mechanically constrained gels (Figure 1.1). Fibrin-based constructs have the 
added advantage of enhanced matrix remodeling compared to collagen constructs. 
Neonatal SMCs secrete more collagen in fibrin gels compared to collagen gels and have 
superior mechanical properties (65). Significant elastogenesis occurs within SMC-
entrapped fibrin constructs (66), a result that has not been seen in the collagen 
counterpart. Our lab has also assessed gene expression over five weeks of culture for 
fibrin-based constructs (67). Increased expression of tropoelastin, collagen, and lysyl 
oxidase correlated with measured quantities of elastin and collagen deposition. Over 
weeks three to five of this study, organized, cross-linked collagen and elastin were 
detected, which was associated with an increase in mechanical properties.  
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Further, these media-equivalents can be endothelialized, with surface coverage 
greater than 98.8% and high endothelial cell retention rates (96.5%) under physiological 
shear stress (68). Swartz et al. implanted fibrin-based, endothelialized constructs into the 
jugular veins of lambs, which remained patent for up to 15 weeks. This result is 
promising as examination of the explants showed extensive matrix remodeling, with 
production of collagen and elastin fibers, as well as improved mechanical properties (69). 
However, these constructs would be composed primarily of fibrin at the time of 
implantation as they were cultured in vitro for only 2-3 weeks prior to implantation. The 
constructs were strong enough to withstand implantation into the venous circulation, but 
will require extensive strengthening if they are to be used for artery replacement.  
 
 
Figure 1.1: Medial layer fabrication. A) A solution containing fibrinogen, thrombin and cells is 
injected into a glass mold containing an inner nonadhesive mandrel with stoppers at each end. B) 
The solution is allowed to gel for 30 minutes at 37C and then the fibrin gel construct is removed 
from the outer glass mold and transferred to cell culture media. C) Over time, cell-induced 
compaction around the nonadhesive mandrel leads to circumferential alignment of the cells and 
fibrils (modified from figure by B. Isenberg). 
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1.7 Methods to Improve Mechanical Properties 
While the results with fibrin-based scaffolds have been promising, the mechanical 
properties of biopolymer approaches remain inferior to native arteries. A number of 
conditions have been explored in order to improve the mechanical properties of 
biopolymer constructs, including alteration of medium conditions, addition of growth 
factors, gel cross-linking and mechanical conditioning. Inherent in these studies is the 
acknowledgement that substrate signaling from the ECM and chemical and mechanical 
signaling from the surrounding media are important for regulating processes such as cell 
growth, matrix synthesis and differentiation.   
1.7.1 Chemical Signaling 
In order to optimize the fabrication of fibrin-based vascular grafts, the culture 
conditions and addition of supplements are important parameters for producing large 
improvements in collagen and elastin production and tissue strength and stiffness. 
Previous work by our group, with disc-shaped gels or 8 mm diameter tubular gels, has 
shown improved collagen deposition and mechanical properties when vSMC fibrin 
constructs were cultured with insulin and TGF-β (65). The quantity of crosslinked elastic 
fibers was also enhanced by supplementation with TGF- β and insulin in neonatal vSMC 
fibrin constructs, and these additives overcame ascorbate's inhibition of elastogenesis in 
fibrin (66). These optimizations in construct culture will be utilized in the fabrication of 
small-diameter, fibrin-based vascular grafts.  
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1.7.2 Mechanical Conditioning 
During natural growth and function, another set of signals is imposed by the 
mechanical environment. As discussed earlier in this chapter, in the vessel wall, this 
signaling is due to the hemodynamics of the vascular system and includes shear stress, 
tangential forces acting on ECs and to a lesser extent SMCs due to transverse (interstitial) 
flow, and mechanical stretch, a cyclic circumferential stress caused by blood pressure. 
Application of these mechanical signals during in vitro culture of tissue-engineered 
vessels could provide a method to influence tissue development, by enhancing ECM 
synthesis or altering cell proliferation or phenotype.  
Cyclic stress caused by blood pressure plays a significant role in regulation of 
blood vessel remodeling and thus, intuitively, may be useful in regulating the 
development of tissue-engineered blood vessels. Studies have shown that cyclic strain 
can be used to regulate the phenotype of vascular SMCs in two-dimensional (70, 71) and 
three-dimensional culture (55, 72, 73). Groups studying cyclic strain of SMCs in three-
dimensional collagen and synthetic material scaffolds have reported increased collagen 
(55, 56, 73-75) and elastin (74) deposition, cell proliferation (55, 73, 74) and 
improvements in construct mechanical properties (55, 56, 63, 74). Niklason et al. seeded 
bovine aortic SMCs on porous tubes of polyglycolic acid and then perfused the constructs 
with medium at 2.75 Hz with 5% radial distention. After 8 weeks, the mean burst 
pressure of strained constructs was 2000 mmHg compared to 300 mmHg in the static 
vessels. The collagen content and SMC densities were also significantly higher in the 
strained constructs and the histological appearance was similar to that of native vessels 
(55, 56). Nerem et al. looked at short-term cyclic distention of SMC-seeded collagen 
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tubular constructs at 1 Hz and 10% strain for 4 and 8 days. Distention yielded increases 
in construct mechanical properties and improved circumferential alignment of SMCs 
throughout the construct wall (63, 76).  
To date, most three-dimensional construct studies have focused on a single 
loading condition, based on a typical resting physiological condition or the capabilities of 
the bioreactor system used. Optimal cyclic loading for the largest improvements in tissue 
structure and mechanical properties may involve pulse shapes or strain values that differ 
from the single loading values chosen in these experiments. Our lab has examined the 
effect of cyclic distention parameters on collagen-based tubular constructs with adult rat 
aortic SMCs (77). Strain, stretch time, and relaxation time were all shown to be important 
variables in controlling contruct mechanical properties. Altering the stain imposed over 
the course of construct culture has also been examined. By conditioning with 
incrementally increasing cyclic stain, human dermal fibroblasts (HDFs) and porcine 
interstitial valve cells (PIVCs) in fibrin-based tubular constructs have been cultured to 
reach mechanical properties (78), including burst pressures (79), near those of native 
vessels.  
1.7.3 Controlled Fibrin Degradation 
While fibrin has become a common biopolymer for use in cardiovascular (80-83) 
and vascular tissue engineering (64-67, 69, 84-87), the effects of fibrin degradation rates 
on new matrix synthesis is poorly defined. Fibrin can be degraded by plasmin in vivo and 
in vitro, and the degradation rate varies with concentration of plasmin, the local 
environment and the fibrinolytic nature of the surrounding cells. Fibrin degradation can 
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be modulated by the addition of plasmin inhibitors, such as aprotinin or ε-aminocaproic 
acid (ACA), which have been widely used in tissue engineering (88-92) to maintain the 
fibrin scaffold while new matrix is synthesized. A closer examination of the effect of 
fibrin degradation rate on new matrix deposition may allow for better control of this 
parameter, leading to improvements in construct composition and mechanics. 
1.8 Endothelium Formation 
1.8.1 Endothelial Cell Source 
A variety of endothelial cell (EC) sources have been examined for vascular tissue 
engineering, including artery- and vein-derived ECs and adipose-derived microvascular 
ECs. All of these sources would require secondary surgical procedures prior to use and 
expansion times dependent on their proliferation rates. Adipose-derived ECs are more 
abundant than vessel wall cells and can be isolated in quantities such that in vitro 
expansion is not necessary; however, clinical trials with these cells have had inferior 
results compared to the use of vein-derived ECs. Progressive intimal thickening was 
found when adipose-derived ECs were used, likely due to the presence of contaminating 
myofibroblasts in the isolated cells. Thus, use of these cells would require in vitro 
purification to remove contaminating cells that promote intimal hyperplasia (93).  
Blood outgrowth endothelial cells (BOECs) are a promising source of EC for in 
vitro neoendothelium formation. These cells are isolated by outgrowth of circulating 
progenitor cells from a 50-100 ml blood sample (94-97). In studies with human BOECS, 
these cells were shown to have a robust proliferative capacity, expanding from 20 cells to 
10
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cells in 9 weeks (95). BOECs uniformly express endothelial cells markers VE-
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cadherin, CD31, P1H12, thrombomodulin, von Willebrand factor, flk-1, and CD36 but do 
not express the hematopoietic cell markers CD45 or CD14. They have the typical 
endothelial cell cobblestone morphology, take up acetylated low density lipoprotein 
(acLDL) and contain Weibel-Palade bodies (95, 96). As identified by the presence of 
CD36, a marker of microvascular ECs, and the absence vascular cell adhesion molecule-1 
(VCAM-1) and tissue factor (TF) as well as weak expression of intercellular adhesion 
molecule-1 (ICAM-1), BOECs have the phenotype of non-activated, microvascular 
endothelial cells (95). BOECs provides a source of autologous cells that could be derived 
from the patient’s own blood, which would limit the need for long term anti-coagulation 
therapy and reduce graft rejection.  
1.8.2 Neoendothelium Assessment 
Rigorous assessment of endothelial cells seeded on vascular grafts in vitro will 
yield important insight into the functionality of the formed endothelium. Adhesion, 
morphology, and junction formation will give an idea as to the maturity of the 
neoendothelium. This endothelium needs to remain intact under physiological shear 
stress, reorient in the flow direction, and be responsive to shear stress. The 
thrombogenicity of the seeded tissue can then be assessed by examination of key 
molecules involved in clotting, platelet and leukocyte adhesion, and fibrinolysis. In vitro 
functional tests will be important benchmarks for examination of potential graft issues 
and outcomes (10).  
Assessment of endothelium formation on vascular grafts will require implantation 
to determine full functionality. However, this leads to a number of complications with 
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choice of an appropriate animal model. Species-dependent differences in endothelial and 
blood cells make autologous implantation with non-human cells an incomplete picture 
(98). However, use of human cells will require immunosuppressant drugs or use of 
immunodeficient animals. This makes in vitro assessment methods using human cells and 
blood important supplementary studies. 
1.9 Conclusions 
A successful tissue engineered vascular graft will likely require a careful 
prescription of a number of the mechanical and chemical cues described above. The 
following chapters will examine methods to exploit these signaling mechanisms to 
improve the matrix properties and cell phenotype of fibrin-based bioartificial arteries. 
Chapter 2 will examine the role that the fibrin scaffold has in the overall structure, by 
altering fibrin degradation through the use of a fibrinolytic inhibitor and examining 
changes in cellularity and new matrix deposition. Chapter 3 utilized the outcomes from 
Chapter 2 to develop a functional, small diameter bioartificial artery seeded with rat 
BOECs. Chapter 4 will then examine the use of shear stress conditioning to alter the 
phenotype of human BOECs and examine adhesion and thrombogenicity on bioartificial 
vascular grafts.  
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Chapter 2: Fibrin-Based Tissue Construct Degradation and 
Remodeling 
2.1 Introduction 
This chapter examines the importance of fibrin degradation in new matrix 
deposition in fibrin-based constructs. Methods to optimize fibrin degradation will require 
an understanding of the effects of fibrin degradation and the generation of fibrin 
degradation products in matrix deposition and cell proliferation. This chapter has been 
published in a modified form in Tissue Engineering Part A (1). Fibrin zymography was 
performed by Justin Weinbaum and the development of the ELISA for fibrin degradation 
products (FDPs) is the work of Sandra Johnson. 
The plasma protein fibrinogen has been widely utilized in the field of tissue 
engineering. Scaffolds fabricated from fibrin gel have been successfully employed for 
growth of bone marrow stromal cells (2), chondrocytes (3), osteoblasts (4), and nerve 
axons (5). They have been used as scaffolds in cardiovascular tissue engineering (6-9) 
and seeded with smooth muscle cells (SMCs) for vascular tissue engineering (10-18). 
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Fibrin gel has also been explored as a method for in vitro and in vivo cell delivery (19-21) 
and drug delivery (22). Furthermore, fibrin glues are already FDP approved and have a 
proven track in surgery and clinical practice as a hemostatic agent (23).  
As a biopolymer, fibrin has a number of advantages, including the option for 
direct cell entrapment during construct fabrication, the availability of sites for cellular 
adhesion and binding of matrix molecules and growth factors, and the ability to produce 
alignment of cells and fibrils in gels that are mechanically constrained during gel 
compaction (24, 25). Fibrin-based constructs undergo extensive matrix remodeling as the 
cells degrade fibrin and deposit extracellular matrix (ECM) (12-14). vSMC secrete more 
collagen and elastin in fibrin gel compared to collagen gel, producing constructs with 
superior mechanical properties (11, 13).  
Fibrin gel is formed by the thrombin-catalyzed self-assembly of fibrin monomers, 
derived from fibrinogen, into native protein filaments. This process forms a fibrin gel 
entrapping the cells suspended in the fibrinogen solution, analogous to the entrapment of 
platelets in a fibrin clot during wound healing (26, 27). The serine protease plasmin acts 
in vivo to resorb the thrombus, after activation of the zymogen plasminogen by urokinase 
(uPA) or tissue plasminogen activator (tPA) (28). Fibrin degradation can be modulated 
by the addition of plasmin inhibitors, such as aprotinin or ε-aminocaproic acid (ACA). 
ACA inhibits uPA (29), tPA (30), and plasmin (31, 32), and is widely used in tissue 
engineering to slow fibrin degradation (20, 33-36).  
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Figure 2.1: Fibrinolysis and inhibition by Aminocaproic Acid (ACA). 
 
Controlling the rate of fibrinolysis is of great importance when using fibrin gel as 
a tissue scaffold. Extensive degradation of the gel before the cells secrete sufficient ECM 
results in construct failure; however, excessive fibrinolytic inhibition could limit fibrin 
remodeling into tissue and also result in failure. This is one practical reason why the rate 
of fibrin degradation needs to be carefully controlled. Fibrin gels are more than inert 
scaffolds for cell seeding, though. As a biopolymer, fibrin has protein and cellular 
binding sites that create a bioactive surface for cell growth. Its presence in the system 
may improve initial seeding as well as construct growth over time (20). It is also possible 
that the degradation of fibrin into fibrin degradation products (FDP) may provide direct 
stimulus for the cells. FDP have been shown to have biological activity in simplified 
systems and may aid in the remodeling of the fibrin constructs. For example, plasmin-
generated FDP fragment E and atherosclerotic plaque extracts have been shown to have 
mitogenic effects on SMCs (37), and plasmin-derived FDP stimulated collagen synthesis 
in the chick chorioallantoic membrane model (38).  
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The goal for this study was to examine how fibrin degradation affects 
proliferation of and matrix deposition by vSMC in fibrin-based tissue constructs. An 
ELISA was developed to monitor levels of bovine FDP in the medium of fibrin-based 
tissue constructs. The fibrinolytic inhibitor ACA was utilized to alter fibrin degradation 
by plasmin and examine the effects on collagen and elastin deposition and cell 
proliferation in fibrin constructs over long-term culture. FDP concentrations in the 
interstitial fluid of the constructs were measured in order to estimate the FDP 
concentrations in proximity to the vSMC during construct degradation. To determine if 
these concentrations of FDP were bioactive, cell cultures were supplemented with 
exogenous FDP over a range of concentrations and changes in cellularity and collagen 
content were measured. Finally, to demonstrate that FDP were bioactive in the tissue 
constructs, exogenous FDP were added under conditions of fibrin degradation inhibition.    
2.2 Materials and Methods 
2.2.1 Cell Culture  
vSMC were isolated from 1-3 day old Fischer rat aortae, as previously described 
(12). Cell type was verified by staining with α-smooth muscle actin and smooth muscle 
myosin heavy chain antibodies (Abcam Inc., Cambridge, MA; Figure 2.2). The cells were 
maintained in DMEM/F12 supplemented with 100 U/ml penicillin, 100 U/ml 
streptomycin (Invitrogen, Carlsbad, CA), and 15% fetal bovine serum (FBS; Thermo 
Fisher Scientific, Waltham, MA). All culture flasks were seeded with 20,000 cells/cm
2
, 
split near confluence, and used at passage six for construct fabrication. 
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Figure 2.2: Neonatal rat SMCs display a normal SMC phenotype. At passage 6, 
vSMCs express A) α-smooth muscle actin and B) smooth muscle myosin heavy chain. 
 
2.2.2 Fabrication of Fibrin-based Adherent Disc Constructs  
Adherent disc constructs were prepared as previously described (12). For these 
studies, the initial concentrations were 5x10
5
 vSMC/ml and 3.3 mg/ml fibrinogen solid 
(F4753, Sigma Aldrich, St. Louis, MO); 200 l of fibrin gel was used for each 1 cm 
diameter disc construct. After fibrin gelation, construct medium consisting of 
DMEM/F12, antibiotic/antimycotic (Invitrogen), 10% FBS, 50 µg/ml ascorbate (Sigma 
Aldrich), 1 ng/ml TGF-β (R&D Systems, Minneapolis, MN), and 2 µg/ml insulin (Sigma 
Aldrich), plus 3, 6, or 12 mM ACA (Thermo Fisher Scientific) was added at an initial 
volume of 2 ml per construct and replaced with 1 ml of this supplemented medium every 
2-3 days.  A medium sample was collected prior to each medium change. Constructs 
were harvested weekly for 5 weeks. 
In a separate set of experiments, constructs grown in 3 and 12 mM ACA received 
0, 100, 250 or 500 µg/ml bovine plasmin-derived FDP 24 hours after casting and again 
A B 
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with each medium change. FDP were formed as described in the ELISA section. 
Constructs were harvested at 1 week. 
2.2.3 Fabrication of Fibrin-based Tubular Constructs 
The fabrication of tubular constructs has been previously described (39). The 
tubular constructs were prepared using the same fibrin gel solutions as the disc 
constructs, however the solution of fibrinogen, thrombin, and cells was injected into a 
tubular glass mold 7.5 cm long with a 9 mm outer diameter and a 2 mm inner glass 
mandrel. The mandrel was pre-coated in 5% Pluronics F127 (Sigma) for 3 hours to limit 
adhesion between the fibrin gel and the mandrel. The fibrinogen solution was allowed to 
gel for 30 minutes and then the mandrel and fibrin gel was ejected from the glass mold 
and cultured in the same medium as the adherent disc constructs. Constructs were 
incubated statically on the mandrel and medium was changed three times per week until 
harvest at 5 weeks. 
2.2.4 ELISA for Bovine Fibrin Degradation Products  
FDP present in media were quantified with a competitive ELISA using anti-
bovine fibrinogen (American Diagnostica Inc., Stamford, CT) as the primary antibody 
and purified bovine fibrinogen (Aniara, Mason, OH) as the coating antigen and 
concentration standard.  This fibrinogen was converted to fibrin using the same 
conditions as construct preparation, digested overnight at 37C with human plasmin 
(Sigma Aldrich) at 0.04 U/mg protein in 50 mM Tris, 100 mM NaCl, 10 mM CaCl2, pH 
7.6.  Plasmin was quenched with aprotinin (Sigma Aldrich) at 100 KIU/ml and the digest 
(BV-FDP) was adjusted to 1 µg/ml in PBS. 
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EIA/RIA plates (Corning Inc., Lowell, MA) were coated overnight at 4C with 
BV-FDP.  All other incubations were 1 hour at room temperature in PBST.  The plate 
was then blocked with 1% BSA (IgG and protease free, Jackson ImmunoResearch 
Laboratories, Inc., West Grove, PA).  Solutions of primary antibody (3.33 µg/ml) plus 
either known amounts of BV-FDP or diluted sample media were incubated, added to the 
plate and incubated again to allow free antibody to bind to the FDP coated on the plate.  
Since the ELISA also detected fibrinogen products in FBS, both media and standards 
were at kept at the same FBS concentration.  Attached primary antibody was bound to an 
HRP-conjugated secondary antibody (Jackson ImmunoResearch) used at 1:50,000. The 
bound HRP was incubated with TMB substrate solution (Thermo Fisher Scientific) to 
yield color inversely proportional to FDP concentration.  After quenching with 2.5 M 
H2SO4, the plates were read at 450 nm with background subtraction (BioTek Instruments, 
Inc., Winooski, VT). Completely digested vSMC constructs contained 330 µg FDP.   
In one set of experiments, constructs were harvested daily and pooled to allow for 
quantification of interstitial FDP. In these studies, 100 KIU/ml aprotinin and 10 μM 
Galardin (Millipore, Billerica, MA) were added to the medium one hour prior to harvest 
and samples of medium were collected for quantification. Then, all medium was 
aspirated from the construct surface and the constructs were collected into chilled vials 
and centrifuged at 10,000 x g at 4C for 15 minutes. The supernatant was collected and 
used to quantify FDP within the construct via ELISA. 
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2.2.5 Fibrinogen Zymography  
Polyacrylamide gels were prepared with the addition of 375 g/ml fibrinogen to 
the resolving phase. Medium, human activated plasmin, or 2-antiplasmin (Abcam Inc.) 
were loaded as indicated then separated by electrophoresis. The gel was rinsed, extracted 
in 2.5% Triton X-100 (Sigma Aldrich), rinsed again, then incubated in reaction buffer (50 
mM Tris pH 7.4, 1 mM CaCl2, 1 mM MgCl2) at 37C overnight. ACA was added to the 
buffer as indicated. Digested gels were stained (Blue BANDit, Amresco Inc., Solon, OH) 
then scanned for qualitative analysis.  
2.2.6 Stimulation of Cell Monolayers  
vSMC were plated in 6 well plates at an initial density of 20,000 cells/cm
2
 and 
were maintained in construct medium. At 24 hours and again with every feeding, either 
BV-FDP (0, 100, 250, 500 μg/ml) or ACA (0, 3, 6, 12 mM) was added to the medium. 
The medium was changed on day 3 and 6 and harvested at 1 week. 
2.2.7 Biochemical and Histochemical Analysis 
DNA was quantified with a modified Hoechst assay (40). Cellularity was 
determined assuming 7.6 pg of DNA per cell (41). Collagen content was measured with 
the hydroxyproline assay of Stegemann and Stadler (42), with collagen per sample 
calculated using a conversion factor of 7.46 µg of collagen per µg of 4-hydroxyproline 
(43). Elastin content was measured using the modified ninhydrin assay (13, 44).  
Constructs for histology were fixed in 4% paraformaldehyde for 3 hours, followed 
by infiltration with a solution of 30% sucrose and 5% DMSO. Samples were frozen in 
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OCT (Tissue-Tek, Torrance, CA), sectioned into 9 µm thick cross-sections and then 
stained with Lillie’s trichrome and Picrosirius red (45). Images were taken with an Zeiss 
Axiovert or Olympus IX70 inverted microscope equipped with color CCD camera. For 
Picrosirius red imaging, samples were placed between crossed plane polarizers. 
2.2.8 Mechanical Testing 
Tubular constructs were sectioned into 2-3 mm long rings and mechanically 
tested using a Microbionix mechanical testing system (MTS Systems). Before testing, 
tissue thickness was measured using a 50-g force probe attached to a displacement 
transducer. Rings were mounted and tested as previously described (46). True strain was 
calculated based on the change in length of the tissue over time. The stress was calculated 
as force divided by the initial cross-sectional area. The elastic modulus was determined 
by linear regression of the linear region of the stress-strain curve. 
2.2.9 Statistical Analysis 
Statistical analysis was performed using one-way ANOVA for cell culture studies 
conducted with one time point and two-way ANOVA for 5-week construct studies and 
construct studies with combined ACA and FDP treatments in GraphPad Prism software 
for Windows (GraphPad Software, Inc., San Diego, CA). Tukey post hoc analysis was 
conducted to evaluate significant differences. A significance level of α=0.05 was used for 
all tests. Pearson’s correlation coefficient was calculated to examine the correlation 
between fibrin degradation and ECM deposition or cellularity. Linear regression was 
performed to examine the relationship between FDP concentration in the culture medium 
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and collagen deposition. The best fit line and 95% confidence intervals are shown in 
Figure 2.3D. 
 
2.3 Results 
2.3.1 ACA leads to both a delay and decrease in FDP release. 
Fibrin-based tissue constructs cultured in the absence of plasmin inhibition are 
completely degraded within 24 hours of casting, which is prevented by addition of ACA 
to the medium. The ACA acts to inhibit plasmin activity, limiting the rate of fibrin 
degradation and maintaining the fibrin scaffold while SMCs produce new ECM. To 
examine the effect of plasmin inhibition on scaffold digestion, an ELISA was developed 
to quantify FDP in the culture medium. This allowed for the non-destructive monitoring 
of fibrin degradation. Of particular interest were the times of peak fibrin degradation, the 
time course of fibrin degradation, and the cumulative FDP generated.  
Addition of varying concentrations of ACA to the tissue constructs produced 
large differences in the rate of fibrin degradation, the peak FDP concentrations, and the 
time of maximal FDP release. Tissue constructs cultured with high ACA released few 
FDP, never exceeding a medium concentration of approximately 20 µg/ml (Figure 2.3A). 
For intermediate and low ACA concentrations, the maximal FDP concentration increased 
to approximately 50 and 120 µg/ml, respectively. Higher ACA concentrations also 
shifted the time of maximal FDP generation. Peaks in FDP generation occurred earliest 
for the low ACA samples and latest for the high ACA samples, at days 8 and 18, 
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respectively. After 5 weeks in culture, nearly 90% of the initial fibrin had been digested 
in the low ACA constructs, while in high ACA constructs only 40% of the initial fibrin 
was digested (Figure 2.3B). 
 
 
Figure 2.3: Plasmin inhibition reduces and delays FDP release from tissue 
constructs. A) FDP concentrations in the culture medium were measured for 5 weeks. 
Each data point represents analysis of pooled medium from five constructs at each ACA 
concentration (low, intermediate, and high, corresponding to 3, 6, and 12 mM ACA, 
respectively). B) Cumulative FDP release over 5 weeks is shown, expressed as a 
percentage of the initial fibrin that has been degraded. 
 
2.3.2 Fibrinolytic activity in the culture medium is primarily due to plasmin. 
To identify the enzyme(s) relevant to fibrinolysis in the constructs, fibrinogen 
zymography was used by preparing polyacrylamide gels supplemented with the same 
fibrinogen used in construct fabrication. Medium from constructs cultured overnight 
without ACA, representing peak plasmin activity, served as a positive control for this 
assay. The primary fibrinolytic bands appeared as a doublet near 72/74 kD and a poorly 
resolved doublet near 140 kD (Figure 2.4A). Addition of ACA at the levels used in 
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construct culture inhibited digestion by all species, pointing to their identity as complexes 
of the serine protease plasmin. This study, in agreement with previous work (47), 
demonstrates that vSMC use endogenous plasminogen activators, such as uPA, to 
activate plasminogen present in serum (48), producing plasmin that can be used for 
fibrinolysis. 
Purified plasmin migrates as a doublet near 72/74 kD that, in the presence of 
serum-containing culture medium, shifts largely to the doublet at 140 kD, consistent with 
the migration of plasmin and the plasmin/2-antiplasmin complex, respectively (49, 50). 
To confirm this, a mixture of plasmin with purified 2-antiplasmin was analyzed by 
zymography, and this migrated as the same 140 kD doublet (Figure 2.4B). Since 
plasminogen binds to 2-antiplasmin 1000-fold more weakly than plasmin (KD = 3 nM 
and 3 M for plasmin and plasminogen, respectively) (32), and assuming a constant 2-
antiplasmin serum concentration, this complex should be relatively insensitive to 
plasminogen and correlate with plasmin activity. In addition, the 72/74 kD band could 
easily be confused with a fibrinolytic activity present in serum. Therefore, the 140 kD 
species was chosen for following plasmin activity generated by the constructs.  
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Figure 2. -antiplasmin complexes are detectable in the conditioned 
medium of tissue constructs. A, ACA added to the zymogram reaction buffer decreases 
fibrinolytic activity in a concentration dependent manner. B, Plasmin binds to 2-
antiplasmin in FBS-containing culture medium to form a SDS-resistant 140 kD complex. 
Plasmin migrated as a doublet (black arrowheads) that shifted completely or partially to a 
high molecular weight complex (white arrowhead) in the presence of 2-antiplasmin or 
serum-containing medium, respectively. * denotes fibrinolytic activity found in FBS. C, 
Plasmin in tissue construct medium decreased over time and in response to plasmin 
inhibition. “M” denotes fresh construct medium. The white arrowhead indicates the 
plasmin/2-antiplasmin complex identified in Figure B. The black arrowhead indicates a 
high molecular weight protein found in the culture medium that served as a loading 
control.  
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2.3.3 Plasmin activity precedes FDP release into the medium. 
Medium samples from constructs incubated in varying ACA concentrations were 
analyzed for plasmin activity. As expected, the 140 kD bands associated with plasmin 
complexes were identified in the culture medium, and this plasmin activity appeared as 
early as day three, prior to the peak FDP levels identified by ELISA (Figure 2.4C). 
Constructs grown in low levels of ACA showed the greatest initial fibrinolytic activity in 
the culture medium, which declined after several medium changes and was at background 
levels within two weeks. In contrast, the culture medium of constructs grown in high 
levels of ACA showed a more sustained fibrinolytic profile with lower levels of initial 
activity, consistent with sustained FDP production (Figure 2.3A). After two weeks, the 
band intensity in high ACA constructs also decreased, but remained above background 
levels. Similar patterns of fibrinolytic activity to that seen for the 140 kD complex were 
seen with bands at 110/120 and 230 kD, which are presumably also plasmin complexes.  
2.3.4 Reduced ACA leads to higher collagen and elastin deposition and increased 
cellularity. 
Constructs were harvested weekly to examine the effects of ACA on collagen and 
elastin deposition and construct cellularity. Collagen and elastin levels increased over the 
5-week culture period in all groups (Figure 2.5A,B). Collagen content was consistently 
higher for constructs grown in low ACA, while high ACA samples had the lowest 
collagen content. Elastin levels showed a similar trend. There was a positive correlation 
between the percentage of FDP that had been degraded and both the collagen (r
2
=0.81, 
p<0.001) and elastin (r
2
=0.69, p<0.001) content. The weekly amounts of collagen and 
elastin deposited so that times of peak elastin and collagen deposition could be compared 
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with the concentration of FDP in the medium during the preceding week. For the low 
ACA group, collagen deposition was highest during the first week and decreased weekly, 
except for a spike at week 4 (Figure 2.5C). Constructs grown in higher concentrations of 
ACA, which had delayed peaks in fibrin degradation (Figure 2.3A), had delayed peaks in 
collagen deposition as well: the intermediate and high ACA groups had maximal collagen 
deposition in the second week. A positive correlation was found between the 
concentration of FDP in the medium and the collagen produced each week during the 
first two weeks of remodeling (r
2
=0.84, p<0.01) (Figure 2.5D). In contrast to the collagen 
results, weekly elastin deposition did not correlate with FDP concentrations in the 
medium (Figure 2.5E). (r
2
=0.34), p=0.22). Over the first four weeks, elastin 
deposition/week increased for the low ACA group and was consistently elevated 
compared to the high ACA group. 
Increased collagen and elastin content of the low ACA tissue constructs could be 
due in part to higher cellularity. By week 1, the vSMC in all constructs had proliferated, 
with highest construct cellularity occurring in the constructs grown in the lowest ACA 
concentration (Figure 2.5F). The cellularity increased in all three groups over the course 
of the five weeks, with the highest number of population doublings occurring in the first 
week for all ACA concentrations.  
However, the increased cellularity does not entirely explain the higher collagen in 
the low ACA group: in the first week, vSMC deposited more collagen per cell in the low 
ACA constructs than in the intermediate and high ACA constructs (Figure 2.6). Since the 
higher collagen deposition in the low ACA group cannot be fully explained by the 
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increased cellularity of these constructs, other possible factors influencing collagen 
deposition will be examined. 
Trichrome and Picrosirius red staining of constructs harvested at 5 weeks revealed 
the differences in fibrin remodeling that occurred depending on ACA concentration 
(Figure 2.7). The low ACA constructs showed extensive remodeling with visible collagen 
deposition, while the high ACA constructs had more limited remodeling and minimal 
collagen staining. A thickness difference is also apparent in these constructs, with the less 
remodeled, high ACA constructs consistently appearing thicker than the low ACA 
constructs. Nuclear staining with Hoechst 33342 confirmed higher cellularity in the low 
ACA constructs compared to the high ACA constructs at 1 week (Figure 2.8A,B), as well 
as at the 5 week experimental end point (Figure 2.8C,D). 
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Figure 2.5: Plasmin inhibition decreases collagen and elastin content and cellular 
proliferation in tissue constructs. A) Collagen and B) elastin contents increased with 
time and were lower with higher ACA treatment. C) Net collagen deposited per week, 
and E) net elastin deposited per week are shown to depict times of peak ECM deposition. 
D) A correlation exists between the FDP concentration 24 hours prior to harvest in the 
medium and the collagen deposited for that week during the first two weeks of 
remodeling (r
2
=0.84, p<0.01). Dashed lines represent the 95% confidence band for the 
regression line. F) Cellularity of constructs decreased with increasing ACA 
concentrations. Values are mean ± SEM for 5 constructs in all panels. 
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Figure 2.6: Collagen deposited per cell was higher in the low ACA constructs during 
the first week.  * indicates a significant difference (p<0.05) from low ACA samples.  
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Figure 2.7: Histological sections show enhanced remodeling of low ACA constructs. 
A) Lillie’s trichrome staining of five-week constructs shows enhanced fibrin remodeling 
in the low ACA constructs. Collagen-rich regions stained green, residual fibrin and other 
non-collagenous protein are red, and nuclei stained black. The 3 mM ACA construct has 
visible collagen staining and more extensive remodeling than the higher (6, 12 mM) ACA 
constructs. B) Picrosirius red staining indicates increased and/or more mature collagen 
content in low ACA constructs. Images were exposed identically to visualize staining in 
the 3 mM construct. Scale bar=50 μm.  
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Figure 2.8: Increased cellularity is apparent in low ACA constructs. Hoechst 33342 
staining of SMC nuclei shows increased staining in A,C) 3 mM ACA constructs 
compared to B,D) 12 mM ACA constructs. Staining was performed at A-B) 1 week of 
culture and C-D) 5 weeks of culture.  
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To address the functional consequence of reduced collagen content in fibrin-based 
constructs, tubular constructs were cultured in varying ACA concentrations and harvested 
after 5 weeks for mechanical testing. Use of 3 mM ACA produced tubular constructs that 
were too difficult to handle, and could not be measured accurately for thickness or 
mechanical properties using our current methods. This also made the 3 mM ACA 
constructs unpractical as vascular grafts, thus only higher ACA concentrations (6, 9 and 
12 mM ACA) were examined. Tubular constructs cultured in 6 mM ACA had higher 
collagen and cell densities compared to 12 mM ACA constructs (Figure 2.9A,B). The 6 
mM constructs were also stiffer than the 12 mM constructs (Figure 2.9C). As was 
apparent in the histology for the disc constructs, the tubular constructs were thicker when 
high ACA was used (Figure 2.9D), however this did not affect the final length of the 
tubular constructs (Figure 2.9E). Lillie’s trichrome stains of the tubular constructs show 
higher staining for collagen, both on the luminal and abluminal surface, for constructs 
grown in low ACA (Figure 2.10). These results compare well to the results with fibrin 
discs and illustrate that the increased collagen deposition correlates with increased 
construct stiffness. 
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Figure 2.9: ACA decreases collagen and cell density, as well as the stiffness, of 
tubular fibrin-based tissue constructs after 5 weeks in culture. A) collagen density 
and B) cell density of constructs were decreased with high ACA treatment. C) High ACA 
decreased Young’s modulus of tubular tissue constructs. D) Constructs grown with high 
ACA were thicker than low ACA constructs. E) There was no significant difference in 
final length of the constructs at 5 weeks. Values are mean ± standard deviation for 6 
samples. 
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Figure 2.10: Lillie’s trichrome staining of tubular constructs shows decreased fibrin 
remodeling with high ACA treatment. The lumenal surface of the tube is oriented 
towards the upper left. Collagen is stained green, residual fibrin and other non-
collagenous proteins are red, and nuclei are black. The low ACA construct has visible 
collagen staining and more extensive remodeling than the high ACA constructs. Scale 
bar=20 μm. 
 
2.3.5 ACA and FDP affect collagen deposition in vSMC culture. 
ACA may influence cellularity and collagen deposition in the fibrin-based 
constructs through a number of mechanisms. To determine if ACA had a direct biological 
effect on the cells, 0, 3, 6, and 12 mM ACA were used to supplement the medium of 
vSMC grown on tissue culture plastic, and the cell and collagen contents were quantified 
after 1 week. As was seen in the constructs (Figure 2.6), significant decreases in collagen 
deposition per cell occurred at the higher ACA concentrations (Figure 2.11A). There was 
no difference in cellularity between groups (Figure 2.11B). 
To examine potential stimulatory effects of FDP, plasmin-derived FDP were used 
to supplement the medium of vSMC cultures. There was a 50% increase in collagen 
deposited per cell when 250 or 500 µg/ml FDP was added (Figure 2.12A), but no 
difference in cellularity (Figure 2.12B). 
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Figure 2.11: Addition of ACA to vSMC on tissue-culture plastic decreased collagen 
deposition. A) vSMC deposited less collagen per cell when 6 or 12 mM ACA was added. 
B) Cellularity was not altered by addition of ACA to the medium medium. Values for 
cellularity and collagen deposition per cell were normalized to the untreated control. 
Values are mean ± SEM for 6 wells for all panels. * indicates a significant difference 
compared to control (p<0.05). 
 
 
 
Figure 2.12: Addition of plasmin-generated FDP to vSMC on tissue-culture plastic 
increased collagen deposition. A) Addition of 250 or 500 μg/ml FDP increased collagen 
deposition per cell. B) Cellularity was not altered by addition of FDP to the medium. 
Values for cellularity and collagen deposition per cell were normalized to the untreated 
control. Values are mean ± SEM for 6 wells for all panels. * indicate a significant 
difference compared to control (p<0.05).  
 
0 3 6 12
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
1.1
[ACA] (mM)
N
o
rm
a
liz
e
d
 C
o
lla
g
e
n
/c
e
ll
0 3 6 12
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
1.1
[ACA] (mM)
N
o
rm
a
liz
e
d
 C
e
llu
la
ri
ty
A B 
A B 
52 
2.3.6 Higher concentrations of FDP are measured within the construct interstitial 
fluid than in the overlying medium. 
The maximal FDP concentration measured in the construct medium was roughly 
120 μg/ml (in the low ACA constructs), which is not in the range shown to provide 
biological activity in vSMC culture (Figure 2.12A). However, the concentration of FDP 
within the interstitial fluid of the constructs may have been higher due to a high rate of 
FDP production versus slow diffusion of FDP into the medium and/or binding 
interactions of FDP with ECM that retarded FDP diffusion into the medium. To examine 
this possibility, low ACA constructs were harvested for interstitial FDP measurement 
daily and compared to the medium FDP measurement. There were large differences in 
these values (Figure 2.13). The largest differences occurred on the days after a medium 
change, when 6-9 fold increases in FDP concentration were measured within the 
interstitial fluid. The average difference over the 8 days was approximately a 5-fold 
increase in FDP measured in the interstitial fluid compared to the medium. After 8 days, 
sufficient volumes of interstitial fluid were not available for harvest from the constructs. 
This study was done with a different isolation of vSMC, which most likely accounts for 
the decreased fibrinolysis in these results as compared to the earlier study (Figure 2.4A). 
However, it proves that substantially higher concentrations of FDP may be present within 
the construct than are measured within the overlying medium. 
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Figure 2.13: The FDP concentration measured in the interstitial fluid of the 
construct is higher than the FDP concentration measured in the overlying medium. 
FDP were measured in the medium or interstitial fluid daily for one week. Higher 
concentrations of FDP were present in the interstitial fluid than in the medium for 
constructs in 3 mM ACA based on one-way ANOVA (p<0.05). Values are mean ± 
range/2 for n=2. Medium changes occurred on days 3 and 6 and are depicted in the 
figures with a square around the day; the medium was sampled for the FDP measurement 
immediately prior to the medium change, thus the medium values are always lower on 
the following day. 
 
2.3.7 Addition of FDP to construct culture increases collagen deposition. 
Supplementation of construct medium with plasmin-derived FDP for one week 
led to increased collagen deposition (Figure 2.14A) without affecting cellularity (Figure 
2.14B). Supplementing with 250 and 500 µg/ml FDP led to increased collagen deposition 
per cell in low ACA constructs, while an increase in collagen deposition in the high ACA 
constructs only occurred when 500 µg/ml FDP was added. The FDP concentration 
profiles shown in Figure 2.13 are from the same second set of experiments and thus 
represent the low and high ACA constructs that received no added FDP. There was no 
difference in collagen deposited per cell for these controls (Figure 2.14A) as there was in 
previous experiments with a different isolation of vSMC (Figure 2.6). This may be due to 
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the lower fibrinolysis in these constructs during week one for both low and high ACA as 
compared to the earlier experiments (Figure 2.3A).   
 
Figure 2.14: Constructs supplemented with high FDP concentrations had increased 
collagen deposition per cell. A) Collagen deposited per cell was enhanced when 
constructs were supplemented with FDP. B) Cellularity of constructs was not affected by 
addition of FDP. Values are mean ± SEM for 5 constructs for both panels. * indicates 
significant differences (p<0.05) compared to low ACA control (3 mM ACA). # indicates 
significant difference (p<0.05) compared to high ACA control (12 mM ACA). 
2.4 Discussion 
ACA has documented potency against plasmin, uPA, and tPA over the range of 3-
12 mM used in this study (29-31). This potency was confirmed by the effective inhibition 
of zymography using these concentrations. Plasmin inhibition by ACA, either directly or 
through plasminogen activators, has broad effects on fibrin remodeling driven by vSMC 
in fibrin-based tissue constructs. Most directly, inhibition prevents the degradation of the 
network of fibrin fibrils that entraps the vSMC. Without ACA, active plasmin in the 
system leads to rapid digestion of the fibrin and resulted in the destruction of the tissue 
construct in less than 24 hours. The use of ACA delayed fibrin degradation, with 
increasing concentrations of ACA leading to delayed and diminished FDP production. 
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While a fibrinolytic inhibitor such as ACA is necessary in the system in order to control 
fibrin degradation, this study shows that ACA can also have negative side effects. 
Increasing the ACA concentration led to less remodeled constructs, with lower cellularity 
and lower collagen and elastin content. 
 The reasons for these negative outcomes with high ACA usage were explored in 
this chapter. During the first two weeks of construct incubation, the FDP concentration in 
the medium was highly correlated with collagen deposition. This indicates two likely 
possibilities for how ACA effects fibrin remodeling: 1) degradation of fibrin is required 
for new matrix deposition or cell proliferation and/or 2) FDP have a direct biological 
effect on vSMC that leads to increased matrix deposition or cell proliferation. In support 
of the latter, vSMC cultures and fibrin constructs supplemented with 250 or 500 µg/ml 
FDP deposited more collagen per cell than the untreated controls, indicating FDP 
generation during remodeling of fibrin constructs has the potential for direct biological 
activity. Cellularity in vSMC culture and constructs was not altered by FDP addition. 
FDP levels within the construct, and hence the effective local concentration of FDP seen 
by the cells, were found to be, on average, 5-fold higher than the concentration measured 
in the medium. Constructs cultured in 3 mM and 6 mM ACA had peak FDP of 120 and 
50 µg/ml in the medium and thus could be expected to reach a biologically active FDP 
concentration within the interstitial fluid of the construct. Since FDP generation is 
severely reduced when high concentrations of ACA are utilized, FDP-mediated collagen 
deposition is more likely to occur at lower ACA concentrations. 
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In addition to inhibition of FDP generation, inhibition of plasminogen activation 
could have other negative effects on vSMC proliferation and matrix production. In vSMC 
culture, ACA negatively affected matrix deposition, as treatment with the higher 
concentrations of ACA (6 and 12 mM) led to decreased collagen deposition per cell. This 
indicates that ACA has broader effects than just limiting fibrin degradation. Many growth 
factors are sequestered in the ECM in a latent form; plasmin activity has been shown to 
release TGF-, IGF, and FGF2 from these latent complexes, leading to increased 
mitogenic activity (51-53). TGF- in particular has been shown to increase transcription 
and deposition of collagen vSMC in fibrin-based tissue constructs (13, 54). Thus, the use 
of ACA may not only inhibit fibrinolysis; it may also inhibit other positive effects of 
plasmin in our system.  
Though increased fibrin degradation was shown to influence cellularity, 
especially during the first week, our results did not implicate FDP signaling or adverse 
effects of the ACA in cell proliferation. Cell density and contact, composition and density 
of the matrix, and thickness of the tissue may influence this parameter. Furthermore, the 
cellularity of these constructs is defined by vSMC survival as well as proliferation, 
confounding the analysis of vSMC DNA measurements alone. This makes a complete 
understanding of the effects of a three-dimensional matrix on cell survival and 
proliferation, and more specifically the effects of fibrin degradation on these parameters, 
complex and unattainable from the current data sets. Unlike collagen density, the 
cellularity of the constructs does not directly affect construct mechanics; increased 
cellularity does not necessarily equate with higher collagen deposition or mechanical 
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properties. Understanding the reasons for increased vSMC cellularity in lower ACA 
constructs could be an interesting line of questioning, but may not lead to the overall goal 
of a stronger construct. 
This study demonstrates that plasmin can have multiple effects with regard to 
fibrin remodeling by vSMC in fibrin-based tissue constructs. Plasmin acts to degrade 
fibrin, which correlates positively with deposition of new ECM molecules collagen and 
elastin. One key byproduct of plasmin activity is the generation of FDP, which we have 
shown to increase collagen deposition by vSMC in monolayer culture and in the 
constructs. Therefore, in order to ultimately fabricate a fibrin-based tissue construct for 
implantation, the time course of plasmin activity and the associated rate of FDP 
generation must be carefully prescribed. This will be of particular importance as new 
cells types are considered or for the eventual use of autologous cells for implant. 
Different cell isolations can be expected to have varied fibrinolytic activity; thus, careful 
monitoring of fibrinolysis will be necessary to allow for appropriate remodeling of fibrin-
based tissue constructs.  
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Chapter 3: Fabrication of Fibrin-Based Arteries Seeded 
with Rat Blood Outgrowth Endothelial Cells 
3.1 Introduction 
The small-diameter media equivalents (MEs) fabricated in Chapter 2 will require 
endothelialization to limit the need for anti-coagulation therapy during implantation. 
With the goal of producing a complete artery, including medial and intimal layers, this 
chapter will examine the formation of an endothelium on the MEs. Use of an inbred rat 
strain for the vascular smooth muscle cells (vSMCs) and endothelial cells (ECs) should 
allow for implant studies in the infrarenal abdominal aorta of adult rats with minimal 
anti-coagulant and immunosuppressant therapy. This will be important for examining in 
vivo remodeling of the fibrin-based arteries, as well as ensuring appropriate burst 
pressures and thromboresistance can be maintained after implantation. 
Fibrin has been shown to be a good matrix for cell adhesion (1) and, for this 
reason, has been utilized to coat synthetic vascular grafts prior to endothelialization (2). 
Swartz et al. seeded ovine umbilical vein ECs on vSMC entrapped MEs after two weeks 
of culture and allowed the ECs to proliferate for 10 days until confluence was reached. 
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These constructs were then implanted in the jugular vein of lambs for 15 weeks, after 
which time vWF staining showed EC were adherent on the lumenal surface (3). This is a 
promising first result with fibrin-based grafts, however the study brings up a number of 
questions. As the implanted ECs were not labeled, the source of the ECs on the lumenal 
surface post-excision could not be addressed. These cells could be the initial cells seeded 
on the graft or they may be ECs that have re-endothelialized from the host lamb, either by 
ingrowth from the anastomoses or through hematogenous seeding of ECs or their 
precursors. Further, as the ECs were seeded on the ME after only 2 weeks, this lumenal 
surface is likely largely composed of unremodeled fibrin. To be able to withstand arterial 
pressures, the MEs will need to be cultured in vitro longer and allowed to go through 
more extensive remodeling. This will likely affect the ECM composition at the lumenal 
surface, as well as EC adhesion. 
Past work by our lab has utilized rat vECs on media equivalents fabricated with 
entrapped vSMCs that were cultured for 5 weeks. In these studies it was shown that MEs 
could be seeded with near confluent monolayers (98.8 ± 0.9%) by 48 hours post-seeding. 
vEC retention under shear stress was also high; retention was 96.5 ± 4.4% when steady, 
laminar shear stress for 48 hours at 10 dynes/cm
2
. After 24 hours of steady, laminar flow, 
a subset of the samples was exposed to pulsatile flow with a mean shear stress of 10 
dynes/cm
2
 for 24 hours; retention of vEC in this group was 94.3 ± 4.3% (4). Though the 
mechanical properties of these MEs did not reach the required burst pressures necessary 
for implant, these results are a good first indication that endothelial cells can be seeded on 
the remodeled fibrin MEs and remain adherent under shear stress. 
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The following chapter examines the use of rat blood outgrowth endothelial cells 
(RBOECs) for endothelium formation on rat vSMC-entrapped fibrin-based MEs. BOECs 
represent an easily accessible source of endothelial cells, with a high proliferative 
capacity and a stable endothelial cell phenotype (5). The research in the following chapter 
is necessary for the development of a non-immunosuppressed animal model, as well as 
more generally for validation of the use of RBOECs with vascular grafts. The MEs with 
optimized fibrin degradation from Chapter 2 will be used for these studies. These MEs 
were also optimized at 1-2 mm inner diameter sizes and a final length of 3-4 cm to ensure 
the RBOEC-seeded ME will be an appropriate size for eventual inter-positional implant 
into the rat aorta.  
3.2 Materials and Methods 
3.2.1 Cell Source 
RBOECs were isolated and expanded from 8 week old Fischer rats by Dr. Robert 
P. Hebbel’s lab, as previously described for murine BOECs (6). The protocol for rat 
blood collection was approved by the University of Minnesota Institutional Animal Care 
and Use Committee (IACUC). RBOECs were cultured in EGM medium (EBM-2 
medium with EGM Singlequot supplement kit; Clonetics) supplemented with an 
additional 8% fetal bovine serum (FBS; Hyclone), 1% penicillin/streptomycin 
(Invitrogen), and 0.22 mg/mL dibutyryl cyclic adenosine monophosphate (cAMP; Sigma-
Aldrich, Inc.). RBOECs were cultured on type I rat tail collagen-coated flasks and 
subcultured upon reaching 90% confluence using 0.25% trypsin EDTA (Gibco Invitrogen 
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Co.). RBOECs were cryopreserved in 90% FBS with 10% dimethyl sulphoxide (Sigma-
Aldrich, Inc) and used at from passage 8-14. Where specified, RBOECs expressing 
Green Fluorescent Protein (GFP-RBOEC) were utilized from passage 15-20. Fischer rat 
vascular SMCs were isolated as described in chapter 2 and utilized for ME fabrication at 
passage 6. 
3.2.2 Fibrin-based ME Fabrication 
Fibrin-based MEs were fabricated as described in the previous chapter. For these 
studies, the initial concentrations were 5x10
5
 vSMC/ml and 3.3 mg/ml fibrinogen solid 
(F4753, Sigma Aldrich, St. Louis, MO). MEs were fabricated with a 2 mm inner mandrel, 
and an outer tubular glass mold with an inner diameter of 9 mm and length of 7.5 cm.  
After fibrin gelation, the MEs were cultured in medium consisting of DMEM/F12, 
antibiotic/antimycotic (Invitrogen), 10% FBS, 50 µg/ml ascorbate (Sigma Aldrich), 1 
ng/ml TGF-β (R&D Systems, Minneapolis, MN), 2 µg/ml insulin (Sigma Aldrich), and 6 
mM ACA (Thermo Fisher Scientific). Medium was changed every 2-3 days until MEs 
were used for RBOEC seeding at 5 weeks. The mechanical properties and composition of 
MEs cultured with these conditions was examined in Chapter 2 (Figure 2.9, 2.10), 
however the use of a different isolation of vSMC and a different lot of fibrinogen made 
re-characterization necessary. In an attempt to improve ME mechanical properties, a 
subset of MEs was cultured with 5 ng/ml EGF instead of TGF-β.  
3.2.3 ME Characterization 
Histology, biochemical analysis of collagen, elastin, total protein and cellularity, 
and uniaxial tensile testing were performed as described in Chapter 2. Burst pressure and 
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compliance of the MEs were also assessed by applying an increasing intraluminal 
pressure until rupture. A syringe pump in line with a pressure transducer was utilized to 
inflate the ME after it has been attached to hose barbs and a barb fitting capped at one 
end (Figure 3.1). MEs were pressurized with HBSS at a rate of approximately 5 mmHg/s. 
Constructs were preconditioned to 120 mmHg repeatedly prior to inflation to failure and 
the outer diameter was continuously monitored using a laser micrometer (Mitutoyo, 
LSM-503H). Diameter and pressure were logged using Labview software and 
compliance of the constructs was calculated based on measurements between 80 and 120 
mmHg to approximate rat blood pressure. The mean physiological compliance was 
described as a change in diameter (Δd/d) for a pressure rise from 80 mmHg to 120 mmHg 
and was expressed as a % per mmHg.   
 
Figure 3.1: System for testing burst pressure and compliance. A syringe pump was 
used to pressurize the vessel, while a pressure transducer and laser micrometer collect 
pressure and diameter data using LabView software. 
 
3.2.4 RBOEC Characterization 
Cell type was initially characterized by Dr. Robert Hebbel’s lab by positive 
immunostaining for endothelial cell markers VE-Cadherin, von Willebrand Factor 
(vWF), FLK-1, and RECA-1 and negative staining for CD14, a monocyte marker. 
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Further staining was performed in our lab using rabbit anti-vWF antibody (10 μg/ml; 
Abcam) and Cy3-conjugated donkey anti-rabbit secondary antibody (1:200 dilution; 
Jackson Immuno).  
RBOECs were also examined for uptake of acetylated low density lipoprotein 
labeled with 1,1'-dioctadecyl 3,3,3',3'-tetramethyl-indocarbocyanine perchlorate (Dil-
acLDL; Biomedical Technologies, Inc). RBOECs were seeded at 20,000 cell/cm
2
. After 
48 hours in culture, 10 μg/ml Dil-acLDL in EGM medium was added to the cells for 4 
hours at 37C. RBOEC cultures were rinsed with Hanks balanced salt solution (HBSS), 
then fresh EGM medium added and cells were imaged by epifluorescent microscopy for 
ac-LDL uptake. RBOEC cultures without Dil-acLDL and vSMC cultures exposed to Dil-
acLDL were used as negative controls.  
3.2.5 Tubule Formation on Matrigel or Fibrin 
300 μl of cold matrigel (BD Biosciences) was added to wells of a 24 well plate. 
Matrigel was allowed to gel for 30 minutes at 37C prior to seeding with 10,000 
RBOECs/cm
2 
in EGM medium. Every 24 hours for 4 days, the wells were imaged for 
formation of tubule-like structures and network formation. 
As a second substrate, fibrin gels were also used to examine tubule formation. 
Acellular fibrin gels were formed in 24 well plates, using 3.3 mg/ml fibrin solid and 300 
μl gel per well and the same methods described for fibrin gels in Chapter 2. RBOECs 
were seeded at 10,000 cells/cm
2
 on the surface of these gels, and formation of tubule-like 
structures examined. Prior to imaging, RBOECs were stained with Dil-acLDL, as 
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described previously, to improve visualization. Images were taken daily for 4 days post-
seeding.  
3.2.6 RBOEC Monolayer Shear Stress Experiments 
RBOECs were seeded on collagen-coated Permanox slides at 40,000 cells/cm
2
. 
These cells were cultured for 48 hours, at which time confluence was reached, and then 
the slides were exposed to steady, laminar shear stress in a commercial parallel plate flow 
system (Streamer; Flexcell International Corp) (Figure 3.2). Flow was initiated at 0.5 
dynes/cm
2
 and increasing to 5 dynes/cm
2
 at a rate of 0.5 dynes/cm
2
 every 5 minutes. 
Shear stress was applied for 24 hours and then the RBOECs were fixed with cold, 4% 
PFA fixation for 10 minutes. Fixed RBOEC monolayers were stained for 1 hour with 
mouse anti-rat vascular cell adhesion molecule-1 (VCAM-1, 5 μg/ml; Santa Cruz 
Biotech), mouse anti- rat intercellular adhesion molecule-1 (ICAM-1, 2 μg/ml; Santa 
Cruz Biotech), or mouse IgG antibody at the same concentrations (Jackson Immuno) in 
phosphate buffered saline (PBS). After rinsing, Cy3-conjugated Donkey anti-mouse 
secondary antibody (1:200; Jackson Immuno) in PBS was applied for 45 minutes. Cell 
nuclei were stained with Hoechst 33342 at 1 μg/ml for 10 minutes and mounted with a 
glass coverslip and Vectashield fluorescent mounting medium (Vector Labs).  All images 
were collected using an Olympus inverted microscope and analyzed using NIH Image J 
Software. Cell numbers per image were derived by fixed thresholding of the images, 
followed by counts of the independent Hoechst nuclei. These values were normalized to 
the known surface area of the image to yield cell density measurements.   
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Figure 3.2: Flexcell Streamer System. This system allows application of shear stress to 
six slides simultaneously. A) Streamer device. B) Closed flow loop with medium 
reservoir, peristaltic pump, pulse dampender, and the Streamer device. (Figures from 
Flexcell International, www.flexcellint.com) 
  
3.2.7 Thrombin Activation of BOECs in Monolayer Culture 
BOECs were seeded on collagen-coated Permanox slides as described above. 
After 48 hours the cells were exposed to 2 U/ml thrombin for 24 hours in EGM medium. 
RBOEC activation was assessed through immunostaining for known activation markers 
by fixing and staining for ICAM-1 and VCAM-1, as described in the prior section. 
3.2.8 Endothelialization of MEs 
After 5 weeks of culture, remodeled fibrin tissue constructs were slit axially and 
placed lumenal surface down on a glass slide using a method adapted from Kladakis et 
al.(7) (Figure 3.3A-C). A rectangular Delrin ring with a 1.5 mm high wall was placed 
around the piece of tissue and filled with a solution of 4% low gel temperature agarose 
(A0701; Sigma). A glass slide was placed on top of the Delrin ring, and the agarose was 
allowed to gel. The sandwiched agarose and tissue was flipped and the top glass slide 
removed, exposing the lumenal surface of the construct. A second Delrin ring was placed 
on top of the first to form a well for cell culture medium. HBOECs or HUVECs in 
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suspension were labeled with 2.5 μM CellTracker Green (Invitrogen) for 15 minutes at 
37C and then were seeded on the lumenal surface of the tissue constructs. The cells were 
seeded slowly, drop-wise onto the tissue at a concentration of 2 x 10
6
 cells/ml, with 
approximately 100,000 cells added per square centimeter of tissue. One hour after 
seeding 5 ml of EGM medium was added to each well. 24 hours after seeding, the 
medium was changed to remove non-adherent cells. As controls in the shear stress 
experiments, RBOECs were seeded on collagen-coated Permanox slides at the same 
density. 
 
Figure 3.3: Diagram of endothelialization and parallel plate flow chamber setup. A) 
MEs are slit open axially and embedded lumen side down in agarose on a glass slide. A 
second slide is place on top. B) After the agarose gels, the system is flipped and the glass 
slide in contact with the ME can then be removed, exposing the lumenal surface. C) 
RBOECs are seeded on this surface and either cultured statically or D) placed in a PPFC 
where steady, laminar shear stress can be applied by the flow EGM medium across the 
lumenal surface. 
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3.2.9 Shear stress Experiments on MEs 
New parallel plate flow chambers (PPFCs) were designed to allow mounting of 
tissue in the system. These PPFCs were fabricated based off the designs of Levesque and 
Nerem (8) and Nauman et al (9) and meet a number of requirements: 1) provide steady, 
uniform laminar flow across the surface of the construct, 2) allow mounting of an axially-
sliced ME flush to the bottom surface, and 3) permit visualization by microscopy in real 
time (Figure 3.3; 3.4). 
This system has been chosen for its well-defined flow conditions. Steady, laminar 
flow can be achieved through the use of parallel plate, channel flow geometry where the 
channel height (h) is much less than either the length (L) or width (b). To ensure two-
dimensional, fully developed flow across the specimen, a small Reynolds number (Re) 
and estimated entrance length (Le) are desired:  
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Here, the Reynold number and entrance length have been expressed in terms of the wall 
shear stress (  ), gap thickness (h), and the viscosity ( ) and density ( ) of the perfusion 
medium. By knowing the volumetric flow rate (Q) or pressure gradient (
  
  
), the wall 
shear stress (  ) can be determined: 
   
   
   
                                                  (3.2.9-3) 
   
  
 
  
  
                                                 (3.2.9-4) 
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The dimensions of the channel are 1.8 cm with a length of 5 cm, and a channel height that 
is determined by the inclusion of a silicone gasket of 250 µm. For each experiment, this 
height was confirmed by measuring the chamber with and without the gasket inserted 
using a laser micrometer.  
Each PPFC was run independently in a closed loop, with a reservoir that allows 
gas exchange, a peristaltic pump, and a pulse dampener. A flow probe (Transonic 
Systems) and blood pressure transducer (Harvard Apparatus) were used to measure and 
confirm flow rate and pressure. EGM medium was used to prime the PPFC and flow loop 
prior to loading the GFP-RBOECs seeded on type I rat tail collagen-coated Permanox 
slides or embedded MEs on glass slides (Figure 3.4). GFP-RBOECs were cultured 
statically for 48 hours prior to loading in the PPFC and then were exposed to shear stress 
starting at 0.5 dynes/cm
2
 and increasing to 5 dynes/cm
2
 at a rate of 0.5 dynes/cm
2
 every 5 
minutes. Shear stress was held at 5 dynes/cm
2
 for 24 hours prior to harvest of the GFP-
RBOEC-seeded ME or collagen-coated slides.  
For short duration shear stress experiments, GFP-RBOEC were seeded on the 
collagen-coated slides or MEs as previously described. The GFP-RBOEC were then 
loaded in the PPFCs and the shear stress gradually increased at 0.5 dynes/cm
2
 every 
minute; however, prior to start of flow and then at 1, 5, 10, 25 dynes/cm
2
 the shear stress 
was held for 20 minutes and then the surfaces imaged using an Olympus inverted 
microscope. These images were analyzed with ImageJ software (NIH) by fixed 
thresholding of the images and then quantification of the percentage of the image area 
covered by GFP-RBOECs.    
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Figure 3.4: PPFC with ME. The ME embedded in agarose is loaded in the PPFC with a 
0.25 mm silicone gasket on top to create the flow channel. Use of glass slides to create 
the chamber walls allows for real-time visualization of fluorescently-labeled RBOECs 
with an Olympus inverted microscope.  
 
3.2.10 Live/Dead Staining of vSMC MEs 
To ensure that the vSMC in MEs embedded in agarose were still living, non-
agarose embedded MEs, MEs 2 hours post-embedding, and MEs 24 hours post-
embedding were incubated in 4 μM calcein AM and 4 μM ethidium homodimer 
(Invitrogen) in PBS for 30 minutes at 37C. MEs were rinsed with PBS and then imaged 
with FITC and TRITC fluorescent filters on an Olympus IX70 inverted microscope. Live 
cells convert cell-permeant calcein AM to fluorescent calcein via intracellular esterase 
activity, producing fluorescent green cells. Dead cells take up ethidium homodimer 
through damaged membranes and the dye binds to nucleic acids, which enhances the 
fluorescences and stains the dead cells read.  
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3.2.11 Statistical Analysis 
Statistical analysis was performed using GraphPad Prism software for Windows 
(GraphPad Software, Inc., San Diego, CA). Two-way ANOVA with Bonferroni post hoc 
analysis was conducted to evaluate significant differences between groups in the short 
duration shear stress experiments. Student t-tests were performed for comparisons of 
experiments with two groups. A significance level of α=0.05 was used for all tests. All 
graphs indicate mean ± standard error of the mean (SE).  
3.3 Results 
3.3.1 ME Characterization 
MEs were fabricated using the same methods as found in Chapter 2, however the 
use of a new isolation of vSMCs and a different lot of fibrinogen lead to different 
remodeling properties. Thus, the ME composition (Table 3.1) and mechanical properties 
(Table 3.2) are reported for the vSMC MEs utilized for these studies. A subset of MEs 
was supplemented with EGF instead of TGF-β. MEs cultured with EGF had higher 
cellularity and collagen deposition (Table 3.1), as well as a higher ultimate tensile 
strength (UTS), Young’s modulus, and burst pressure (Table 3.2). The properties of these 
MEs were still inferior to the native rat aorta. Figure 3.5 illustrates the conditioning 
curves and pressurization to failure steps of the burst pressure testing of a representative 
ME that was cultured with EGF. 
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Table 3.1: Composition of MEs. 
 Total Protein 
(mg/ml) 
Collagen 
(mg/ml) 
Elastin 
(mg/ml) 
Cellularity 
(Million/ml) 
ME + TGF-β 249±19 9.2±0.2 0.25±0.02 24.9±3.7 
ME + EGF 163±11 22.3±3.8 0.16±0.06 186±47 
Mean ± standard deviation for n=5-6 MEs.  
 
Table 3.2: Mechanical properties of MEs and native rat aorta. 
 Thickness 
(mm) 
UTS  
(MPa) 
Modulus  
(MPa) 
Burst Pressure 
(mmHg) 
Compliance 
(%/100 mmHg) 
ME + TGF-β 0.27±0.01 0.29±0.02 0.50±0.03 127±78 N/A* 
ME + EGF 0.33±0.02 0.35±0.03 1.15±0.20 497±203 4.6 ±1.3 
Native rat aorta 0.12±0.01 3.52±0.62 14.07±2.05 1174±131*  
Mean ± standard deviation for n=5-6 MEs or aortic segments. *Compliance was measure from 80-120 
mmHg, however many ME + TGF-β samples burst in this range. Compliance is not reported for these 
values. *Estimated from the measured UTS, wall thickness (t) and radius (r) using BP=UTS*t/r. 
 
 
 
Figure 3.5: Burst pressure testing of MEs. A) The ME was pre-conditioned from 80-
120 mmHG at a rate of 3 mmHg/s prior to B) inflation to failure. This data was collected 
from a ME supplemented with EGF. 
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Prominent collagen deposition was evident in the MEs cultured with TGF-β or 
EGF, as seen with Lillie’s trichrome staining (Figure 3.6). Collagen-staining was seen 
throughout the ME, however it was most apparent on the lumenal surface. In Lillie’s 
trichrome staining non-collagenous proteins, including fibrin, stain red. The lumenal 
surface of the MEs stained more strongly for these proteins, most likely indicating the 
presence of higher quantities of residual fibrin on this surface.  
 
Figure 3.6: Histology of ME sections after 5 weeks in culture. Lillie’s Trichrome stain 
of A) ME cultured with TGF-β and B) ME cultured with EGF. Collagen-rich regions 
stain green, residual fibrin and other non-collagenous proteins are red and nuclei stain 
black. Scale bar = 200 μm. 
 
3.3.2 RBOEC Characterization 
RBOECs and GFP-BOECs (Figure 3.7A) were characterized by immunostaining 
to ensure phenotypic similarities to mature endothelial cells. These cells stained 
positively for VE-Cadherin, vWF, Flk-1, and RECA-1, all markers found on mature 
endothelial cells (Figure 3.7B-E).  RBOECs and GFP-BOECs were negative for CD14, a 
marker of monocytes (not shown). These cells also had functional characteristics similar 
to mature ECs; they took up ac-LDL (Figure 3.7F) and formed tubules on matrigel 
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(Figure 3.7G). Groups have reported that ECs can also form tubules on fibrin gels (10), as 
well as within fibrin gels (11). We examined this attribute with RBOECs seeded on 
acellular fibrin gels. Using our standard fibrin concentration for vascular grafts and 
seeding RBOECs at a low initial density, tubule-like structures formed on the surface of 
fibrin gels (Figure 3.8). These tubules formed predominately in areas of low cell density, 
while other regions of the gels had near complete monolayer formation. 
 
Figure 3.7: Characterization of RBOECs. A) Image showing GFP expression by 
RBOECs. B) VE-Cadherin. C) vWF. D) Flk-1. E) RECA-1. F) DiI acLDL uptake. G) 
Tubule formation on matrigel. (Images courtesy of Sethu Nair and Dr. Arif Somani). 
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Figure 3.8: Tubule formation on 3 mg/ml fibrin gel. A,C) Transmission images. B,D) 
Fluorescent images of RBOECs stained with Dil-acLDL. Scale bar = 200 μm and applies 
to all images.  
 
VCAM-1 and ICAM-1 expression by RBOECs was examined in response to a 
number of stimuli. An initial interesting point, however, is that the RBOECs expressed 
VCAM-1 and ICAM-1 without stimulation, a results that is not reported for human EC 
(12) or human BOECs (5) in vitro. VCAM-1 expression has been previously reported for 
mouse BOECs (6) as well as low, constitutive expression on the mouse aortic 
endothelium (13). This indicates that the basal levels of VCAM-1 and ICAM-1 may 
differ between species. However, this could also be due to the effects of the in vitro 
culture conditions. When RBOECs were cultured in MCDB 131 containing FBS but no 
additional supplements, VCAM-1 expression decreased compared to the EGM medium, 
which contains a variety of cytokines and growth factors (Figure 3.9A). While our 
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interest is not in the effects of the media on BOEC activation, this does show that the 
VCAM-1 and ICAM-1 expression by RBOECs in vitro may be a result of their specific 
culture conditions.  
Stimulation with thrombin has been shown to increase VCAM-1 and ICAM-1 
expression by human umbilical vein endothelial cells (14). In experiments with 2 U/ml 
thrombin added to RBOEC culture for 24 hours, VCAM-1 expression was elevated 
(Figure 3.9B). This shows that the RBOECs are responsive to an agonist and that the 
basal levels of VCAM-1 expression can be elevated by stimulation. 
 
Figure 3.9: VCAM-1 expression by RBOECs. A) VCAM-1 expression is lower in 
MCDB 131 medium (p<0.5). B) VCAM-1 expression is increased by stimulation with 
thrombin. Plots show mean ± SE for n=3 samples. 
  
For these studies, we were interested in finding an inflammatory marker that was 
also shear stress dependent. This would allow us to examine the effects of shear stress on 
the RBOECs and ensure they are shear stress responsive. The application of shear stress 
has been shown to modulate expression of ICAM-1 and VCAM-1, however this 
modulation is magnitude dependent; Low shear stress and disturbed flow have different 
effects on VCAM-1 and ICAM-1 expression than physiological shear stress (12, 15). For 
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these experiments, we were limited in the magnitude of shear stress we could impose by 
poor retention of RBOECs at higher shear stresses. Shear stresses above 5 dynes/cm
2
 led 
to loss of RBOECs over a 24 hour period. At 5 dynes/cm
2
 RBOECs were well retained 
on the collagen-coated surface (Figure 3.10A). Furthermore, at 5 dynes/cm
2
 shear stress 
was able to modulate the expression of VCAM-1 (Figure 3.10B), decreasing its 
expression by approximately 50%. No significant difference in ICAM-1 expression was 
shown between static and shear stress exposure (Figure 3.10C). Higher shear stresses 
may be required to be able to cause or detect modulation of ICAM-1 expression. 
 
Figure 3.10: Shear stress effects the expression of VCAM-1 by RBOECs. A) Shear 
stress applied for 24 hours at 5 dynes/cm
2
 does not alter the cell density of RBOEC 
monolayer cultures. B) VCAM-1 expression. *VCAM-1 expression is reduced in 
RBOEC exposed to shear stress (p<0.05). C) ICAM-1 expression. Plots show mean ± SE 
for n=3 samples. 
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3.3.3 Endothelialization of MEs 
MEs were slit open and embedded lumenal surface up in agarose. To ensure that 
the application of 37-39 C agarose and the subsequent culture of the tissue in in this 
substrate did not lead to significant cell death, cells were examined for calcein AM and 
ethidium homodimer staining at 1 hour and 24 hours post-embedding. vSMCs stained 
strongly and uniformly for calcein AM, a marker of living cells at both time points and in 
control, non-embedded MEs. Dead cells that took up ethidium homodimer were sparse in 
all samples. Representative images from 24 hour samples are shown in Figure 3.11A,B. 
GFP-RBOECs were seeded on non-stained MEs immediately post-embedding. 
After 24 hours the RBOECs were adherent and spread (Figure 3.11C,D). RBOECs 
adhered to the exposed surface of the bioartificial matrix but did not adhere to the agarose 
that surrounded this tissue (Figure 3.11D). 
 RBOECs were seeded on the vSMC remodeled-fibrin matrix at a subconfluent 
density, 50,000 cells/cm
2
, or a supraconfluent density, 200,000 cell/cm
2
. 24 hours after 
seeding the RBOECs were labeled with DiI-acLDL and examined for adhesion and 
confluence. The RBOECs that were seeded at less than confluence initially were able to 
proliferation on the matrix, reaching confluence by 96 hours (Figure 3.12A,B). RBOECs 
that were seeding with more cells than were required to form a confluent monolayer were 
confluent at 48 hours and maintained a monolayer through 2 more days of culture (Figure 
3.12C,D).  
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Figure 3.11: Endothelialization of MEs. MEs were embedded in agarose and seeded 
with GFP-RBOECs. To ensure that the method for embedding with agarose did not lead 
to vSMC death, 24 hours after embedding the vSMC were examined for staining with A) 
calcein AM for live cells and B) ethidium homodimer for dead cells. While many spread 
cells were visible in the tissue, few dead cells were present. C,D) GFP-BOECs were 
seeded on the tissue and imaged after 24 hours. C) Middle regions of the tissue showed 
good coverage. D) Images on the edge of the tissue show that the GFP-BOECs only 
adhere to the tissue and not to the agarose.   
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Figure 3.12: RBOECs seeded on MEs. RBOECs were seeded at A,B) subconfluent 
(50,000 cells/cm
2
) or C,D) supraconfluent densities, then labeled with DiL-acLDL and 
examined at A,C) 48 hours  and B,D) 96 hours.  
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3.3.4 RBOECs remained adherent on MEs when exposed to shear stress  
RBOECs were seeded on MEs and remained adherent when exposed to steady, 
laminar shear stress of 5 dynes/cm
2
. A confluent monolayer was present after 24 hours of 
flow exposure, as illustrated by images of DiI-acLDL-labeled RBOECs in cross-sections 
and en face (Figure 3.13).  
 
 
Figure 3.13: RBOECs remain adherent under 5 dynes/cm2 shear stress on MEs. 
RBOECs were seeded on MEs for 48 hours and then either A,B) cultured statically or 
C,D) exposed to shear stress for 24 hours. RBOECs were labeled for visualization with 
DiL-acLDL and imaged A,C) in 9 μm cross-sections or C,D) en face on fixed tissue.  
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 Short duration shear stress experiments were performed up to a shear stress of 25 
dynes/cm
2
. GFP-RBOECs were seeded on collagen-coated Permanox slides or MEs. 
After 48 hours of culture, the RBOEC-seeded substrates were imaged and then exposed 
to a ramped shear stress. At 1, 5, 10, and 25 dyne/cm
2
 the shear stress was held for 20 
minutes and images collected. RBOEC coverage on the MEs at 1, 5, 10 or 25 dynes/cm
2
 
did not vary significantly from the initial, static coverage; however there was a drop in 
RBOEC coverage on the collagen-coated surfaces at 25 dynes/cm
2
 compared to the initial 
coverage (Figure 3.14). A significant difference did not exist between the two surfaces at 
25 dynes/cm
2
. At all shear stress levels and both substrates, RBOECs remained spread 
and, even for the subset with the lowest coverage, 25 dynes/cm
2
 shear stress with 
RBOECs on collagen-coated surfaces, greater than 80% coverage was maintained. 
 
Figure 3.14: RBOEC coverage of bioartificial tissue or type I collagen-coated plastic 
after exposure to shear stress. RBOECs were seeded on type I collagen-coated TCP or 
bioartificial tissue and incrementally exposed to 1, 5, 10,  or 25 dynes/cm
2
 for 20 minutes 
and GFP-RBOEC surface coverage calculated based on the GFP staining. Plot show 
mean ± SE for n=3 samples. *Significant difference compared to static samples on the 
same substrate (p<0.05). 
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3.4  Discussion 
The design of a small-diameter vascular graft has been referred to as a Holy Grail 
of tissue engineering (16, 17). This chapter examines methods to fabricate an entirely 
biological vessel, from formation of the medial, load-bearing layer, to seeding of 
endothelial cells to form a neoendothelium. The medial layer was formed from vSMCs 
embedded in a fibrin gel. Over time, the vSMC compact the gel and deposit new ECM. 
Optimizing the culture conditions and supplements for these MEs has been shown in to 
be an important method for improving collagen and elastin synthesis (18-22). Previous 
reports have shown that EGF improved cellularity and collagen deposition by dermal 
fibroblast in fibrin gels compared to control and TGF-β supplemented gels (23). We 
found similar results for our MEs, however the control (no EGF or TGF-β) MEs were too 
thin and weak for reliable testing. By supplementing with EGF we were able to reach 
maximal burst pressures of approximately 800 mmHg. Though resting systolic pressure 
in a rat is 120 mmHg, MEs for implant should be able to tolerate properties in large 
excess of this resting peak. Preliminary implants with MEs with burst pressures of 
approximately 400 mmHg were able to withstand short durations (hours) interpositionally 
in the rat aorta without rupture (Appendix B), which indicates that MEs fabricated with 
EGF may have sufficient burst pressures for implant studies in the rat abdominal aorta. 
However, vSMC MEs were plagued with a number of issues that are not as 
prevalent with other cell types in our lab, such as human dermal fibroblasts; vSMC MEs 
were inconsistent in their properties, with big differences depending on the isolation, the 
passage number, and the fibrinogen lot, as well as between fabrications and between 
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dishes from the same fabrication. This made the development of reproducible MEs that 
could reach near-native mechanical properties a difficult endeavor. These studies, 
including characterization of the RBOECs and seeding of these cells on the vSMC MEs, 
will be useful preliminary studies for the eventual development of a fibrin-based 
construct for use in a rat model. However, methods to improve reproducibility with the 
rat vSMCs will be necessary prior to implantation.  
Prior to seeding RBOECs on the lumenal surface of the MEs, these cells were 
characterized by immunostaining as well as basic functional assays. RBOECs displayed a 
phenotype typical of a mature endothelial cell, as they stained positively for VE-Cadherin 
and vWF. They also had functional characteristics similar to mature ECs; they took up 
ac-LDL and formed tubules on matrigel. These results compare well with BOEC 
characterizations for other species (5, 6).  
RBOECs also formed tubule-like structures on fibrin, a result that has been shown 
for other types of ECs (10, 11). Further studies will clearly need to be performed to 
ensure formation of tubule lumens, as well as examination of the RBOECs within fibrin 
gels not simply seeded on top of fibrin. However, this was a promising initial finding; it 
demonstrates a functional attribute of RBOECs that compares well with what has been 
found with mature ECs and is of particular interest in our lab, as the angiogenic potential 
of RBOECs could be used in conjunction with our fibrin-based technologies to form 
vascularized tissues.   
RBOECs responded to stimuli in an expected manner for endothelial cells. 
Thrombin stimulated VCAM-1 expression in RBOECs, while shear stress applied at 5 
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dynes/cm
2
 for 24 hours was able to decrease VCAM-1 expression. As we are ultimately 
interested in RBOEC response to shear stress and the ability to form a quiescent, non-
activated monolayer, ICAM-1 and VCAM-1 were chosen based on their shear stress-
dependence (15) and their implication in leukocyte adhesion and inflammation. While 
these results were able to show that RBOECs are responsive to shear stress, poor 
retention of the RBOECs on collagen-coated plastic during 24 hours of shear stress made 
analysis at higher shear stress values impossible.  
RBOECs were able to adhesion and proliferate on the ME lumenal surface. Using 
a custom-designed PPFC, steady, laminar shear stress was applied to the constructs. 
Good retention of the RBOEC could be maintained at 5 dynes/cm
2
 for a 24 hour period, 
however similar results with cell loss were encountered at higher shear stress levels. 
Short duration shear stress studies on both MEs and collagen-coated surfaces implicate 
the longer flow duration as part of the problem. Greater than 80% coverage was 
maintained collagen-coated slides at shear stresses up to 25 dynes/cm
2
. No significant 
loss was apparent with shear stresses up the highest tested (25 dynes/cm
2
) on the MEs. 
This indicates that loss of the RBOECs occurs over longer durations that the 20 minute 
increments we were examining.  
A number of methods could be examined for improving RBOEC adhesion, as well 
as for diagnosing the issue. Though various shear stress ramping profiles were examined 
for RBOECs, possibly an even slower increase, such as increasing over days instead of 
hours or holding at a low shear stress for longer durations prior to ramping to a set shear 
stress, might allow the cells to adapt and remain adherent on the surface.  A variety of 
integrins play a pivotal role in EC adhesion to the ECM, including αVβ3 and α5β1 for 
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fibrin and fibronectin binding (24). Integrin expression by RBOECs could be examined 
and compared to other rat EC types. This could help in diagnosing whether there is an 
issue with the underlying matrix or the phenotype of the RBOECs. Decreasing the trypsin 
concentration has been shown to improve EC adhesion to fibronectin by increasing α5β1 
integrin retention during cell lifting (25). Thus, the integrin expression profile might yield 
insight into the reasons for RBOEC detachment. Further studies could also examine 
RBOEC versus mature rat ECs on various matrix coatings under shear stress.  
This chapter describes a basic characterization of the medial and endothelial layer 
of a bioartificial vascular graft. These results show that vSMC MEs with burst pressures 
up to 800 mmHg can be fabricated and seeded with a confluent layer of RBOECs. 
RBOECs were shown to have a typical EC phenotype, take up acLDL, form tubules on 
matrigel and fibrin, and respond to thrombin and shear stress stimuli. The RBOEC could 
adhere to fibrin-based grafts, proliferate, and form a monolayer on the surface. RBOECs 
would maintain a confluent monolayer on the vSMC MEs when exposed to 5 dynes/cm
2
 
shear stress for long durations, or 25 dynes/cm
2
 for short durations. Future work aimed at 
improving vSMC ME reproducibility and RBOEC adhesion could transition this work 
into a functional, rat aortic implant. 
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Chapter 4: Adult Blood Outgrowth Endothelial Cells in 
Vascular Tissue Engineering 
4.1 Introduction 
Human blood outgrowth endothelial cells (HBOECs) are a promising cell source 
for vascular tissue engineering. These cells can be isolated by outgrowth of circulating 
endothelial progenitor cells (EPCs) from a patient blood sample (1) and thus could 
provide a convenient source of autologous endothelial cells for seeding on tissue-
engineered vessels prior to implantation. HBOECs, also called endothelial colony 
forming cells (ECFCs) and late outgrowth EPCs, have been shown to uniformly express 
endothelial cell markers, form tubular structures de novo, have typical endothelial cell 
morphology, and a robust proliferative capacity, expanding from 20 cells to 10
19 
cells in 9 
weeks (1). HBOECs are negative for hematopoietic cell markers CD45, CD14 and 
CD115 and do not phagocytize bacteria (1-4). This is in contrast to other putative EPCs, 
termed early outgrowth endothelial cells or colony forming unit endothelial cells (CFU-
ECs), which do not form vessels in vivo, will ingest bacteria, and express hematopoietic, 
as well as endothelial, cell markers (3). These CFU-ECs are likely of hematopoietic 
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origin (3, 5-8), but may express endothelial cell markers due to the uptake of platelet 
microparticles by mononuclear cells (9). This distinction between various cells termed 
EPCs in the literature is an important one, as unlike CFU-ECs, HBOECs have the 
potential to provide a highly proliferative, autologous endothelial cell source for vascular 
grafts.  
Endothelial cells make up the interface between the bloodstream and vascular 
tissue and play a crucial role in vascular protection, prevention of thrombosis, regulation 
of nutrient delivery, control of vessel diameter and tone, and hemostasis. These properties 
of the endothelium appear to be highly influenced by the mechanical environment, with 
extensive evidence indicating an important role for mechanical factors in influencing 
endothelial cell structure, growth, and function. Shear stress on the endothelium is critical 
for maintenance of a thromboresistant surface, control of vessel diameter and vascular 
permeability, and even endothelial cell survival (10-12).  
These essential functions of the endothelium must be fulfilled by a successful 
vascular graft. Indeed, several mechanisms of small diameter graft failure, such as 
thrombosis and inflammation, are most likely caused by a lack of a properly formed 
endothelium (11). For this reason, rigorous assessment of HBOECs is required to ensure 
successful use of these cells for vascular grafts. The endothelial layer needs to be 
confluent and remain adherent under normal physiological shear stresses, acting as a 
barrier between the blood and the procoagulant, sub-endothelial surface. Furthermore, 
these cells need to be in a non-activated, quiescent state, producing protective molecules 
that suppress platelet adhesion and activation, such as prostacyclin (PGI2) and nitric 
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oxide (NO), anticoagulation factors, such as thrombomodulin (TM), and fibrinolytic 
factors. In conjunction with this phenotype, HBOECs should show limited expression of 
proinflammatory molecules, such as intercellular adhesion molecule-1 (ICAM-1), 
vascular cell adhesion molecule-1 (VCAM-1), P-Selectin, and E-Selectin (11, 13). 
In vitro and in vivo studies have examined EPCs derived by a variety of methods 
for seeding on synthetic grafts (14-17), decellularized grafts (18) and tissue-engineered 
blood vessels (19, 20). Fewer studies have examined the specific HBOEC population for 
this same purpose (21, 22). However, these initial reports are promising as good HBOEC 
retention is reported on synthetic materials. 80% of ovine BOECs were retained on 
cholesterol-modified polyurethane after 2 hours of flow exposure at 75 dynes/cm
2
 (22). 
BOECs derived from cord blood have been shown to adhere on fibronectin or smooth 
muscle cell (SMC) monolayers at supraphysiological shear stresses (up to 300 
dynes/cm
2
) for short durations and align with flow after 48 hours of shear stress exposure 
at a physiological shear stress (15 dynes/cm
2
) (23). Importantly, HBOECs have been 
successfully isolated from patients with coronary artery disease (CAD) (24), indicating 
that isolation of adult HBOECs may be a viable option for seeding of vascular grafts for 
bypass surgery.  
To examine the suitability of adult HBOECs for use in vascular tissue 
engineering, the shear stress responsiveness of these cells was examined on bioartificial 
tissue formed from neonatal human dermal fibroblasts entrapped in tubular fibrin gels. 
During four weeks in culture, the HDFs degrade the initial fibrin scaffold and deposit 
new extracellular matrix (ECM), producing bioartificial tissue. The tissue strengthens and 
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stiffens over time, producing a matrix that more closely mimics native vascular tissue 
(25-27). Immunohistochemistry was used to identify predominate ECM on the surface of 
the bioartificial tissue, as well as ECM deposited by the HBOECs post-seeding. Cell 
density, elongation, alignment, NO production, and expression of the proinflammatory 
molecules ICAM-1 and VCAM-1 by HBOECs under shear stress were compared to 
human umbilical vein endothelial cells (HUVECs) to determine if HBOEC flow 
responses were similar to mature endothelial cells. A whole blood assay was used to 
examine platelet adhesion to HBOEC- and HUVEC-seeded constructs pre-exposed to 
shear stress.  
4.2 Materials and Methods 
4.2.1 Cell Source 
HBOECs were isolated and expanded from the peripheral blood of healthy, 
human volunteers, as previously described (28). The protocol for blood collection was 
approved by the University of Minnesota Institutional Review Board. The cells were 
maintained in endothelial growth medium (EGM; EBM-2 medium with EGM Singlequot 
supplement kit; Clonetics) supplemented with 8% additional fetal bovine serum (FBS; 
Hyclone), and 1% penicillin/streptomycin (Invitrogen). HBOECs were plated onto rat tail 
collagen I (BD Biosciences) and subcultured at 80-90% confluence using 0.05% trypsin 
EDTA (Gibco Invitrogen Co.). Flow cytometry of HBOEC isolations ensured positive 
staining for endothelial cell markers, including VE-Cadherin and P1H12, and negative 
staining for CD14 and CD45. These cells also displayed the characteristic cobblestone 
morphology of ECs, formed tubules in Matrigel, and took up acetylated low density 
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lipoprotein (acLDL; Biomedical Technologies, Inc). HBOECs were used from passage 8-
12 for all experiments. For comparison, human umbilical vein endothelial cells 
(HUVECs; Clonetics) were maintained in the same culture medium and used from 
passage 4-6. 
Neonatal human dermal fibroblasts (HDFs; Clonetics) were maintained in 50:50 
DMEM/F12 medium (Invitrogen; Calsbad, CA) supplemented with 10% fetal bovine 
serum (FBS, Hyclone), 100 U/ml penicillin (Invitrogen), 100 μg/ml streptomycin 
(Invitrogen), and 2.5 μg/ml amphotericin-β (Invitrogen). HDFs were plated at 8,500 
cells/cm
2
, passaged at 100% confluence, and used at passage 9.  
4.2.2 Fibrin-based Vascular Graft Fabrication 
Tubular fibrin constructs were made as previously reported (29). Briefly, HDFs 
suspended in DMEM were mixed into a solution of bovine fibrinogen (Sigma) in 20 mM 
Hepes-buffered saline. A mixture of bovine thrombin (Sigma) and calcium chloride in 
DMEM was then added to the suspension, mixed well, and injected into tubular glass 
molds measuring 8 cm long and 9 mm in inner diameter and containing 2 mm glass rods 
with stoppers on either end. The glass rods had been coated in 5% Pluronics F127 
(Sigma) for three hours to reduce adhesion between the fibrin gel and the mandrel. Final 
gel component concentrations were 3.3 mg/ml fibrin, 500,000 HDF/ml, 0.2 U/ml 
thrombin and 1.2 mM CaCl2. The solution was allowed to gel at 37ºC for 30 minutes, at 
which time the outer mold was removed and the constructs placed in DMEM 
supplemented with 10% FBS, 10 U/ml penicillin, 100 μg/ml streptomycin, and 2.5 μg/ml 
amphotericin-β. 2 μg/ml insulin and 50 μg/ml ascorbic acid were added to the medium to 
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enhance fibrin gel remodeling into tissue. Construct medium was changed 3 times per 
week until use at 4 weeks. Vascular constructs at 4 weeks were 3-4 cm long and 2 mm in 
diameter, with a wall thickness of approximately 200 μm.  
4.2.3 HBOEC and HUVEC Seeding on Bioartificial Tissue  
After 4 weeks, remodeled fibrin tissue constructs were slit axially and placed 
lumenal surface down on a polycarbonate sheet using a method adapted from Kladakis et 
al.(30). A polycarbonate cap with a 3 mm high groove was placed around the piece of 
tissue and filled with a solution of 4% low gel temperature agarose (A0701; Sigma). The 
agarose was allowed to gel and then the polycarbonate sheet was removed, exposing the 
lumenal surface of the construct (Figure 4.1A). A Teflon ring was placed around the cap 
to form a well for cell culture medium. HBOECs or HUVECs were labeled with 2.5 μM 
CellTracker Green (Invitrogen) and then were seeded on the lumenal surface of the tissue 
constructs. The cells were seeded slowly, drop-wise onto the tissue at a concentration of 
2x10
6
 cells/ml so as to achieve a seeding of 100,000 cells/cm
2
. One hour after seeding the 
tissue was rinsed with HBSS to remove non-adherent cells and 4 ml of EGM medium 
was added to each well. For TNF-α activation or shear stress experiments, cells were 
allowed to adhere for 24 hours prior to start of the experiment. 
4.2.4 Cell Staining 
HBOEC and HUVEC expression of thrombomodulin (TM), tissue factor (TF), 
endothelial nitric oxide synthase (eNOS), VCAM-1, ICAM-1 and VE-Cadherin was 
examined by immunocytochemistry. Cells seeded for 48 hours in EGM medium on tissue 
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culture plastic coated with type I rat tail collagen or whole tissue were rinsed with Hanks 
balanced salt solution (HBSS), fixed in 4% paraformaldehyde for 10 minutes, and 
blocked with 5% normal donkey serum for 1 hour at room temperature. Samples were 
incubated with mouse anti-human TM (5 μg/ml; American Diagnostica), goat anti-human 
TF (10 μg/ml; American Diagnostica), rabbit anti-human eNOS (4 μg/ml; Santa Cruz), 
mouse anti-human VCAM-1 (5 μg/ml; Chemicon), mouse anti-human ICAM-1 (5 μg/ml; 
Chemicon), goat anti-human VE-Cadherin (10 μg/ml; Santa Cruz) and isotype matched 
controls for 1 hour. After rinsing, Dylight 549 conjugated, host-matched secondary 
antibody (1:400; Jackson Immuno) was applied for 1 hour at room temperature. Hoechst 
33342 (1 ug/ml; Invitrogen) was used for staining of nuclei. Images were captured using 
epi-fluorescent microscopy (Olympus IX700) and confocal microscopy (Olympus 
Fluoview 1000). Measurement of the integrated fluorescent density per image for 
VCAM-1 and ICAM-1 was obtained with ImageJ software (NIH), as were cell counts per 
image. The integrated density per cell was calculated for each image and background 
values of the matched species IgG controls were subtracted. 
4.2.5 Vascular Graft ECM Characterization 
Constructs for histology were fixed in 4% paraformaldehyde for 3 hours at 4C, 
followed by overnight infiltration with 30% sucrose and 5% dimethyl sulfoxide (DMSO) 
in phosphate buffered saline (PBS). Samples were frozen in OCT (Tissue-Tek, Torrance, 
CA), sectioned into 9 µm thick cross-sections and stained with Lillie’s trichrome (31).  
Construct sections were also stained for the presence of various ECM proteins by 
immunohistochemistry. Sections were incubated with rabbit anti-human collagen I (2 
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μg/ml; Novus Biologicals), collagen IV (6 μg/ml; Abcam), laminin (10 μg/ml; Abcam), 
and fibronectin (1 μg/ml; American Diagnostica), goat anti-human fibrinogen (2 μg/ml; 
American Diagnostica), and isotype matched controls in 5% normal donkey serum in 
PBS (Jackson Immuno) overnight. After rinsing, sections were incubated with Dylight 
549 donkey anti-rabbit or anti-goat (1:400 dilution, Jackson Immuno) in PBS for 45 
minutes and counterstained for 10 minutes with Hoechst 33342 (1 μg/ml; Invitrogen).  
4.2.6 Shear Stress Experiments 
The polycarbonate caps with the embedded tissue seeded with HBOECs or 
HUVECs (Figure 4.1A) were placed in parallel plate flow chambers (PPFCs) modified 
from the design of Sakariassen et al (Figure 4.1B) (32). The PPFC had a slot height of 0.5 
mm, with a tapered inlet and outlet, reaching a final width of 1 cm. This chamber was 
redesigned from the chamber used in chapter 3 so that whole blood studies could also be 
run in the chamber. Thus, glass was removed from the system to limit platelet activation, 
the entire body is fabricated with polycarbonate, and inlet and outlet regions now allow 
for less turbulent flow of blood or cell culture medium. 
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Figure 4.1: Parallel plate flow chamber for application of shear stress on HBOEC- 
and HUVEC-seeded bioartificial tissue. A) Polycarbonate cap used for embedding 
bioartificial tissue in agarose. This cap can then be placed in B) and utilized in C) a 
closed loop consisting of a medium reservoir, a peristaltic pump and a pulse dampener. 
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The chamber was assembled in a closed loop consisting of a medium reservoir 
allowing for gas exchange, a peristaltic pump (Cole-Parmer, Vernon Hills, Illinois), and a 
pulse dampener (Cole Parmer) (Figure 4.1C). The system was primed with the EGM 
medium prior to placing the tissue within the system and then the flow rate was increased 
0.5 dyne/cm
2
 every minute, starting at 3 dynes/cm
2
 and increasing to 15 dynes/cm
2
. 
Steady laminar shear stress was applied for 24 hours and then the constructs were 
harvested for analysis. In the case of TNF-α exposure, 10 U/ml TNF-α was added to 
static and flow samples at the time flow was started.  
For short duration shear stress experiments, the shear stress was ramped as 
described; however, at 0, 1, 5, 10, 15 and 25 dynes/cm
2
 the shear stress was held for 20 
minutes and then the construct surface was imaged. HBOECs were seeded on bioartificial 
tissue and Type I collagen-coated tissue culture plastic (TCP) for 24 hours prior to 
application of shear stress. 12 images per sample were obtained of the CellTracker 
Green-labeled HBOECs using an Olympus IX70 inverted microscope. Images were 
thresholded at a fixed level and analyzed with ImageJ software (NIH) for % area 
coverage of the tissue surface. Unseeded TCP and bioartificial tissue were used as 
negative controls.  
4.2.7 Cell Retention, Orientation and Alignment 
HBOECs and HUVECs were stained and imaged for VE-Cadherin and Hoechst 
as described above. Confocal images were taken at 20x and 40x to eliminate imaging of 
Hoechst staining of the HDF nuclei. The number of nuclei per image were counted using 
ImageJ software and normalized to the area of the image to give a cell density. To 
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quantitate cell orientation and alignment, ImageJ software was used to outline each cell, 
based on the VE-Cadherin staining, and calculate the area, perimeter, major axis, minor 
axis, and angle of the major axis (cell alignment) with the flow direction. The shape 
index was calculated using: 
            
      
          
 
The shape index is a measure of the elongation of a cell and is equal to one for a 
circle and zero for a line. Decreasing values thus indicate that cells are becoming more 
elongated. 
4.2.8 Scanning Electron Microscopy 
Samples for scanning electron microscopy (SEM) were prepared using the 
fixation procedure of Ishihara et al.(33), with minor alterations for our tissue engineered 
constructs. Briefly, samples were removed from the PPFC, rinsed quickly with 37C 
Hanks balanced salt solution (HBSS), and then fixed with cold 3% glutaraldehyde for 2 
hours, washed with cold 5% sucrose for 1 hour and post-fixed with 1% osmium tetroxide, 
all on ice and in 0.1 M sodium cacodylate pH 7.3. After graded ethanol dehydration, 
samples were CO2 critical point dried, ion sputter coated with platinum to ~2 nm, and 
viewed in a Hitachi S-4700 or S-900 at 3.0 kV. 
4.2.9 NO Production 
Medium samples were collected from HUVEC and HBOEC seeding bioartificial 
tissue after 24 hours of static culture of exposure to 15 dynes/cm
2
 shear stress. Samples 
were frozen at -80C, lyophilized, and reconstituted at 2.5x the initial concentration. A 
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commercially available kit was used to convert nitrate to nitrite, followed by the 
spectrophotometric quantitation of nitrite levels using Griess Reagent (Calbiochem, San 
Diego, CA). 
4.2.10 Whole Blood Assay 
A platelet adhesion assay was performed with 1 U/ml heparinized whole blood in 
the PPFCs described above. Whole blood was collected from healthy, consenting donors 
under University of Minnesota Institutional Review Board approval and used at 37C 
within 2 hours of the blood draw. The system was primed with HBSS at 37C prior to 
loading with whole blood. The initial 5-10 ml of blood was discarded to remove any 
blood that had mixed with the HBSS and then the system was run as a closed loop at a 
shear rate of 400 s
-1
. After 20 minutes of whole blood exposure, HBSS was run through 
the system for 2 minutes to remove unbound platelets and leukocytes. The samples were 
removed from the flow chamber and fixed with 4% PFA for 10 minutes and then rinsed 
with HBSS. The tissue was simultaneously stained for EC junctions with goat anti-human 
VE-Cadherin and platelets with mouse anti-human GP-1b (1 μg/ml; Abcam) for 1 hour at 
room temperature. After rinsing with PBS, Dylight 549 donkey anti-mouse and Dylight 
649 donkey anti-goat secondary antibody (1:400; Jackson Immuno) were applied for 45 
minutes, followed by staining with Hoechst 33342 for 10 minutes. Samples were imaged 
on an Olympus Fluoview 1000 confocal microscope and platelet and leukocyte coverage 
quantified using ImageJ software. Images were converted to binary images by use of a 
fixed threshold. These images were used to calculate the area coverage of platelets or 
leukocytes. Values were normalized to the HBOEC static group.  
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4.2.11 Statistical Analysis 
Statistical analysis was performed using GraphPad Prism software for Windows 
(GraphPad Software, Inc., San Diego, CA). One-way and multivariate ANOVA with 
Bonferroni post hoc analysis was conducted to evaluate significant differences between 
groups. A significance level of α=0.05 was used for all tests. All graphs indicate mean ± 
standard error of the mean (SE).  
4.3 Results 
4.3.1 HBOECs formed a confluent monolayer on bioartificial tissue 
HBOECs adhered to the bioartificial tissue and formed a confluent monolayer 
(Figure 4.2A-C). The cells had typical cobblestone morphology, stained for VE-Cadherin 
and maintained cell-to-cell contact (Figure 4.2B,C). The HBOECs also expressed 
thrombomodulin (Figure 4.2D), an important endothelial anticoagulant molecule, while 
showing limited tissue factor expression (Figure 4.2E) until exposed to the agonist TNF-α 
(Figure 4.2F). Staining throughout the thickness of the tissue showed that TNF-α 
stimulated TF expression by the HBOECs on the lumenal surface as well as by the 
underlying fibroblasts.  
Non-endothelialized and HBOEC-seeded bioartificial tissue was stained for ECM 
molecules to assess the protein composition at the lumenal surface. The tissue was 
embedded in agarose with the lumenal surface exposed and cultured with or without 
HBOECs for 7 days. Immunostaining for fibrin, fibronectin, collagen I, collagen IV, and 
laminin highlighted the presence of all of these ECM proteins throughout the unseeded 
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(Figure 4.3A-E) and HBOEC-seeded tissue (Figure 4.3F-J). Residual fibrin, fibronectin 
and collagen I were present on the lumenal surface (Figure 4.3A-C); however, collagen 
IV and laminin staining was limited on the lumenal surface of the unseeded tissue (Figure 
4.3D,E). This is in contrast to the HBOEC-seeded tissue, where a distinct band of 
collagen IV and laminin were present on the lumenal surface (Figure 4.3I,J). This 
alteration on the lumenal surface of the HBOEC-seeded tissue is indicative of new ECM 
deposition by the HBOECs.  
 
Figure 4.2: HBOECs seeded on bioartificial tissue. A) Cross sectional and B-C) En 
face images of CellTracker Green-labeled HBOECs seeding on bioartificial tissue show 
that the HBOECs form a confluent monolayer on the tissue surface. Nuclei of HBOEC 
and HDF in the tissue are stained blue and VE-Cadherin staining is pseudo-colored red. 
D) HBOECs on the bioartificial tissue express TM. E) TF expression by HBOEC on 
unstimulated tissue and F) after exposure to TNF-α. B-D) Scale bar = 50 μm. E-F) Scale 
bar = 25 μm. 
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Figure 4.3: ECM staining of bioartificial tissue. A-E) Bioartificial tissue stained for 
ECM components. F-J) Bioartificial tissue seeded with HBOECs for 7 days prior to 
staining. A,F) Fibrin staining. B,G) Fibronectin staining. C,H) Collagen I staining. D,I) 
Collagen IV staining. E,J) Laminin staining. The lumenal surface is on the left side of 
each image, nuclei counterstained with Hoechst 33342. Scale bar = 100 μm. 
4.3.2 HBOECs remained adherent on bioartificial tissue under physiological shear 
stress and elongate in the flow direction 
HBOECs were seeded on collagen-coated TCP or bioartificial tissue and allowed 
to adhere for 24 hours. Surfaces were then exposed to increasing shear stress for 20 
minute durations at each shear stress step (1, 5, 10, 15, 25 dynes/cm
2
). HBOECs on 
collagen-coated TCP maintained 82.6 ± 1.2% surface coverage at 25 dynes/cm
2
 (Figure 
4.4). Surface coverage was improved by seeding on bioartificial tissue, with a surface 
coverage of 94.4 ± 0.6% at 25 dynes/cm
2
. Surface coverage began to drop for HBOEC on 
TCP beginning at 15 dynes/cm
2
, but was not significantly lower for HBOEC on 
bioartificial tissue until 25 dynes/cm
2
.  
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Figure 4.4: HBOEC retention under physiological shear stress for short durations. 
HBOECs were seeded on Type I collagen-coated TCP or bioartificial tissue and 
incrementally exposed to 1, 5, 10, 15, or 25 dynes/cm
2
 for 20 minutes and HBOEC 
surface coverage calculated based on the CellTracker Green staining. Plot shows mean ± 
SE for n=3 samples. *Significant difference compared to 1 dynes/cm
2
 samples on the 
same substrate (p<0.05). # Significant difference between HBOEC on TCP and 
bioartificial at the same shear stress.   
 
To examine long term seeding on bioartificial tissue, HBOECs and HUVECs 
were seeded at a cell density near confluence and allowed to adhere for 24 hours. After 
24 hours, seeded tissue was either maintained in static culture for another 24 hours 
(Figure 4.5A,C) or placed in a parallel plate flow chamber and laminar, steady shear 
stress applied at 15 dynes/cm
2
 (Figure 4.5B,D). After 24 hours under flow, HBOECs and 
HUVECs had begun to elongate in the flow direction, as illustrated with VE-Cadherin 
staining. VE-Cadherin staining of the cell junctions was visible in all samples and 
confirmed that HBOEC and HUVEC under flow still maintain a confluent monolayer. 
Though the HBOECs and HUVECs exposed to flow showed a marked change in cell 
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morphology, the cell density was not significantly altered by application of shear stress 
(Figure 4.5E). HBOEC and HUVEC elongation and alignment were quantified for 
comparison by calculation of the cell shape index and alignment angle. These 
measurements confirmed that by 24 hours, HBOECs and HUVECs were elongating and 
aligning in the flow direction (Figure 4.5F,G). There was no significant difference 
between HBOECs and HUVECs in shape index or the strength of alignment with flow by 
24 hours.  
HBOECs statically cultured on bioartifical tissue formed a confluent monolayer 
of cobblestone morphology with bulging nuclei and perinuclear regions (Figure 4.6A). 
After exposure to flow the cells were beginning to elongate in the direction of flow 
(Figure 4.6B), while maintaining confluence and cell-cell overlapping at regions of tight 
junctions (34) (Figure 4.6C). Both the static and flow conditioned cells showed numerous 
microvilli and cytoplasmic filaments characteristic of endothelial cells (33). 
In one set of experiments, HBOEC and HUVEC cell death was higher than usual 
for unknown reasons. However, an endothelial cell-specific phenomenon was noticeable 
in these cultures; HBOEC and HUVECs both maintained a confluent monolayer, 
rearranging underneath the dead cell to maintain endothelium integrity (Figure 4.7). 
HBOECs migrated or expanded underneath the dead cell and established tight junctions 
concurrent with dead cell detachment (Figure 4.7A,B). This EC-specific function has 
been shown for mature endothelial cells responding to injury (35, 36) and was visible in 
HUVEC cultures as well (Figure 4.7C,D). Reidy et al. show that as injured ECs retract 
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the adjoining cells migrate into the space, maintaining monolayer integrity and ensuring 
continuous coverage of the subendothelium (36). 
 
 
 
Figure 4.5: Retention, elongation, and alignment of HBOECs and HUVECs seeded 
on bioartificial tissue and exposed to shear stress. A-D) VE-Cadherin staining of A-B) 
HBOECs and C-D) HUVECs. A,C) Statically cultured cells. B,D) Cells cultured under 
15 dynes/cm
2
 for 24 hours. E) Cell density, F) elongation, and G) alignment of HBOECs 
and HUVECs after exposure to shear stress or static culture. The elongation is given as a 
shape index where 0 is a line and 1 is a circle. Cell alignment is given on a scale from 
perfectly aligned cells (0) to no alignment (45). *p<0.05 compared to static conditions. 
All plots show mean ± SE for n=3 independent experiments. Scale bar = 50 μm and 
applies to all images. 
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Figure 4.6: SEM of HBOECs on bioartificial tissue. HBOECs were A) cultured 
statically or B-C) exposed to 15 dynes/cm
2
 shear stress for 24 hours. A) HBOECs 
cultured statically had distinct cell boundaries and prominent nuclei. B) HBOEC 
elongation occurred in the flow direction. C) High magnification image of HBOEC 
junctions after exposure to flow. D) Non-endothelialized section of bioartificial tissue 
showing smooth surface of fibroblasts and underlying ECM. A,B,D) Scale bar = 10 μm. 
C) Scale bar = 3 μm. 
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Figure 4.7: Maintenance of endothelial integrity. A) HBOECs with classic endothelial 
cobblestone morphology and dead cell, denoted “D”.  HBOECs have moved or expanded 
underneath the dead cell and are establishing tight junctions (arrows) concurrent with 
dead cell detachment. B) Newly forming filamentous connection, as seen in lower right 
in A. C) HUVECs with dead cell “D” showing same reorganizing behavior D) Higher 
magnification of C showing junctions in the area likely occupied by the dead cell before 
detachment.  
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4.3.3 Expression of proinflammatory molecules VCAM-1 and ICAM-1 can be modulated 
with shear stress and TNF-α stimulation 
HBOEC expression of VCAM-1 and ICAM-1 after TNF-α stimulation was 
confirmed in static culture on collagen-coated TCP (Figure 4.8). This result agree with 
previous reports for the HBOEC response to TNF-α (1) and motivates our interest in 
examining VCAM-1 and ICAM-1 expression on bioartificial tissue as well as the 
potential for shear stress to modulate adhesion molecule expression. 
 
Figure 4.8: VCAM-1 and ICAM-1 expression on non-stimulated and TNF-α 
stimulated HBOECs cultured on collagen-coated TCP. A,C) VCAM-1 expression and 
B,D) ICAM-1 expression in A,B) unstimulated and C,D) TNF-α stimulated HBOECs. 
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Application of 15 dynes/cm
2
 shear stress for 24 hours did not significantly alter 
VCAM-1 or ICAM-1 expression by HBOECs or HUVECs compared to static culture 
(Figure 4.9). Background due to non-specific binding of the VCAM-1 and ICAM-1 
antibodies was subtracted from adhesion molecule expression during quantification by 
subtraction of mouse IgG control values, thus the values near zero indicate minimal 
expression of either VCAM-1 or ICAM-1, under static or shear stress culture, as these 
groups could not be distinguished statistically from the IgG controls.   
To examine the responsiveness of the HBOECs to an inflammatory stimulus, 10 
U/ml TNF-α was added to the cultures for 24 hours, during static culture or shear stress 
exposure. Addition of TNF-α increased VCAM-1 and ICAM-1 expression for both cell 
types, while shear stress was able to modulate this effect; shear stress conditioning 
combined with TNF-α stimulation decreased VCAM-1 and ICAM-1 expression 
compared to the static, TNF-α treated cells. VCAM-1 and ICAM-1 expression in the flow 
conditioned, TNF-α stimulated cells remained higher than the static or flow cultured, 
non-stimulated HBOECs and HUVECs. This indicates that HBOECs, like HUVECs, are 
responsive to biochemical inflammatory stimuli and modulate this response under steady 
laminar shear stress.  
Based on multivariate ANOVA, the major source of variation in VCAM-1 and 
ICAM-1 expression was accounted for by the application of shear stress or TNF-α; 
however, cell type was a significant source of variability for VCAM-1 expression as well 
(p<0.05). VCAM-1 expression by HBOECs was elevated compared to HUVECs when 
114 
TNF-α was applied to statically cultured cells. Cell type was not a significant source of 
variability for ICAM expression.   
 
Figure 4.9: VCAM-1 and ICAM-1 expression by HBOECs and HUVECs seeded on 
bioartificial tissue and cultured under static or flow conditions for 24 hours, in the 
presence or absence of TNF-α. A) VCAM-1 Expression. B) ICAM-1 Expression. Plots 
show mean ± SE for n=3 tissue samples. *Significant increase over static and flow 
groups of the same cell type (p<0.05). **Significant increase over all other groups of the 
same cell type (p<0.05).  
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4.3.4 eNOS expression and NOx production were elevated by exposure to shear stress 
After 24 hours of static culture or shear stress exposure at 15 dynes/cm
2
, HBOECs 
seeded on the bioartificial tissue were stained for eNOS (Figure 4.10A-B). eNOS was 
localized to the HBOEC layer on the lumenal surface of the tissue. While eNOS staining 
of the statically cultured HBOECs was sporadic throughout the HBOEC layer (Figure 
4.10A), flow conditioning increased the eNOS intensity and created a continuous band of 
eNOS throughout the HBOEC monolayer (Figure 4.10B).  
To assess the effect of higher eNOS expression by HBOEC or HUVEC, NO 
production was measured for these same samples. NO production was measured via the 
quantitation of NO byproducts, nitrate and nitrite, in the cell culture medium after 24 
hours of static culture or flow conditioning at 15 dynes/cm
2
 (Figure 4.10C). Similar basal 
levels of NO were seen in HUVEC and HBOEC static culture. Nitric oxide production 
was elevated approximately 19-fold in HBOEC and HUVEC cultures when shear stress 
was applied for 24 hours.  
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Figure 4.10: eNOS expression and NOx production by HBOEC and HUVEC seeded 
on bioartificial tissue and cultured under static and flow conditions for 24 hours. 
eNOS staining of HBOEC cross-sections after A) static culture or B) flow exposure. C) 
NO production was quantified by measurement of total nitrate and nitrite in the HBOEC 
and HUVEC culture medium. Values are normalized to the statically cultured HBOEC 
value. Plot shows mean ± SE for n=3 independent experiments. *NO production by 
HBOEC and HUVECs cultured under flow conditions increased compared to HBOEC 
static culture (p<0.01). Scale bar = 100 μm. 
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4.3.5 Platelet adhesion was lower following exposed to shear stress 
As an in vitro method for examining the functional effect of HBOEC and 
HUVEC seeding on the bioartificial tissue, endothelialized and non-seeded tissue was 
exposed to 1 U/ml heparinized whole blood in PPFCs for 20 minutes and platelet 
adhesion to the exposed surfaces was then quantified (Figure 4.11A,B). Activation of 
HBOECs with TNF-α for 4 hours prior to application of the whole blood increased 
platelet adhesion to the surface (Figure 4.11A). Platelet surface coverage was higher on 
non-seeded tissue (11.0±2.8%) than on HBOEC-seeded tissue (0.5±0.1%) or HUVEC-
seeded tissue (0.5±0.1%). Thus, HBOECs, like HUVECs, show decreased platelet 
adhesion compared to unseeded tissue.  
A subset of the HBOEC- and HUVEC-seeded tissue was exposed to 15 dynes/cm
2
 
shear stress for 24 hours prior to whole blood exposure. Pre-conditioning of the HBOECs 
and HUVECs with shear stress decreased platelet adhesion compared to the statically 
cultured cells. Higher platelet adhesion on the static samples could be due to application 
of shear stress for the first time during the whole blood study. This loss might not occur 
for HBOECs or HUVECs that were pre-exposed to shear stress prior to the whole blood 
study. The alternative is that shear stress modulates the phenotype of the endothelial 
cells, decreasing platelet adhesion. 
To examine the likelihood of these two possibilities, tissue samples were stained 
en face or after sectioning for VE-Cadherin and the platelet marker, GP-1b (Figure 
4.11C-E). Images indicated monolayer coverage after whole blood exposure for samples 
that were both statically cultured and shear-conditioned prior to the whole blood assay. 
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Platelet binding most often appeared co-localized with the VE-Cadherin stain (Figure 
4.11C). Platelets adhered near the junctions of cells, primarily as individual platelets 
(Figure 4.11C,D) and occasionally as small aggregates (Figure 4.11E).  
 
Figure 4.11: Platelet adhesion on HBOEC- and HUVEC-seeded bioartificial tissue 
pre-conditioned with 15 dynes/cm2 shear stress for 24 hours. A) Normalized platelet 
coverage. HBOEC-seeded tissue was compared to HBOEC-seeded tissue that was pre-
exposed to TNF-α for 4 hours or non-seeded tissue. All groups were normalized to the 
statically cultured HBOEC group. *p<0.001 compared to unstimulated HBOEC. 
#p<0.001 compared to stimulated and non-stimulated HBOEC-seeded tissue. B) 
HBOEC- and HUVEC-seeded tissue was statically cultured or exposed to 15 dynes/cm
2
 
shear stress for 24 hours prior to whole blood exposure. *p<0.05 compared to the 
statically cultured cells of the same EC type. C) En face image of platelet localization. 
Scale bar = 25 μm. Images of cross-sections showing D) platelet localization and E) 
platelet aggregation on the surface of statically cultured HBOECs. Scale bar = 50 μm. 
Plots show mean ± SE for one representative experiment with n=3 tissue samples.  
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4.4 Discussion 
The fabrication of a small-diameter vascular graft will require the incorporation of 
a non-thrombogenic lumenal surface, most likely through the formation of a functional 
neoendothelium, in order to obviate the need for anti-coagulation therapy. HBOECs are a 
promising cell source for this application, as they can be easily and non-invasively 
isolated, are highly proliferative, and do not suffer from smooth muscle cell 
contamination issues. The successful use of HBOECs for vascular tissue engineering will 
require 1) formation of a confluent monolayer on the tissue surface, 2) retention of the 
HBOEC under physiological shear stress, and 3) presentation of a non-thrombogenic and 
anti-inflammatory phenotype. As with native endothelium, responsiveness of the HBOEC 
to physiological shear stress will likely be necessary for the maintenance of a 
thromboresistant phenotype. 
 To address these requirements, bioartificial tissue was fabricated for HBOEC 
seeding. Tubular fibrin gels with entrapped HDF were allowed to remodel for 4 weeks as 
the HDFs degraded the fibrin and deposited new ECM, including fibronectin, laminin, 
and collagen I and IV, as shown in this study. The lumenal surface of the tissue stained 
positively for fibrin, fibronectin, and collagen I; however, collagen IV and laminin were 
primarily localized on the ablumenal surface. Fibronectin (37-40), laminin (37, 41, 42), 
collagen I (37, 38, 42), and fibrin (42-44) are all adhesion proteins that have been utilized 
to improve retention of ECs on vascular grafts, suggesting that a cell-produced matrix 
rich with these components would be conducive to EC adhesion and retention. Previous 
work with fibrin grafts made with SMCs had different localization of these adhesion 
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proteins; fibronectin and laminin were present on the lumenal surface, with collagen I 
primarily localized on the ablumenal surface (29).  
HBOECs were seeded on the lumenal surface of HDF remodeled tissue, where 
the cells deposited new ECM, which appeared as localized bands of the basement 
membrane proteins collagen IV and laminin on the lumenal surface of the tissue. These 
bands were not present in the non-endothelialized tissue. The deposition of laminin and 
collagen IV was shown after 7 days of HBOEC culture since increases in fluorescent 
intensity at the lumenal surface were not obvious by the 2 day time point. While all of the 
flow studies were started after only 24 hours of seeding, these staining results do show 
that HBOECs are depositing collagen IV and laminin on bioartificial tissue over the 
course of the first week. 
HBOEC adhesion and morphology was assessed on the bioartificial tissue. By 24 
hours post-seeding, HBOECs formed a confluent monolayer of cells, with cell-to-cell 
junction formation, as assessed by VE-Cadherin staining and SEM. SEM of the BOECs 
after static culture or 24 hours of shear stress on the bioartificial tissue illustrates 
alignment of the HBOECs with flow, as well as maintenance of a confluent monolayer 
and cell-cell overlap at regions of tight junctions. The morphology is similar to that 
reported for other EC types reported in the literature (45), including the presence of cilia 
on the cell surface (33). 
 To assess HBOEC retention and alignment under flow conditions, a shear stress 
of 15 dynes/cm
2
 was applied to mimic physiological arterial flow. When exposed to 15 
dynes/cm
2
 shear stress for 24 hours, HBOECs remained adherent, maintained a similar 
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cell density and VE-Cadherin staining, and elongated and aligned with flow. These 
results compared well with the HUVEC control cells used in these experiments, as well 
as with cell retention reported for cord blood-derived OECs (23) and short duration, high 
shear stress experiments with HBOECs (21, 22, 24).  
While HBOECs grown as monolayers on collagen-coated tissue culture plastic 
show limited expression of the proinflammatory markers ICAM-1 and VCAM-1 (1), 
expression of these markers may be altered depending on the underlying matrix as well as 
the presence of secondary cell types. SMC-EC co-culture has been shown to increase 
gene and protein expression of activation markers such as VCAM-1, ICAM-1, and E-
selectin, while shear stress modulates this expression (46, 47). Shear stress also alters 
activation marker expression in TNF-α stimulated and unstimulated EC monolayers (48-
52). Like mature ECs, HBOECs upregulate VCAM-1 and ICAM-1 when exposed to 
TNF-α, a proinflammatory cytokine (53). Similar to results found with HBOECs seeded 
on type I collagen (1), HBOECs seeded on bioartificial tissue express low levels of 
VCAM-1 and ICAM-1 until exposed to TNF-α. However, TNF-α stimulated ICAM-1 
and VCAM-1 expression was diminished by shear stress when TNF-α was administered 
during flow conditioning. These studies demonstrate that shear stress conditioning may 
be useful in decreasing surface expression of various procoagulation molecules on 
HBOECs, thereby promoting an anti-inflammatory phenotype, as reported for other ECs. 
Shear stress can also be used to increase eNOS expression and NO production in 
mature ECs (54-56). NO promotes blood vessel vasodilation, inhibits platelet adhesion 
and aggregation, and is constitutively expressed in native ECs, primarily through eNOS 
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activity (57-59). Thus, production of NO is a necessary phenotype for functional 
HBOECs seeded on bioartificial tissue. Similar basal levels of NO were produced by 
HUVECs and HBOECs cultured statically. We have shown that HBOECs increased total 
NO production when cultured with steady laminar shear stress for 24 hours, as did the 
HUVEC control cells. This correlates with increased staining for eNOS in tissue cross-
sections. 
Though assessment of HBOEC retention and function in vivo will be necessary 
for a full consideration of HBOEC function, in vitro studies allowed comparison of 
HUVECs and HBOECs for a number of quantifiable parameters. As a functional test, we 
developed a whole blood study to examine platelet adhesion under flow. Though the ideal 
in vitro whole blood experiment would be performed with non-anticoagulated blood 
drawn directly into the flow chamber from the donor, that setup requires that blood be 
drawn from the donor for the full duration of the experiment and limits the flow rate that 
can be applied. Thus, most platelet adhesion studies with whole blood rely on the use of 
anticoagulated blood, often with heparin as the anticoagulant of choice. Platelet adhesion 
to a number of surfaces is Mg
2+
-dependent, which rules out the use of citrated blood (60). 
A sub-therapeutic level of heparin, which prevented clotting during collection but 
enabled clotting on extended exposure to bioartificial tissue or collagen surfaces, was 
used for these studies.  
Bioartificial tissue seeded with HBOECs or HUVECs or left unseeded was 
exposed to whole blood at a shear rate of 400 s
-1 
to mimic blood flow in human arteries. 
This equates to a wall shear stress of approximately 15 dynes/cm
2
. Platelet coverage was 
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dramatically reduced on HBOEC-seeded bioartificial tissue as compared to non-seeded 
tissue. HBOECs and HUVECs had similar levels of platelet coverage, both when 
statically cultured and when pre-conditioned with shear stress for 24 hours prior to whole 
blood exposure. Pre-conditioning of the HBOECs or HUVECs with 15 dynes/cm
2
 shear 
stress for 24 hours reduced platelet adhesion compared to statically cultured samples. 
Though a limited loss of statically cultured HBOECs or HUVECs during exposure to 
whole blood could not be fully ruled out, fluorescent micrographs indicated that 
monolayer coverage by the HBOECs and HUVECs was preserved.  
Two likely possibilities exist for the decreased platelet adhesion on shear stress 
pre-conditioned surfaces. Pre-conditioning may have improved monolayer integrity, 
while blood flow over statically cultured HBOECs and HUVECs may have disrupted the 
endothelium, exposing the subendothelial matrix and increasing platelet adhesion on 
these substrates. However, increased thromboresistance of ECs under shear stress may 
also be responsible for decreased platelet adhesion. We have shown that HBOECs and 
HUVECs exposed to shear stress express higher levels of NO, while other groups have 
reported increased EC expression of PGI2, NO, thrombomodulin, and tissue plasminogen 
activator, and decreased expression of plasminogen activator inhibitor type-1 with shear 
stress (61). Lund et al. showed that HBOECs have lower tissue factor and higher eNOS 
gene expression when exposed to shear stress (62). This switch to a more 
thromboresistant phenotype with shear stress exposure could account for the decreased 
platelet adhesion on the shear stress pre-conditioned surfaces. Either of these 
possibilities, however, leads to the same conclusion: that pre-conditioning with shear 
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stress has the potential to improve the functional outcome with HBOEC and HUVEC 
neoendothelium. 
Methods to improve HBOEC adhesion and function upon implantation will be 
important benchmarks in developing a functional tissue-engineered vascular graft. As 
shear stress has been shown to have important effects on EC phenotype, adhesion, and 
function, shear stress preconditioning may represent another strategy for utilizing 
HBOECs successfully in endothelium formation. Shear stress preconditioning of EC-
seeded vascular grafts prior to implantation or exposure to high flow rates has been 
shown to improve EC adherence and phenotype (63-66). Our results with HBOECs 
seeded on bioartificial tissue indicate that 1) HBOECs are shear stress responsive and 2) 
HBOECs can be pre-conditioned with shear stress in vitro to increase NO production and 
decrease platelet adhesion.        
These results illustrate the potential utility for HBOECs in vascular tissue 
engineering, as not only do the cells adhere to the bioartificial tissue and remain adherent 
under physiological shear stress, they also exhibit low expression of activation markers 
and reduced platelet binding compared to unseeded tissue. Furthermore, exposure to 
shear stress decreased ICAM-1 and VCAM-1 expression on TNF-α stimulated HBOECs, 
increased eNOS expression and NO production, and decreased platelet adhesion during 
whole blood flow. These outcomes indicate that HBOECs are shear stress responsive and 
are functionally similar to HUVECs in their response to shear stress and their ability to 
limit platelet binding to a bioartificial vascular graft.  
125 
4.5 References 
1. Lin, Y., Weisdorf, D.J., Solovey, A., and Hebbel, R.P. Origins of circulating 
endothelial cells and endothelial outgrowth from blood. The Journal of clinical 
investigation 105, 71, 2000. 
2. Ingram, D.A., Caplice, N.M., and Yoder, M.C. Unresolved questions, changing 
definitions, and novel paradigms for defining endothelial progenitor cells. Blood 106, 
1525, 2005. 
3. Yoder, M.C., Mead, L.E., Prater, D., Krier, T.R., Mroueh, K.N., Li, F., Krasich, 
R., Temm, C.J., Prchal, J.T., and Ingram, D.A. Redefining endothelial progenitor cells 
via clonal analysis and hematopoietic stem/progenitor cell principals. Blood 109, 1801, 
2007. 
4. Hirschi, K.K., Ingram, D.A., and Yoder, M.C. Assessing identity, phenotype, and 
fate of endothelial progenitor cells. Arteriosclerosis, thrombosis, and vascular biology 28, 
1584, 2008. 
5. Rehman, J., Li, J., Orschell, C.M., and March, K.L. Peripheral blood "endothelial 
progenitor cells" are derived from monocyte/macrophages and secrete angiogenic growth 
factors. Circulation 107, 1164, 2003. 
6. Zhang, S.J., Zhang, H., Wei, Y.J., Su, W.J., Liao, Z.K., Hou, M., Zhou, J.Y., and 
Hu, S.S. Adult endothelial progenitor cells from human peripheral blood maintain 
monocyte/macrophage function throughout in vitro culture. Cell research 16, 577, 2006. 
7. Harraz, M., Jiao, C., Hanlon, H.D., Hartley, R.S., and Schatteman, G.C. CD34- 
blood-derived human endothelial cell progenitors. Stem cells (Dayton, Ohio) 19, 304, 
2001. 
8. Rohde, E., Malischnik, C., Thaler, D., Maierhofer, T., Linkesch, W., Lanzer, G., 
Guelly, C., and Strunk, D. Blood monocytes mimic endothelial progenitor cells. Stem 
cells (Dayton, Ohio) 24, 357, 2006. 
9. Prokopi, M., Pula, G., Mayr, U., Devue, C., Gallagher, J., Xiao, Q., Boulanger, 
C.M., Westwood, N., Urbich, C., Willeit, J., Steiner, M., Breuss, J., Xu, Q., Kiechl, S., 
and Mayr, M. Proteomic analysis reveals presence of platelet microparticles in 
endothelial progenitor cell cultures. Blood 114, 723, 2009. 
10. Davies, P.F. Flow-mediated endothelial mechanotransduction. Physiological 
reviews 75, 519, 1995. 
11. Wu, K.K., and Thiagarajan, P. Role of endothelium in thrombosis and hemostasis. 
Annual review of medicine 47, 315, 1996. 
12. Gimbrone, M.A., Jr., Topper, J.N., Nagel, T., Anderson, K.R., and Garcia-
Cardena, G. Endothelial dysfunction, hemodynamic forces, and atherogenesis. Annals of 
the New York Academy of Sciences 902, 230, 2000. 
126 
13. McGuigan, A.P., and Sefton, M.V. The influence of biomaterials on endothelial 
cell thrombogenicity. Biomaterials 28, 2547, 2007. 
14. He, H., Shirota, T., Yasui, H., and Matsuda, T. Canine endothelial progenitor cell-
lined hybrid vascular graft with nonthrombogenic potential. The Journal of thoracic and 
cardiovascular surgery 126, 455, 2003. 
15. Shirota, T., He, H., Yasui, H., and Matsuda, T. Human endothelial progenitor 
cell-seeded hybrid graft: proliferative and antithrombogenic potentials in vitro and 
fabrication processing. Tissue engineering 9, 127, 2003. 
16. Griese, D.P., Ehsan, A., Melo, L.G., Kong, D., Zhang, L., Mann, M.J., Pratt, R.E., 
Mulligan, R.C., and Dzau, V.J. Isolation and transplantation of autologous circulating 
endothelial cells into denuded vessels and prosthetic grafts: implications for cell-based 
vascular therapy. Circulation 108, 2710, 2003. 
17. Allen, J.B., Khan, S., Lapidos, K.A., and Ameer, G.A. Toward engineering a 
human neoendothelium with circulating progenitor cells. Stem cells (Dayton, Ohio) 28, 
318, 2010. 
18. Kaushal, S., Amiel, G.E., Guleserian, K.J., Shapira, O.M., Perry, T., Sutherland, 
F.W., Rabkin, E., Moran, A.M., Schoen, F.J., Atala, A., Soker, S., Bischoff, J., and 
Mayer, J.E., Jr. Functional small-diameter neovessels created using endothelial 
progenitor cells expanded ex vivo. Nature medicine 7, 1035, 2001. 
19. Schmidt, D., Asmis, L.M., Odermatt, B., Kelm, J., Breymann, C., Gossi, M., 
Genoni, M., Zund, G., and Hoerstrup, S.P. Engineered living blood vessels: functional 
endothelia generated from human umbilical cord-derived progenitors. The Annals of 
thoracic surgery 82, 1465, 2006. 
20. Aper, T., Schmidt, A., Duchrow, M., and Bruch, H.P. Autologous blood vessels 
engineered from peripheral blood sample. Eur J Vasc Endovasc Surg 33, 33, 2007. 
21. Thebaud, N.B., Bareille, R., Remy, M., Bourget, C., Daculsi, R., and Bordenave, 
L. Human progenitor-derived endothelial cells vs. venous endothelial cells for vascular 
tissue engineering: an in vitro study. Journal of tissue engineering and regenerative 
medicine 4, 473, 2010. 
22. Stachelek, S.J., Alferiev, I., Connolly, J.M., Sacks, M., Hebbel, R.P., Bianco, R., 
and Levy, R.J. Cholesterol-modified polyurethane valve cusps demonstrate blood 
outgrowth endothelial cell adhesion post-seeding in vitro and in vivo. The Annals of 
thoracic surgery 81, 47, 2006. 
23. Brown, M.A., Wallace, C.S., Angelos, M., and Truskey, G.A. Characterization of 
umbilical cord blood-derived late outgrowth endothelial progenitor cells exposed to 
laminar shear stress. Tissue Eng Part A 15, 3575, 2009. 
24. Stroncek, J.D., Grant, B.S., Brown, M.A., Povsic, T.J., Truskey, G.A., and 
Reichert, W.M. Comparison of endothelial cell phenotypic markers of late-outgrowth 
endothelial progenitor cells isolated from patients with coronary artery disease and 
healthy volunteers. Tissue Eng Part A 15, 3473, 2009. 
127 
25. Grassl, E.D., Oegema, T.R., and Tranquillo, R.T. A fibrin-based arterial media 
equivalent. Journal of biomedical materials research 66, 550, 2003. 
26. Syedain, Z.H., Weinberg, J.S., and Tranquillo, R.T. Cyclic distension of fibrin-
based tissue constructs: evidence of adaptation during growth of engineered connective 
tissue. Proceedings of the National Academy of Sciences of the United States of America 
105, 6537, 2008. 
27. Ahmann, K.A., Weinbaum, J.S., Johnson, S.L., and Tranquillo, R.T. Fibrin 
Degradation Enhances Vascular Smooth Muscle Cell Proliferation and Matrix Deposition 
in Fibrin-Based Tissue Constructs Fabricated In Vitro. Tissue Eng Part A, 2010. 
28. Lin, Y. Phenotypic characterization of outgrowth endothelial cells from cultures 
of peripheral blood and feasibility studies of using these cells in biomedical applications. 
2003. 
29. Isenberg, B.C., Williams, C., and Tranquillo, R.T. Endothelialization and flow 
conditioning of fibrin-based media-equivalents. Ann Biomed Eng 34, 971, 2006. 
30. Kladakis, S.M., and Nerem, R.M. Endothelial cell monolayer formation: effect of 
substrate and fluid shear stress. Endothelium 11, 29, 2004. 
31. Kiernan, J.A. Histological and histochemical methods : theory and practice. 
Oxford [U.K.] ; Boston: Butterworth-Heinemann, 1999. 
32. Sakariassen, K.S., Aarts, P.A., de Groot, P.G., Houdijk, W.P., and Sixma, J.J. A 
perfusion chamber developed to investigate platelet interaction in flowing blood with 
human vessel wall cells, their extracellular matrix, and purified components. The Journal 
of laboratory and clinical medicine 102, 522, 1983. 
33. Ishihara, T., Ferrans, V.J., Jones, M., Boyce, S.W., and Roberts, W.C. Occurrence 
and significance of endothelial cells in implanted porcine bioprosthetic valves. The 
American journal of cardiology 48, 443, 1981. 
34. Bowman, P.D., Ennis, S.R., Rarey, K.E., Betz, A.L., and Goldstein, G.W. Brain 
microvessel endothelial cells in tissue culture: a model for study of blood-brain barrier 
permeability. Annals of neurology 14, 396, 1983. 
35. Mohtai, M., and Yamamoto, T. Smooth muscle cell proliferation in the rat 
coronary artery induced by vitamin D. Atherosclerosis 63, 193, 1987. 
36. Reidy, M.A., and Schwartz, S.M. Endothelial injury and regeneration. IV. 
Endotoxin: a nondenuding injury to aortic endothelium. Laboratory investigation; a 
journal of technical methods and pathology 48, 25, 1983. 
37. Anderson, J.S., Price, T.M., Hanson, S.R., and Harker, L.A. In vitro 
endothelialization of small-caliber vascular grafts. Surgery 101, 577, 1987. 
38. Kaehler, J., Zilla, P., Fasol, R., Deutsch, M., and Kadletz, M. Precoating substrate 
and surface configuration determine adherence and spreading of seeded endothelial cells 
on polytetrafluoroethylene grafts. J Vasc Surg 9, 535, 1989. 
128 
39. Kesler, K.A., Herring, M.B., Arnold, M.P., Glover, J.L., Park, H.M., Helmus, 
M.N., and Bendick, P.J. Enhanced strength of endothelial attachment on polyester 
elastomer and polytetrafluoroethylene graft surfaces with fibronectin substrate. J Vasc 
Surg 3, 58, 1986. 
40. Seeger, J.M., and Klingman, N. Improved in vivo endothelialization of prosthetic 
grafts by surface modification with fibronectin. J Vasc Surg 8, 476, 1988. 
41. Koveker, G.B., Graham, L.M., Burkel, W.E., Sell, R., Wakefield, T.W., Dietrich, 
K., and Stanley, J.C. Extracellular matrix preparation of expanded 
polytetrafluoroethylene grafts seeded with endothelial cells: influence on early platelet 
deposition, cellular growth, and luminal prostacyclin release. Surgery 109, 313, 1991. 
42. Xiao, L., and Shi, D. Role of precoating in artificial vessel endothelialization. 
Chinese journal of traumatology = Zhonghua chuang shang za zhi / Chinese Medical 
Association 7, 312, 2004. 
43. Gosselin, C., Vorp, D.A., Warty, V., Severyn, D.A., Dick, E.K., Borovetz, H.S., 
and Greisler, H.P. ePTFE coating with fibrin glue, FGF-1, and heparin: effect on 
retention of seeded endothelial cells. The Journal of surgical research 60, 327, 1996. 
44. Zilla, P., Fasol, R., Preiss, P., Kadletz, M., Deutsch, M., Schima, H., Tsangaris, 
S., and Groscurth, P. Use of fibrin glue as a substrate for in vitro endothelialization of 
PTFE vascular grafts. Surgery 105, 515, 1989. 
45. Jaffe, E.A., Nachman, R.L., Becker, C.G., and Minick, C.R. Culture of human 
endothelial cells derived from umbilical veins. Identification by morphologic and 
immunologic criteria. The Journal of clinical investigation 52, 2745, 1973. 
46. Chiu, J.J., Chen, L.J., Lee, P.L., Lee, C.I., Lo, L.W., Usami, S., and Chien, S. 
Shear stress inhibits adhesion molecule expression in vascular endothelial cells induced 
by coculture with smooth muscle cells. Blood 101, 2667, 2003. 
47. Chiu, J.J., Chen, L.J., Lee, C.I., Lee, P.L., Lee, D.Y., Tasi, M.C., Lin, C.W., 
Usami, S., and Chien, S. Mechanisms of induction of endothelial cell E-selectin 
expression by smooth muscle cells and its inhibition by shear stress. Blood, 2007. 
48. Ohtsuka, A., Ando, J., Korenaga, R., Kamiya, A., Toyama-Sorimachi, N., and 
Miyasaka, M. The effect of flow on the expression of vascular adhesion molecule-1 by 
cultured mouse endothelial cells. Biochemical and biophysical research communications 
193, 303, 1993. 
49. Morigi, M., Zoja, C., Figliuzzi, M., Foppolo, M., Micheletti, G., Bontempelli, M., 
Saronni, M., Remuzzi, G., and Remuzzi, A. Fluid shear stress modulates surface 
expression of adhesion molecules by endothelial cells. Blood 85, 1696, 1995. 
50. Sheikh, S., Rainger, G.E., Gale, Z., Rahman, M., and Nash, G.B. Exposure to 
fluid shear stress modulates the ability of endothelial cells to recruit neutrophils in 
response to tumor necrosis factor-alpha: a basis for local variations in vascular sensitivity 
to inflammation. Blood 102, 2828, 2003. 
129 
51. Chiu, J.J., Lee, P.L., Chen, C.N., Lee, C.I., Chang, S.F., Chen, L.J., Lien, S.C., 
Ko, Y.C., Usami, S., and Chien, S. Shear stress increases ICAM-1 and decreases VCAM-
1 and E-selectin expressions induced by tumor necrosis factor-[alpha] in endothelial cells. 
Arteriosclerosis, thrombosis, and vascular biology 24, 73, 2004. 
52. Chiu, J.J., Lee, P.L., Chang, S.F., Chen, L.J., Lee, C.I., Lin, K.M., Usami, S., and 
Chien, S. Shear stress regulates gene expression in vascular endothelial cells in response 
to tumor necrosis factor-alpha: a study of the transcription profile with complementary 
DNA microarray. Journal of biomedical science 12, 481, 2005. 
53. Zhang, Y., Ingram, D.A., Murphy, M.P., Saadatzadeh, M.R., Mead, L.E., Prater, 
D.N., and Rehman, J. Release of proinflammatory mediators and expression of 
proinflammatory adhesion molecules by endothelial progenitor cells. American journal of 
physiology 296, H1675, 2009. 
54. Kuchan, M.J., and Frangos, J.A. Role of calcium and calmodulin in flow-induced 
nitric oxide production in endothelial cells. The American journal of physiology 266, 
C628, 1994. 
55. Kuchan, M.J., Jo, H., and Frangos, J.A. Role of G proteins in shear stress-
mediated nitric oxide production by endothelial cells. The American journal of 
physiology 267, C753, 1994. 
56. Yee, A., Bosworth, K.A., Conway, D.E., Eskin, S.G., and McIntire, L.V. Gene 
expression of endothelial cells under pulsatile non-reversing vs. steady shear stress; 
comparison of nitric oxide production. Ann Biomed Eng 36, 571, 2008. 
57. Radomski, M.W., Palmer, R.M., and Moncada, S. Endogenous nitric oxide 
inhibits human platelet adhesion to vascular endothelium. Lancet 2, 1057, 1987. 
58. de Graaf, J.C., Banga, J.D., Moncada, S., Palmer, R.M., de Groot, P.G., and 
Sixma, J.J. Nitric oxide functions as an inhibitor of platelet adhesion under flow 
conditions. Circulation 85, 2284, 1992. 
59. Harrison, D.G., Widder, J., Grumbach, I., Chen, W., Weber, M., and Searles, C. 
Endothelial mechanotransduction, nitric oxide and vascular inflammation. Journal of 
internal medicine 259, 351, 2006. 
60. de Groot, P.G., MJ, I.J., and Sixma, J.J. Platelet adhesion to the subendothelium 
under flow. Methods in molecular biology (Clifton, N.J 96, 159, 1999. 
61. Traub, O., and Berk, B.C. Laminar shear stress: mechanisms by which endothelial 
cells transduce an atheroprotective force. Arteriosclerosis, thrombosis, and vascular 
biology 18, 677, 1998. 
62. Lund, T., Hermansen, S.E., Andreasen, T.V., Olsen, J.O., Osterud, B., Myrmel, 
T., and Ytrehus, K. Shear stress regulates inflammatory and thrombogenic gene 
transcripts in cultured human endothelial progenitor cells. Thrombosis and haemostasis 
104, 582, 2010. 
130 
63. Ott, M.J., and Ballermann, B.J. Shear stress-conditioned, endothelial cell-seeded 
vascular grafts: improved cell adherence in response to in vitro shear stress. Surgery 117, 
334, 1995. 
64. Ballermann, B.J., and Ott, M.J. Adhesion and differentiation of endothelial cells 
by exposure to chronic shear stress: a vascular graft model. Blood purification 13, 125, 
1995. 
65. Baguneid, M., Murray, D., Salacinski, H.J., Fuller, B., Hamilton, G., Walker, M., 
and Seifalian, A.M. Shear-stress preconditioning and tissue-engineering-based paradigms 
for generating arterial substitutes. Biotechnology and applied biochemistry 39, 151, 2004. 
66. Yazdani, S.K., Tillman, B.W., Berry, J.L., Soker, S., and Geary, R.L. The fate of 
an endothelium layer after preconditioning. J Vasc Surg 51, 174, 2010. 
 
 
 
 
 
 
131 
Chapter 5: Discussion and Future Directions 
5.1 Summary of Major Results 
The comprehensive goal of this work was the in vitro fabrication and assessment 
of a completely biological, fibrin-based, small-diameter vascular graft. Two major areas 
were examined to achieve this goal: 1) controlled fibrin degradation and its possible role 
in improving new matrix deposition, cellularity, and ultimately, mechanical properties 
and 2) endothelialization of these grafts to form a complete vessel and ensure 
thromboresistance.  
We hypothesized that controlling the rate of fibrin degradation could allow for 
better matrix formation in our media equivalents (MEs). Further, we were interested in 
possible effects that fibrin degradation products (FDPs) may have on the overall 
remodeling by vascular smooth muscle cells (vSMCs) in the ME. To this end, we 
examined collagen and elastin deposition and cellularity in small fibrin disc constructs 
and small-diameter MEs. In both cases, decreasing the concentration of ACA led to 
increased FDP in the medium and better biochemical and mechanical properties. FDP 
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were shown to be direct physiological stimulators of collagen deposition, a fact that can 
be exploited when fibrin degradation is controlled to allow high concentrations of FDP 
formation. This work was necessary for creation of MEs with good mechanical properties 
that allowed easy handling, as previous vSMC small-diameter vessels had inadequate 
mechanical properties and handling (1). Through semi-optimization of fibrin degradation, 
we were able to create better remodeled MEs that could be utilized for endothelial cell 
seeding experiments. 
Endothelialization of small-diameter MEs is necessary for creation of a non-
thrombogenic surface in vitro. This research sought to examine EC adhesion under 
physiological shear stress and the phenotype of ECs seeded on MEs. A novel EC type, 
blood outgrowth endothelial cells (BOECs), were chosen for these endeavors, as they can 
be isolated non-invasively and grown to cell numbers that far exceed the quantities 
needed for endothelialization of small-diameter vessels. Two BOEC species types were 
examined: 1) rat BOECs were utilized for development of a Fischer rat model and 2) 
human BOECs were employed in order to examine the phenotype of adult BOECs, 
particularly in regard to shear stress response and thrombogencity. RBOECs were shown 
to respond to a number of stimuli in a manner consistent with mature ECs. Further, they 
were adherent on vSMC MEs, could proliferation on this surface, and would remain 
adherent for 24 hours under low shear stress or short durations of high shear stress. 
However, mechanical properties for these vessels were still inferior to native vessels and 
RBOEC monolayers were not maintained under physiological shear stress for long 
durations. 
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By these standards, HBOEC seeding was more successful. HBOECs could be 
seeded on human dermal fibroblast (HDF) MEs to form confluent monolayers and would 
remain adherent under long durations of physiological shear stress. HBOECs were 
responsive to physiological shear stress; shear stress modulated VCAM-1 and ICAM-1 
expression after TNF-α stimulation, increased eNOS expression and NO production, and 
decreased platelet adhesion on HBOEC-seeded MEs. These results indicate that HBOECs 
behave like mature ECs and support their application for tissue-engineered vascular 
grafts. 
Together, these lines of research allowed for the formation of a functional, small-
diameter vascular graft, while elucidating key aspects of the remodeling process and 
endothelial cell phenotype. However, considerable work still remains to be done to 
elucidate the full potential of these vascular grafts. 
5.2 Fibrinolysis 
In Chapter 2 of this work we were able to elucidate some of the key mechanisms 
of fibrin degradation, however only a semi-optimization of the MEs was performed. 
While low concentrations of the fibrinolysis inhibitor ACA lead to improved matrix 
remodeling, there was a limit to the magnitude that ACA could be reduced. Without 
ACA, the vSMC degrade the matrix in less than two days, and if the ACA concentration 
was too low the MEs became too thin to be practical for handling or eventual 
implantation. Thus a future optimization might examine the effect of increasing the initial 
fibrin concentration while decreasing the ACA concentration. This could allow increased 
FDP generation while maintaining the initial fibrin scaffold for a longer duration. 
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However, there is still likely to be an upper limit to initial fibrin concentrations at which 
vSMC are capable of adhering, spreading and remodeling the fibrin matrix, thus a careful 
balanced will likely need to be maintained.   
For the fabrication of MEs with human cells, our lab utilizes human dermal 
fibrobasts (HDF) due to their high collagen deposition and repeatability of results. These 
cells are not as fibrinolytic as vSMCs and do not require the use of a fibrinolytic inhibitor 
to maintain the construct scaffold. However, the effects of ACA on these cells could be 
used to draw more general conclusions about fibrin degradation as they relate to multiple 
cell types. Doping with active plasmin (2), plasminogen activators, such as urokinase 
(uPA) or tissue plasminogen activator (tPA), or directly with FDP as in our studies, 
would be other methods to examine the effects of fibrin degradation or FDP 
concentrations on HDF MEs, with the hypothesis that increased FDP generation could 
lead to improved remodeling.  
5.3 Methods to Improve Mechanical Properties 
Experiments with chemical stimulation have repeatedly shown that, though 
mechanical properties can be improved with numerous supplements, static culture is not 
sufficient for fabrication of biopolymer constructs with mechanical properties of native 
vessels. However, recent work in our lab has shown that mechanical stimuli or ruthenium 
photo-crossing linking is capable of producing fibrin-based MEs with near-native 
mechanical properties. Using cyclic stretch, our lab has been able to achieve burst 
pressures of 1366 ± 177 mmHg with HDF MEs after 5 weeks of culture (3). Ruthenium 
crossing-linking of 9-11 week old MEs produced burst pressures of 980 ± 93 mmHg 
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compared to 317 ± 130 mmHg for the control MEs  (Bjork et al, submitted). While both 
of these methods lead to constructs with high burst pressures, the matrix remodeling and 
quantity of residual fibrin will differ, as will the composition of the extracellular matrix 
(ECM) at the lumenal surface. In the case of cyclic distention, enhanced collagen 
deposition and maturity has been implicated in the improved mechanical properties. Also, 
the flow of medium on the lumenal surface, instead of static culture on a mandrel, will 
likely lead to increased remodeling on the lumenal surface. This is in contrast to the 
ruthenium cross-linking method, which thus far has utilized statically cultured HDF MEs, 
as used in Chapter 4, and thus would be less remodeled at the time of cross-linking unless 
longer static culture periods are used prior to cross-linking.  
Using these methods for enhancing ME mechanical properties, combined with 
HBOEC seeding strategies from Chapter 4, would allow for the formation of a complete, 
tissue-engineered artery. However, the different lumenal matrix compositions of these 
MEs could alter HBOEC seeding on the surfaces, with 4-5 week old ruthenium cross-
linked MEs the most similar to the MEs described in Chapter 4. Both types of enhanced-
mechanical property MEs should be examined for HBOEC seeding, as either could be 
utilized for implantation. This will require, at minimum, a re-examination of HBOEC 
retention on these surfaces under shear stress, which can most easily be accomplished in 
the parallel plate flow chambers (PPFCs) designed in Chapters 3 and 4. 
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5.4 BOEC Sources 
Thus far, HBOEC experiments have utilized cells from isolations of HBOECs 
from two healthy donors. Direct comparison of results with these isolations as well as 
others, at least in terms of HBOEC retention, would allow generalization of these finding 
to a broader population. Furthermore, future studies should examine adhesion under shear 
stress of HBOECs from patients with coronary artery disease (CAD). Though Stroncek et 
al. has shown similar isolation rates for healthy donors and CAD patients and good 
adhesion of these cells under flow (4), their sample size was low (n=13) and proliferative 
BOEC colonies were only isolated from approximately half of the patients. Improving 
this isolation rate would be necessary for making this a more universal approach. The 
CAD study isolated from a 50 ml blood sample, so a larger quantity of blood would 
hopefully improve the isolation rate.  
5.5 Endothelialization of Tubular Constructs 
Thus far, all HBOEC and RBOEC studies were done on MEs that were slit axially 
and laid flat prior to seeding. This allowed for real-time visualization of BOEC adhesion 
and morphology and allowed us to isolate the effects of a well-defined wall shear stress 
from other mechanical effects due to flow through a distensible, tubular ME. However, 
the seeding of tubular constructs will be necessary for implant studies and will require 
different methods for seeding. We have been able to seed HBOECs on tubular NHDF 
MEs using a method developed by our lab (1) and modified for this purpose (Figure 5.1). 
MEs were fabricated as described in Chapter 4, cultured for 4 weeks, then mounted on 
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hose barbs on a brace and a suspension of CellTracker Green-labeled HBOECs at 2 x 10
6
 
cells/ml was injected into the ME. This equates to approximately 200,000 HBOECs/cm
2
. 
The ME was then capped at both ends, placed in a 50 ml conical, and rotated at 2 rpm for 
1 hour (CELLroll; Intergra Biosciences). After 1 hour, the caps were removed and a 
syringe pump was used to flush the ME lumen, removing non-adherent cells, at a rate of 
1 ml/min for 2 minutes with EGM medium. After rinsing, the ME was left uncapped and 
returned to the 50 ml conical and cultured vertically. 
After 24 hours of culture, MEs were harvested using a modified fixation method. 
MEs were flushed with HBSS for 1 minute at a rate of 1 ml/min using a syringe pump 
and then perfusion fixed with cold 4% PFA, again using the syringe pump, at a rate of 1 
ml/min for 10 minutes. After fixation, MEs were rinsed with PBS and slit open using a 
dissection microscope. MEs were then stained for cell nuclei and VE-Cadherin as in 
Chapter 4.  
Good monolayer coverage with HBOECs was achieved using this method (Figure 
5.2). Imaging of CellTracker Green showed spread, adherent HBOECs on the tissue, 
while staining for VE-Cadherin showed junction formation with these cells. Without the 
rinse at 1 hour or with 4 hour seeding times instead of 1 hour, clumps of HBOECs were 
visible on the tissue (Figure 5.3). Thus, the optimization of this protocol was important to 
formation of a HBOEC monolayer. HBOECs demonstrate a tendency to aggregate over 
time, likely due to the lack of available matrix for adhesion given the excess of HBOECs 
utilized to ensure full surface coverage. 
138 
 
Figure 5.1: Method for seeding endothelial cells on tubular vascular grafts. Modified 
from method and figure by B. Isenberg (1). 
  
 
1 hour at 2 rpm 
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Figure 5.2: HBOEC seeding on tubular vascular grafts by rotation for 1 hour. 
HBOECs were seeded by rotation for 1 hour at 2 rpm, followed by rinsing with cell 
culture medium to remove non-adherent HBOECs. Images were taken 24 hours after 
seeding. A confluent monolayer of HBOECs is visible on the ME surface. A) Hoechst 
stain for cell nuclei. B) CellTracker Green-labeled HBOECs. C) VE-Cadherin staining of 
cell junctions. D) Composite image. Scale bar = 100 μm.  
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Figure 5.3: HBOEC seeding on tubular vascular grafts for 4 hours. HBOECs were 
seeded by rotation for 4 hours at 2 rpm, followed by rinsing with cell culture medium to 
remove non-adherent HBOECs. Using an extended seeding time, large aggregates of 
HBOECs were visible on the ME surface. A) Hoechst stain showing cell nuclei. B) 
CellTracker Green-labeled HBOECs. C) VE-Cadherin staining of cell junctions. D) 
Composite image. Scale bar = 100 μm. 
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5.6 Implantation Considerations 
A next logical step for this research involves the use of implant studies. These 
will be necessary to determine full functionality, including adequate burst pressures, 
limitation of intimal hyperplasia and dilation, and thromboresistance, and will allow for 
an examination of matrix remodeling in vivo. Choice of appropriate animal models will 
be necessary; however, a variety of factors will impact this decision. Species-dependent 
differences in endothelial and blood cells make autologous implantation with non-human 
cells an incomplete picture (5) and require that MEs with appropriate mechanical 
properties be made from dermal fibroblasts or SMCs from multiple species; however, use 
of human cells likely will require immunosuppressant drugs or use of immunodeficient 
animals.  
Studies with non-endothelialized, mechanically-conditioned, HDF-embedded 
MEs implanted interpositionally in the infrarenal aorta of nude rats are currently 
underway. With these initial studies we can examine graft incorporation into the host 
tissue, as well as watch for lumen narrowing, aneurysm formation, intact anastomoses, 
and blood infiltration into the graft tissue. Seeding with HBOECs prior to implantation 
would allow for examination of HBOEC adhesion in vivo. However, the approximately 1 
cm long graft is short enough that endothelial cell repopulation from the anastomoses is 
likely (5). This makes it necessary for the HBOECs to be differentiated from the host 
ECs, through pre-labeling, transfection with green fluorescent protein, or immunostaining 
for human EC-specific antigens.   
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For large animal studies, our lab has previous experience in the sheep model. 
Sheep have been described as having a coagulation system that is closer to human than 
either dogs or pigs. The ovine carotid artery is also readily accessible and similar in 
diameter to human peripheral arteries, satisfying the requirement for a small-diameter 
implant location. In addition, implantation of conduits in the neck of sheep is well 
tolerated, with minimal postoperative morbidity (5). 
In preparation for sheep implant studies, our lab has been investigating ovine 
vascular SMCs for fabrication of MEs. To complement this work, ovine BOECs were 
examined for adhesion under shear stress. OBOECs were seeded on NHDF MEs, as 
described in Chapter 4, and culture for 24 hours prior to exposure to short durations of 
shear stress, a method also described in Chapter 4. OBOECs were exposed to shear 
stresses up to 80 dynes/cm
2
 for 20 minutes without a significant cell loss (Figure 5.4). 
Confluent monolayers of OBOECs were also maintained after 24 hours at 15 dynes/cm
2
 
shear stress. Seeding and shear stress retention on the MEs optimized for sheep implant 
will still be necessary; however, these are promising initial findings, as the OBOECs 
remained adherent on the bioartificial tissue at shear stresses above arterial physiological 
shear stress.     
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Figure 5.4: Ovine BOECs cultured on bioartificial tissue exposed to short durations 
of shear stress up to 80 dynes/cm
2
. Mean ± standard error of the mean (SE) for n=3 
samples. 
 
With each model, a different maximum and mean shear stress will be imposed on 
the neoendothelium, dependent on the vessel size and rate of blood flow. Assuming the 
graft diameter is appropriately matched, Table 5.1 lists the mean wall shear stress that 
would be imposed for each species. For similar vessels, these values vary predominately 
based on the size of the animal (6), from a wall shear stress of 70 dynes/cm
2
 in the rat 
infrarenal aorta to 8.4 dynes/cm
2
 for the sheep femoral artery. Assurance that BOECs 
remain adherent at the appropriate shear stress, at least for short durations, will be 
necessary prior to implantation. For sheep femoral artery implant, we have already been 
able to show that OBOECs are retained under physiological shear stress, however for the 
rat implant model, the mean wall shear stress is higher than we have examined for rat or 
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human BOECs. The maximum wall shear stress due to pulsatile flow in the rat aorta 
would reach shear stresses even higher, thus in vitro examination of, and optimization 
for, BOEC retention would be required to ensure maintenance of the endothelium 
immediately upon implant. 
Table 5.1: Mean shear stress for human arteries and implant model vessels. 
Vessel Species Mean Wall Shear Stress (dyne/cm
2
) 
Coronary Artery Human 10-20, mean ~16 (7) 
Infrarenal Aorta Human 4.8 ± 0.3 (6) 
 Rat 70.5  ± 6.7 (6) 
 Mouse 87.6  ± 8.3 (6) 
Common Carotid Artery Sheep 8.4 (5) 
 Baboon 12.6 (5) 
Common Femoral Artery Sheep 11.2 (5) 
 
All flow experiments in these studies utilized steady, laminar shear stress. Steady 
or pulsatile laminar shear stress is considered to be atheroprotective, while reversing, 
oscillatory, or low shear stress is believe to be atherogenic (8, 9). Steady shear stress 
stimulates many of the same endothelial cell responses as pulsatile stress, however there 
are some qualitative and quantitative differences (10-13). Thus, application of pulsatile, 
non-reversing flow in vitro represents another method to improve BOEC phenotype; 
however, the relevance of these in vitro studies to an implant model may be limited. 
Endothelial cells respond quickly to changes in shear stress, thus maintenance of a 
confluent monolayer during implant may be the most important outcome to be gained 
from pre-conditioning studies. Thus, either steady or pulsatile flow could be used for pre-
conditioning as long as a confluent monolayer can be maintained when the cells are 
implanted. In vitro systems can be utilized to mimic the pulsatile shear stress, as well as 
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cyclic stretch, experienced by grafts at implant, and thus serve as an indicator for BOEC 
adhesion after implant. Our lab bioreactors (1, 3) could be modified for this purpose, and 
utilized to examined BOEC adhesion, as well as allow for pre-conditioning of tubular 
constructs leading up to implantation.  
All shear stress experiments thus far have instituted a ramping period such that 
the shear stress is increased incrementally to the final set point. Multiple groups report 
that ECs perform better functionally and are more likely to remain adherent when slowly 
ramped to physiological shear stress or when pre-conditioned with shear stress prior to 
implant (14-17). Thus, the ramping period currently instituted may be necessary for 
BOEC retention. To test this, ramping can be compared to an immediate step increase in 
shear stress to the physiological shear stress. This will mimic the implant conditions, 
where after surgical implant blood flow is re-established quickly at the physiological flow 
rate, as the clamp is removed. The adhesion of BOECs exposed to a single step increase, 
from static to physiological shear stress, will be an indicator of whether BOEC-seeded 
MEs can be implanted after static culture of the BOECs. If significant cell loss is noted, 
pre-conditioning with flow and an incremental ramping of the shear stress will be 
necessary prior to implant.  
5.7 Conclusions 
This dissertation outlines methods, results and analysis in the creation of a 
complete, bioartificial artery through the controlled degradation of an initial fibrin 
scaffold combined with successful seeding and retention of BOECs on this tissue. In vitro 
results indicate the neoendothelium is functional, thromboresistant, and remains adherent 
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under physiological shear stress. Utilizing these results and methods in combination with 
mechanical strengthening methods recently outlined by our lab, we have the potential to 
achieve functional, small-diameter grafts that could withstand arterial implant.     
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Appendix A: Methods 
A.1 Cell Culture 
A.1.1 Porcine Valve Interstitial Cells (PVIC)  
Medium: DMEM/F12 with 10% FBS, 1% Antibiotic/Antimycotic 
To split cells 
1. Split cells when they are 80-90% confluent. 
2. Remove medium and discard. 
3. Rinse flask with PBS (without calcium or magnesium), using approximately 10 
ml per T175. 
4. Add 5ml of 0.25% trypsin warmed to 37C for each T175 flask. 
5. Place flask in incubator, wait about a minute, remove and check for cell rounding 
and release with microscope. Tap flask gently to finish releasing cells, if 
necessary. 
6. Add 1 ml FBS per T175 flask (20% volume of trypsin) to neutralize.  Rinse and 
collect cells into 50 cc conical.   
7. Pellet cells at 220 x g for 5 minutes. 
8. Resuspend cells in medium. Usually resuspending in 3ml per T175 harvested 
gives a final concentration above 3M/ml. 
9. Remove 50 µl of cells and place into microfuge tube containing 200 μl of a trypan 
blue solution. Count cells in hemocytometer.    
10. Plate cells at 1 M per T175, using 30 ml media per flask. 
 
A.1.2 Neonatal Human Dermal Fibroblasts (nhDF) 
Medium: DMEM/F12 with 15% FBS, 1% Pen/Strep 
To split cells 
 Cells are ready to be split when cells are 100% confluent, usually after 4 days. 
1. Remove medium and discard. 
2. Rinse flask with PBS (without Ca and Mg), using about 10 ml per T175. 
3. Add 5 ml of 0.25% trypsin at 37C to each T175 flask. 
4. Incubate cells with trypsin until they have detached from flask surfrace. 
5. Add 1 cc FBS per T175 to neutralize.  Collect cells into a 50 cc conical. Rinse 
flask with PBS and transfer the rinse to the same 50cc conical.   
6. Pellet cells at 220 x g for 5 minutes. 
7. Resuspend cells in media. Use about 3 ml of media per T175. 
8. Remove 50 µl of cells and place into microfuge tube containing 200 μl of a trypan 
blue solution. Count cells in hemocytometer.    
9. Plate cells at 1.5 M per T175, using 30 ml medium per T175 flask. 
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A.1.3 Neonatal Rat Smooth Muscle Cells (nrSMC) 
Medium: DMEM/F12 with 15% FBS and 1% P/S  
Thawing 
1. Thaw 4M nrSMCs from liquid nitrogen storage. Thaw in the 37C bath 
immediately and remove from bath as soon as thawed. 
2.  Dilute 4M cells into 30ml of nrSMC medium pre-warmed to 37C and transfer to 
a T175 flask. 
3. Change the medium on the cells at 24 hours.  
Passaging 
Cells are ready to be split when 90-100% confluent, usually every 3-4 days. 
1. Remove medium from flasks. Wash each flask 2 times with 10 ml PBS. 
2. Add 5 ml warm 0.05% Trypsin/EDTA to each T175 flask. 
3. Transfer flasks to the 37˚C incubator for 2-3 minutes until cells are free floating. 
Monitor detachment with the cell culture microscope. 
4. Add 1 ml FBS to each flask to deactivate trypsin. Collect cells into 50 ml conical 
tube. 
5. Rinse flasks sequentially twice with PBS. Collect rinses into the same 50 ml 
conical tube. 
6. Centrifuge cells at 220 x g for 5 minutes. 
7. Resuspend cells in appropriate medium and count.  
8. Replate cells at 3.5 M/T175 flask (20,000/cm2). 
9. Culture medium should be changed every 2 days, with the first (usually only) 
media change occurring 2 days after plating.  
Freezing cells 
nrSMCs are frozen in 50% culture medium, 45% FBS and 5% DMSO. Cells are 
routinely frozen in 1 ml aliquots containing 2M cells/ml.  
1. Pre-label 1 ml NUNC vials for cell storage and place on ice. Key information: 
Cell type, isolation, passage number, cells/vial, date frozen, initials.  
2. Make up "freezing media": 10% DMSO in FBS and place on ice. 
3. Harvest cells and resuspend at 4 x 106 cells / ml in cell culture medium. 
4.  Gradually add equal volume of "freezing media" to the cell solution and keep on 
ice. Immediately aliquot into freezing vials, 1 ml/vial. 
5. Place vials in freezing container (Mr. Frosty) and put at -80˚C overnight. 
6. Transfer vials to liquid nitrogen storage. 
 
A.1.4 Rat Vascular Endothelial Cells (Source: VEC Technologies) 
Medium: VEC Medium (VEC Technologies). Add 1% Pen/Strep to bottle if it is not 
included. 
Prepare 0.2% Gelatin-coated flasks 
1. Warm gelatin to 37˚C.  
2. Add gelatin to flask, shake back and forth gently to coat the bottom completely, 
then remove excess gelatin. 
3. Allow to dry for at least 30 minutes. 
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Splitting rvECs 
1. Warm VEC EC medium, HBSS and 0.25% Trypsin in 37˚C bath. Total trypsin 
needed per flask: T25 = 1ml, T75 = 2ml, T175 = 5ml 
2. Wash flasks twice with HBSS without Ca and Mg.  
*Note: Washing with PBS will cause cells to detach immediately.  
3. Wash flasks once with 0.25% trypsin/EDTA (T25 = 0.5ml, T75 = 2ml, T175 = 
2.5ml). Let trypsin flow down bottom of flask, then take off immediately. 
4. Add 0.25% Trypsin/EDTA to detach cells. (T25 = 0.5ml, T75 = 2ml, T175 = 
2.5ml). Rock flask to coat surface. Cells will begin to detach immediately. Check 
under microscope. If cells are not floating, monitor progress and gently rock flask 
until they are fully detached. 
5. Immediately add 37˚C VEC EC medium to the flask, collect cells into centrifuge 
tube. Wash flask with additional medium and collect this medium as well. 
6. Plate into gelatin-coated flasks, splitting 1:2 or 1:3. Total amount of medium/ 
flask: T25 = 5ml, T75 = 15ml, T175 = 30ml. 
 
A.1.5 Rat Blood Outgrowth Endothelial Cells (Source: Dr Robert Hebbel’s Lab) 
Medium 
500 ml EBM-2 basal medium (Clonetics #CC-3156) 
EBM-2 Singlequots (Clonetics #CC-4176) 
0.123 g Dibutyryl cyclic AMP (Sigma #D-0627) 
40 ml FBS (heat inactivated; GIBCO #10082-147) 
5 ml antibiotic-antimycotic (A/A) 
To make medium 
1. Add 0.123 g cAMP into 500 ml of warm EBM-2 basal medium. Mix well. 
2. Sterile filter the medium through a 500ml filter unit (0.2 μm) 
3. Add EBM-2 SingleQuots, including the 10 ml aliquot of FBS, 40 ml of additional 
FBS, and 5ml A/A to the filtered EBM-2 medium. 
Rat tail Collagen Type I Solution Preparation 
1. Determine the amount of collagen required to make 500ml of a 0.05mg/ml 
Collagen solution. 
2. Add 0.575 ml of glacial acetic acid to Milli-Q (appropriate amount to make 
500ml of solution. Ie 500ml – volume of collagen that will be added later). 
3. Mix well and sterile filter. 
4. Add respective amount of collagen type 1 for a final concentration of 0.05 
mg/ml, mix well and store at 4C. *Keep the stock collagen solution on ice the 
entire time. 
Prepare Collagen-coated flasks 
1. Add 0.05 mg/ml collagen solution the flasks (7ml for T75, 12 ml for T175). 
Incubate overnight at 37C.  
2. After the overnight coating aspirate the collagen and rinse the flasks with HBSS 
without Ca+, Mg2+ twice. 
3. The coated flask can now be used for cell culture or can be stored at 4C for up to 
3 weeks. Store dry (ie aspirate last HBSS rinse and store as is). 
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Splitting rBOECs 
1. Rinse flask twice with HBSS without Ca+, Mg2+ or phenol red at RT. 
2. Add 0.25% Trypsin-EDTA for a quick rinse (30-60 sec). Add 2 ml per T75 or 
5 ml per T175. 
3. Aspirate off the trypsin rinse and add 0.25% trypsin to detach cells. Add 3 ml 
per T75 or 5 ml per T175. Incubate at 37C, examining cells after 2 minutes. 
Leave trypsin on for up to 5 minutes. Some agitation/knocking of flask is 
required to loosen the cells. 
4. Add FBS to quench the trypsin (0.5 ml for T75, 1 ml for T175) and then 
transfer the cells to a 50cc conical. 
5. Rinse 1-2 times with HBSS and add rinses to the 50cc conical. 
6. Pellet cells at 220 x g for 5 minutes. Then resuspend in rBOEC medium. 
7. Count cells and replate at 1 M cells/T75 in 10 ml of rBOEC medium. 
 
A.1.6 Human/Ovine Blood Outgrowth Endothelial Cells (Source: Dr. Robert Hebbel’s 
Lab) 
Medium 
500 ml EBM-2 basal medium (Clonetics #CC-3156) 
EBM-2 SingleQuots (Clonetics #CC-4176) 
40 ml FBS (heat inactivated; GIBCO #10082-147) 
5 ml pen/strep (Invitrogen) 
Splitting hBOEC or oBOECs 
1. Rinse T75 flask twice with HBSS without Ca+/Mg2+ or phenol red (Gibco 
14175) 
2. Add 0.05% Trypsin-EDTA (3 ml for T75, 5 ml for T175) for approximately 2 
minutes, incubating at 37C. Monitor for cell detachment. 
3. Add FBS (0.5 ml for T75, 1 ml for T175) to quench the trypsin and pipette cell 
solution up and down on flask surface then transfer the solution to a 50cc conical.  
4. Rinse flask with HBSS (6.5 ml for T75, 9 ml for T175) and transfer this to the 
50cc conical as well. 
5. Spin down cells and resuspend in BOEC medium using 1 ml of BOEC medium 
per T75 and 2 ml per T175. Replate on collagen-coated flasks at approximately 
40,000 cell/cm
2
. 
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A.2 Construct Fabrication and Culture 
A.2.1 Media Equivalents 
Mandrel Materials 
10 cm section of glass outer shell (reusable) 
8 cm long glass rod (2 cm) 
Rubber stoppers from ½ cc syringe (Kendall monoject insulin syringes – ½ cc) 
Rubber stoppers from 3 cc syringe (Kendall monoject luer lock syringes – 3cc) 
¼ inch wide Teflon tape 
½ inch wide Teflon tape 
10 cm section of glass outer shell (reusable) 
Contrex EZ powdered enzymatic detergent (Decon Labs Inc.) 
Branson GP “pink” formulated cleaning concentrate (Branson) 
Prepare ME mandrels 
1. Sonicate the mandrel materials and rubber stoppers in the Contrex solution for 30 
minutes w/ heat. Note:  do not put too many stoppers in a jar for sonicating, but be 
sure to use lots of liquid.  For example, do not let stoppers exceed the 200mL 
mark in a 600mL beaker, but fill beaker with liquid up to the 500mL mark. 
2. Rinse once in dH2O and sonicate the parts again in the Branson solution for 30 
minutes w/ heat. 
3. Rince once in  dH2O and sonicate the parts again in dH2O for 30 minutes w/heat. 
4. Rinse once in dH2O and dry parts on a sterile drape. 
5. Once parts are dry, attach the small rubber stoppers and wrap with a 6 cm long 
piece of ¼ inch Teflon tape. 
6. Attach the large rubber stoppers and wrap with a 9 cm long piece of ½ inch 
Teflon tape. 
7. Place the mandrel assemblies in a clean 500ml beaker and sterilize at 121oC for 
10 minutes with 10 minute exhaust.  
Prepare ME glass casing 
1. Rinse glass tubes in dH2O then place in a clean beaker and sonicate 30 minues in 
the Branson solution.  
2. Rince once in  dH2O and sonicate the parts again in dH2O for 30 minutes w/heat. 
3. Rinse once in dH2O and dry parts on a sterile drape. 
4. Place in the same beaker as the ME mandrels and autoclave as stated above.   
Pluronics F127 Solution 
1. Dissolve 5% Pluronic by weight in ddH2O. This may take a couple hours.  
2. Run Pluronic solution through a 0.2 μm filter.  
*Note: The pluronic solution may be used three times, with re-filtration between 
each use. 
ME Fabrication 
1. Coat glass mandrels and shells in Pluronic for 3 hours. 
2. Dry mandrels on a sterile paper towel for 30 minutes. 
3. Place mandrels in the shells using sterile gloves. 
4. Make Fibrinogen, Thrombin and Cell Solutions (A,B,C), as described below. 
NOTE: MEs use approximately 6 mL, HM used 200 uL. The recipe below is for 
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the 3.3 mg/ml fibrin concentration. Make up the thrombin solution as the last step 
just before casting. 
a. Fibrinogen Solution (6 mL total): 
i. 1 mL Fibrinogen (~30 mg/mL)  
ii. 5 mL 20mM HEPES in Saline 
b. Cell Solution 
i. 6x concentration of final (final usually 0.5x106 cells/mL => 3x106 
cells/mL)  
c. Thrombin Solution (~2 mL total): 
i. 2 mL DMEM WITHOUT FBS 
ii. 100 μL Thrombin  
iii. 7.5 μL 2M CaCl2  
5. Add the cells to the fibrinogen solution and then add thrombin to catalyze 
reaction. For 3 MEs we use 10.4 ml fibrinogen solution, 2.6 ml cells, 2.6 ml 
thrombin solution, i.e 4 parts fibrinogen solution, 1 part cell solution, 1 part 
thrombin solution. 
6. Using the largest syringe needle (18G) draw solution into a 20cc syringe, then 
slowly inject each ME with solution by inserting the needle between the stopper 
and the glass casing. 
7. Wrap shells in ethanol-sprayed parafilm and place in the incubator for 30 minutes. 
8. Expel mandrels out of shells using a teflon rod into a 150 mm cell culture dish 
containing 120 ml media. Place 6 MEs per dish.  
9. Place in incubator (37 degrees, 5% CO2). Change media three times per week 
using 100 ml per dish after the first feeding. 
 
Table A.1 Standard culture conditions for PAVC, NHDF, nfSMC Constructs 
 PAVC NHDF nfSMC 
Media DMEM/F12 C. DMEM C. (High 
Fz) 
DMEM, 15% FBS, 1% A/A 
Supplements 2 mg/ml ACA  No ACA 1 mg/ml ACA 
2 μg/ml Insulin Same Same 
1 ng/ml TGF-β  None  Same or add 5 ng/ml EGF  
50 μg/ml Ascorbic Acid  Same Same 
Stock concentrations: 2 g/ml ACA, 2 mg/ml Insulin, 1 μg/ml TGF-β, 5 mg/ml AA, 10 
mg/ml EGF. All supplements stored at 1000x, except ACA is at 100x and EGF is at 
2000x. 
 
A.2.2 Hemispheres 
*Use cell conditions as outlined above. 
1. Use the 1 cm circular borer on the permanox slides or in cell culture plates (6 well 
plates for the NHDFs, 12 well plates for the nfSMCs)  to create a circular area for 
fibrin gel deposition. 
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2. Make up the fibrin gel solutions, as described above. Mix in 4:1:1 ratio the 
fibrinogen, cell and thrombin solutions, as above. Note that each HM takes 200 
μl. 
3. To each etched circle, add 200 μl of solution. Wait 10-15 minutes until HMs 
begin to get cloudy (gelling), then place in incubator.  
4. Add media after 10-20 more minutes. Use the same media noted above. 
A. HM grown on Permanox microscope slides should have an autoclaved 
Teflon ring affixed around the HM with autoclaved vacuum grease before 
2 ml of media is added. 1 ml of media can be used for each subsequent 
feeding. 
B. HM grown in 6-well plates need 5 ml of media for the first feeding and 
3ml thereafter. HM in 12-well plates need 2 ml for the first feeding and 1 
ml thereafter.  
5. Change media 3 times per week. 
A.3 Live Cell Staining 
A.3.1 Live/Dead Stain 
Calcein AM (live cells), Ethidium homodimer (dead cells) 
 Molecular Probes Kit L-3224 
 Storage: -20C, Protected from light. 
1. Calcein AM is susceptible to hydrolysis when exposed to moisture; allow the kit 
to warm to RT prior to opening. 
2. Prepare working solutions in PBS just prior to use.  Determine optimal dye 
concentrations for each cell type. Table A.2 shows concentrations that work for 
NHDFs and rSMCs. 
Table A.2 NHDF and rSMC calcein AM and EthD-1 dye concentrations 
Dye Concentration Dilution FL Filter Emission 
Calcein AM 4 μM  1:1000 FITC Green (Live) 
EthD-1 4 μM 1:500 TRITC Red (Dead) 
 
3. Wash constructs or adherent cells in PBS three times for 5 minutes. Longer rinses 
may be necessary for thick constructs. 
4. Add working solution containing Calcein AM and EthD-1 to cover cells or 
constructs. Incubate 45 minutes at 37C/5% CO2. *Incubate nrSMCs 30 minutes.  
5. Rinse cells or constructs 3 times with PBS. 
6. View/Image with microscope. Red=Dead. Green=Good. 
A.3.2 CellTracker Live Cell Staining (optimized for human BOECs) 
Source: Invitrogen  
Catalog #: C34551 (CellTracker Orange CMRA) 
20 x 50μg dry powder 
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Dyes come in various colors. Green CMFDA and Orange CMRA require 
enzymatic cleavage. 
Storage: -20C, dessicated 
Label Cells 
1. Grow cells in the appropriate culture medium. Cells can be labeled in suspension 
or as a monolayer.  
2. Before opening the dye vial, allow the product to warm to RT. Dissolve the 
lyophilized product in DMSO to 10 mM (9.1 μl DMSO for CMRA, 10.8 μl 
DMSO for CMFDA). Dilute the stock solution 1:4000 in warm EBM-2 basal 
medium (no FBS or supplements) for a final working concentration of 2.5 μM. 
*Store stock solution in duct tape covered desiccator at -20C.  
3. For cells in suspension, harvest cells in the usual method and after centrifugation 
(220 x g for 5 minutes) add the CellTracker working solution to the cell pellet and 
resuspend. For adherent cells, remove the medium and add the CellTracker 
working solution directly to the flask. Incubate the cells in the working solution 
for 15 minutes in the incubator. 
4. Remove the CellTracker solution by centrifuging (cells in suspension; 220 g for 5 
min) or aspiration (adherent cells). Add fresh medium and incubate the cells for 
another 30 minutes on ice (cells in suspension) or in the incubator (adherent 
cells). 
5. After 30 minutes, centrifuge (cells in suspension; 220 g for 5 min) and aspirate off 
medium (cells in suspension and adherent cells) and add fresh medium. 
6. Plate or passage CellTracker Green cells as necessary. Loss of CTG intensity 
happens within a few days for cells that are dividing often (passaged cells), but 
will remain obvious for up to a week when cells are seeded as a monolayer.     
*Fix the cells with 4% formaldehyde in PBS for 10 minutes at room temperature, 
if desired. The formaldehyde used in standard fixation protocols crosslinks the 
amines of the protein– or peptide–dye conjugate, maintaining the fluorescence 
after fixation (and after sectioning of frozen tissue samples). 
 
A.3.3 DiI-ac-LDL Uptake Assay by Endothelial cells 
Source: Biomedical Technologies Inc.   
Catalog #BT-902 
Quantity 200 ug/vial 
Concentration: 200 ug/mL 
Absorbance Ratio Dil/Protein = 555nm/275nm=1.67 
Stable for 3 months when sterile at 4ºC; NEVER FREEZE 
General Protocol for DiI-ac-LDL Staining 
1. Asceptically dilute Dil-Ac-LDL to 10 ug/mL in standard media (1:20).  
2. Add to live cells and incubate for 4 hours at 37°C. 
3.  Remove media containing Dil-Ac-LDL from your culture. 
4. Wash cells several times with probe-free media. 
5. Image cells using Fluorescence imaging with the Rhodamine filter.  
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6.  If desired, continue to culture cells in normal medium. *If continuing to culture 
cells, note that the DiI-ac-LDL may aggregate in the cell over time, producing a 
punctate effect when imaging.  This is normal. However, LDL can also aggregate 
while being stored. To clarify these aggregates out, simply spin in a microfuge for 
2 minutes. 
7. OPTIONAL FIXATION: Rinse cells in warm HBSS, then fix cells in 4% PFA for 
10 minutes.  After fixation, rinse cells 3 times, 5 minutes each in PBS.  * Never 
use methanol or acetone fixation; Dil is soluble in organic solvents. 
8. Seal with Kroenings wax or DAKO fluorescent mounting medium. Do not use 
nail polish. Store at -20°C. 
A.4 Immunochemistry 
A.4.1 Antibodies 
Table A.3 Rat SMCs Antibodies (or contaminating fibroblasts) 
Antigen Source Host Dilution Storage Fixation Antigen 
Retrieval 
Stock Soln 
α SM actin Abcam 
(ab18147) 
mouse 1:200  -20C  4% PFA 0.1% 
Triton-X 
0.1 mg/ml  
Vimentin Chemicon 
(mab3400) 
mouse 1:800  4C 4% PFA 0.1% 
Triton-X 
1 mg/ml 
SM myosin  
heavychain-1 
Abcam 
(ab681) 
mouse 1:200 4C  4% PFA 
(alt: 
acetone 
for 20 
min) 
0.1% 
Triton-X 
(alt: none) 
1-10mg/ml 
*alt: alternative method 
 
Table A.4 Rat EC Antibodies 
Antigen Source Host Dilution Storage Fixation Antigen 
Retrieval 
Stock Soln 
E-Selectin 
(anti-human) 
Santa Cruz 
(sc-14011) 
rabbit 1:100 4C 4% PFA None 200 ug/ml 
ICAM-1 
(anti-rat) 
Santa Cruz 
(sc-19584) 
mouse 1:100 4C  4% PFA None 200 ug/ml 
VCAM-1 
(anti-rat) 
Biolegend 
(200402) 
mouse 1:100 4C  4% PFA None 500 ug/ml  
vWF (anti-
human) 
Abcam 
(ab6994) 
rabbit 1:800 
(1:2000 
IHC) 
-20C  4% PFA 0.1% 
Triton-X 
8.1 mg/ml 
Thrombomod
ulin (anti-rat) 
Amer 
Diagnostica 
(ad3381) 
rabbit 1:100  -20C  4% PFA None 1 mg/ml 
CD31 (anti-
rat) 
BD 
Pharmingen 
mouse 1:50 4C  4% PFA None 1 mg/ml 
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Table A.5 Human EC Antibodies 
Antigen Source Host Dilution Storage Fixation Antigen 
Retrieval 
Stock 
Soln 
CD31 (anti-
human) 
Chemicon 
(mab2148) 
mouse 1:100 4C  4% PFA None 1 mg/ml 
E-Selectin (anti-
human) 
Santa Cruz 
(sc-14011) 
rabbit 1:100 4C 4% PFA None 200 ug/ml 
ICAM-1 (ant-
human) 
Chemicon 
(mab2146) 
mouse 1:200 4C  None 1 mg/ml 
vWF (anti-
human) 
Abcam 
(ab6994) 
rabbit 1:800 -20C 4% PFA 0.1% 
Triton-X 
1 mg/ml 
Thrombomodulin 
(anti-human) 
Xreact: mouse  
Amer 
Diagnostica 
(ad2375) 
mouse 1:100 -20C 4% PFA None 0.5 mg/ml 
Tissue Factor 
(anti-human) 
Amer 
Diagnostica 
(ad4501) 
goat 1:100  4C  4% PFA None 1 mg/ml 
VCAM-1 (anti-
human) 
Chemicon 
(mab2511) 
mouse 1:200  -20C  4% PFA None 1 mg/ml 
NOS3 (anti-
human) 
Santa Cruz 
(sc-654) 
rabbit 1:50, 
(1:100 
IHC) 
4C    0.2 mg/ml 
VE-Cadherin Santa Cruz 
(sc-6458) 
goat  1:100 4C  4% PFA None 1 mg/ml 
 
Table A.6 Ovine EC Antibodies 
Antigen Source Host Dilution Storage Fixation Antigen 
Retrieval 
Stock 
Soln 
vWF (anti-
human) 
Abcam 
(ab6994) 
Rabbit 1:4800 
(1:2000 
IHC) 
-20C 4% PFA 0.1% 
Triton-X 
1 mg/ml 
 
Table A.7 Blood cell Antibodies 
Antigen Source Host 1º 
Dilution 
Storage Fixation Antigen 
Retrieval 
Stock 
Soln 
GP-1b (CD42b; 
anti-human) 
Ab58921 Mouse 1:100 -20C 4% PFA None 0.1 mg/ml 
CD45 Ab10558 Rabbit 1:100 -20C 4% PFA None 1 mg/ml 
 
Table A.8 Extracellular Matrix Antibodies 
Antigen Source Host 1º 
Dilution 
Storage Fixation Antigen 
Retrieval 
Stock 
Soln 
Collagen I 
(anti-human) x-
react: rat 
Novus Bio 
(NB600-
408) 
Rabbit 1:500 -20C  3hr 4% 
PFA 
None 1.12 
mg/ml 
Collagen III 
(anti-human) 
Novus Bio 
(NBP1-
05119) 
Mouse (unstated; 
tried 1:50-
1:500) 
4C    1 mg/ml 
Collagen IV Ab6586 Rabbit 1:100; 
1:200 
-20C 3hr 4% 
PFA 
None 1.2 mg/ml 
Fibrin Amer 
Diag 3462 
Goat 1:500 -20C 3hr 4% 
PFA 
None 1  mg/ml 
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Fibronectin Amer 
Diag 6584 
Rabbit 1:1000 -20C 3hr 4% 
PFA 
None 1 mg/ml 
Laminin Ab11575 Rabbit 1:50  -20C 3hr 4% 
PFA 
None 0.5 mg/ml 
 
Table A.9 Donkey Secondary Antibodies (Jackson Immuno) 
Secondary DyLight 
488 
Dylight 549  Dylight 649 HRP Storage 
Donkey anti-mouse IgG 
(H+L) 
715-485-151 715-505-151 715-495-151 715-035-151 -20C 
Donkey anti-rabbit IgG 
(H+L) 
711-485-152 711-505-152 711-495-152 711-035-152 -20C  
Donkey anti-goat IgG 
(H+L) 
705-485-147 705-505-147 705-495-147 705-035-147 -20C  
* All secondary antibodies stored 1:1 in glycerol in aliquots at -20C. 
 
A.4.2 Immunocytochemistry 
1. Rinse cells or whole tissue in warm HBSS or PBS. *Note: Use HBSS with ECs, 
as rinsing with PBS may lead to cell detachment. 
2. Fix with 4% PFA 10 minutes at room temperature (RT). 
3.  Rinse 3x 3 minutes with PBS (10 minutes per rinse for whole tissue). 
4. OPTIONAL PERMEABLIZATION STEP.  Permeabilize with 0.1% Triton-X for 
5 minutes.  Following this step, rinse 3x with PBS. 
5. Block in 5% normal donkey serum (to match secondary antibody host) for 30 
minutes at RT. 
6. Incubate in 1° antibody (dilutions shown in Antibody tables) 1 hour at RT or 
overnight at 4°C. 
7. Rinse 3x 3 minutes in PBS (10 minute rinses for whole tissue). 
8. Incubate in 2° antibody (Cy2 or Cy3 or DyLight antibodies from Jackson 
Immuno) in PBS 45 minutes at RT. Stock solutions of secondary antibodies are 
stored at 4C for short durations (recommended <6 weeks) in PBS or this stock 
solution can be diluted 1:2 in glycerol and stored at -20C. 
9. Rinse 1x 3 minutes in PBS (10 minute rinse for whole tissue). 
10. Counterstain cell nuclei with Hoechst 33342 at 1 μg/ml for 10 minutes. 
11. Rinse 2 x 3 minutes in PBS (10 minute rinses for whole tissue). 
12. Coverslip with DAKO fluorescent mounting medium. Use the hardset mounting 
medium for whole tissue.  
13. Store in dark at 4°C.  
 
A.4.3 Infiltration and Embedding of Tissue 
Infiltration Solution 1 (IF1) 
30% w/v sucrose + 5% w/v DMSO in 1X PBS 
e.g. for 100 ml: 30 g sucrose  
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5 ml DMSO  
10 ml 10X PBS  
Dilute to 100 ml with ddH2O 
Infiltration Solution 2 (IF2) 
50% v/v infiltration solution 1 and 50% v/v OCT 
Mix well, avoid bubbles or centrifuge briefly to remove bubbles. 
Procedure 
1. Rinse the sample 3 x 10 min in PBS at room temperature on orbital shaker. 
2. Fix the sample for 3 hours at 4oC in 4% paraformeldahyde (PFA) on orbital 
shaker. 
3. Rinse the sample 3 x 10 min in PBS at RT, orbital shaker if possible. 
4. Incubate samples in IF1 overnight at 4oC on a shaker. 
5. Place samples in IF2 for 4 hours at room temperature on a shaker. 
6. Place samples in dry sample block cup and carefully transfer sample to the 
block. Top off with OCT. Freeze in pre-chilled isopentane in liquid N2.  
Freeze until opaque.  Store samples at -80
o
C. 
*Note: All times are dependent on tissue thickness. Times shown are good for 200 
m thick MEs, but should be increase for thicker MEs or native tissue. 
 
A.4.4 Immunostaining of Tissue Sections (non-ECM antibodies) 
1.   After embedding tissue in OCT, cut 9 μm thick cryostat sections and mount 
on glass slides. Store slides at -80°C until needed. 
3.   Before IF staining, warm up slides at room temperature for 30 minutes. Circle 
each section with a pap pen. 
4.   Follow protocol for staining cell monolayers starting at step 6 (A.5.2). 
 
A.4.5 Staining for ECM Proteins  
1. Use 9 μm thick sections on glass slides for staining. Before staining, warm up 
slides at room temperature for 30 minutes. Circle each section with a pap pen. 
2. Block in 5% normal donkey serum (to match secondary antibody host) for 2 
hours at RT. 
3. Incubate in 1° antibody (dilutions shown in Antibody tables) overnight at 4°C. 
4. Rinse 3x 3 minutes in PBS. 
5. Incubate in 2° antibody in PBS 1 hour at RT.  
6. Rinse 3x 3 minutes in PBS. 
7. Stain cell nuclei with Hoechst 33342 (Invitrogen) at 1 μg/ml for 10 minutes. 
8. Coverslip with DAKO fluorescent mounting medium. 
9. Store in dark at 4°C. 
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Appendix B: Implant Studies 
B.1 Background 
MEs fabricated with porcine valve interstitial cells (PVICs) were cultured for at 
least 5 weeks and then endothelialized with Fischer rat vascular endothelial cells for 24-
48 hours prior to implantation in 8-9 week old male Fischer rats. The intent of this initial 
implant study was to examine fibrin construct remodeling in vivo, verify the seeded 
endothelium was robust and would prevent thrombosis, and determine if our constructs, 
with burst pressures of at least 400 mmHg, can withstand rat aortic pressures.  
B.2 Results 
Seven implants were performed (Table 1). Of these, one animal died due to 
technical issues and two due implant rupture. In the other four cases, the cause of death 
was unclear; no mechanical failure occurred and in none of the implants was thrombosis 
apparent. While the short survival time, from 1-7 hours, makes it impossible to 
characterize the in vivo remodeling of our constructs, these results indicate that our 
constructs may be strong enough initially to withstand normal rat aortic pressures.  
 
Table B.1 Summary of PVIC ME Implants  
Implant 
# 
Culture 
Time 
(Weeks) 
EC 
Time 
(Hours) 
Survival 
Time 
(Hours) 
Burst 
Pressure 
(mmHg) Cause of Death 
1 8.5 24 N/A 440 
Technique: attempt to cuff implant for 
surgery 
2 8.5 48 2 422 Rupture longitudinally 
3 6.5 24 2-2.5 425 
Unknown, bleeding from 
anastomoses 
4 6.5 48 6-7 440 Unknown, bleeding from anastomoses 
5 5 24 3 421 
Unknown, bleeding stopped with 
surgical glue 
6 6.5 24 N/A 435 
Nude rat: Did not close after surgery 
due to inability to stop bleeding 
7 6 24 1 407 Rupture 
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Burst pressure testing, histology, and endothelial cell staining (acLDL, vWF) 
were used to characterize constructs pre-implant on endothelialized MEs from the same 
batch.  This allowed confirmation of mechanical properties and good endothelial cell 
coverage prior to implantation. In the first 3 implants, ACA was not contained in the 
medium used for EC seeding in the final pre-implant step, and a degradation of fibrin 
and/or other non-collagenous protein was apparent over the 24-48 hours post-
endothelialization and prior to implantation (Figure 1).  
 
Figure B.1: Lillie’s Trichrome Staining of ME pre- and post-implant. A). Native 
Fischer rat aorta B). 6 week PVIC ME prior to endothelialization C). Endothelialized 
PVIC ME cultured without ACA in the medium starting at the time of endothelial cell 
seeding. D). PVIC construct explant (after 2-2.5 hours implantation).    
B.3 Summary 
A total of 7 implants were performed (6 on fischer rats and 1 on a nude rat). The 
implants were directly sutured in line with the rat infrarenal abdominal aorta, and in later 
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implants, surgical glue was used to stop bleeding from the suture site. Without the use of 
surgical glue, the bleeding could be stopped through application of pressure to the suture 
site, but bleeding would resume 10-15 minutes later. Of the 7 implantation cases, 1 
animal died due to technical issues and 2 due to rupture of the implant. In the other 4 
implants, the cause of death was unclear. It was unlikely that bleeding around the sutures 
was the cause of death, as the amount of blood lost was low and remedying this issue 
through the use of surgical glue did not increase the survival time. No thrombosis 
occurred, however questions were raised as to whether this was due to the presence of a 
confluent endothelium or an effect of hyperacute rejection through dysfunction of the 
coagulation cascade or, perhaps more likely, a response to the aspirin or heparin dose 
administered prior to implantation. The complete lack of clotting at the anastomoses is 
likely the reason for the continued bleeding after implantation. While the short survival 
time, on the order of hours instead of days or weeks, makes it impossible to characterize 
the in vivo remodeling of our constructs, these results indicate that our MEs are may be 
strong enough initially to withstand normal rat aortic pressures. The use of Fischer rat 
cells in the medial layer of our constructs, with continued use of Fischer rat endothelial 
cells, would remove possible issues with immunological rejection due to cell source. 
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Appendix C: Cyclic Distention 
C.1 Background 
This research aimed to address the critical issue of inferior mechanical properties 
of fibrin-based vascular constructs compared to native vessels, through mechanical 
strengthening with cyclic distension. Using a custom built bioreactor system, modified to 
work with 1 mm and 2 mm OD silicone tubing, we were able to cyclically distend tubular 
fibrin constructs with independent control of frequency, duty cycle, and radial distention 
{Isenberg, 2003 #42}. A radial distention of up to 20% could be attained with this 
system. Rat vascular smooth muscle cell (vSMC) constructs, as fabricated in Chapter 2, 
were subjected to cyclic distension using a 10% radial distension, 0.5 Hz frequency and 
12.5% duty cycle (Figure C.1), to mimic the best case conditions demonstrated with 
porcine valve interstitial cells in larger diameter tubular constructs to date . 
 
Figure C.1: Cyclic distention of 2 mm MEs. A) Cyclic Distention profile for vSMC 
MEs distended on silicone tubing. B) Bioreactor for culture and distention of 2 mm MEs. 
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Figure C.1: Effects of CD on vSMC tubular constructs. A) Comparison of statically 
cultured constructs (Static) versus constructs cyclically distended with 10% strain, 0.5 
Hz, and 12.5% duty cycle (CD). Trichrome stain of B) Static and C) CD constructs. 
Mean ± SD for n=4. 
 
C.2 Results 
vSMC MEs were cultured statically for two weeks on a glass mandrel before 
being transferred to 2 mm OD silicone tubing. Half of these MEs underwent cyclic 
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distention and the other half were statically cultured for the next 4 weeks. After 4 weeks 
of cyclic distention, vSMCs had a higher ultimate tensile strength and modulus than the 
statically cultured MEs and had a higher collagen density (Figure C.2A). Histology 
showed a more homogenous collagen distribution in the cyclically distended MEs 
compared to their static counterparts, as well as stronger alignment of the cells in the 
circumferential direction. 
C.3 Summary 
Results for the vSMC constructs support the hypothesis that mechanical stimuli 
can be used to modulate matrix remodeling and improve the mechanical properties of 
fibrin-based media-equivalents. Significant improvements were seen in the ultimate 
tensile strength and modulus of cyclically distended versus statically cultured constructs. 
However, as described in Chapter 3, vSMC MEs had great variability between cell 
isolations, cell passages, fibrinogen lots, and even between fabrications. Experiments 
with vSMCs had great variability in mechanical properties, compaction, and collagen and 
elastin deposition. Thus, while these experiments showed that vSMC were responsive to 
mechanical stimulation, use of these MEs became impractical when MEs could not be 
fabricated with consistent results. 
